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Abstract 
 
Deficits in retrograde axonal transport have been described at a presymptomatic 
stage in the SOD1G93A mouse model of ALS. The early appearance of transport 
defects suggests that they may play an important role in disease pathogenesis. 
However, the causative role of axonal transport deficits in ALS motor neuron 
degeneration has not yet been demonstrated directly. The goal of my PhD project 
was to identify pharmacological enhancers of retrograde axonal transport that could 
be used to prove conclusively whether axonal transport defects play a significant role 
in ALS pathogenesis.   
 
To this aim, I developed and performed a microscopy-based screen for the 
identification of pharmacological enhancers of retrograde axonal transport in motor 
neurons. I was able to demonstrate that the accumulation of α-p75NTR and HCT in the 
cell body of mouse ES-derived motor neurons acts as a sensitive read-out of 
retrograde axonal transport efficiency and using this assay, I identified and validated 
two compounds (A1 and E4) that were able to accelerate retrograde axonal transport 
in motor neurons. 
 
Compound A1 was revealed to be an inhibitor of p38 MAPK. Inhibition of p38 MAPK 
was found to correct deficits in retrograde axonal transport in SOD1G93A motor 
neurons both in vitro and in vivo. Using genetic and pharmacological approaches, I 
was able to demonstrate that p38 MAPKα is responsible for the transport deficits 
observed. Compound E4 was revealed to be an inhibitor of the IGF1 receptor 
(IGF1R). It was found to accelerate retrograde axonal transport in both wild type and 
SOD1G93A motor neurons, but had no effect on anterograde transport speeds.   
 
In conclusion, this thesis work has identified inhibitors of p38 MAPK and IGF1R as 
novel modifiers of retrograde axonal transport and demonstrated that inhibitors of 
p38 MAPKα can be used to determine the role of axonal transport defects in ALS 
pathogenesis. 
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Movie Legends 
 
Movie 1. In vitro axonal transport of p75NTR in primary motor neurons 
Wild type primary motor neurons in MatTek dishes were incubated with AlexaFluor-
647 labelled α-p75NTR for 25 min at 37°C, 5% CO2. After 25 min, motor neurons were 
washed once and then imaged in 2 ml fresh imaging medium. MatTek dishes were 
then placed in an environmental chamber heated to 37°C and imaged using an invert 
Zeiss LSM 780 confocal microscope with the 63X oil immersion objective. Images 
were acquired every 3 s. The video is played at 8 frames/s. The cell body is located 
out of view to the left. Scale bar, 10 µm.  
 
Movie 2. In vitro axonal transport of WGA in primary hippocampal neurons 
Primary hippocampal neurons were plated in two compartment microfluidic 
chambers and quantum dot-labelled WGA was added to the axonal compartment. 
Hippocampal neurons were incubated at 37°C, 5% CO2 for 2 hours, then washed 
with pre-warmed differentiation medium and imaged on an invert fluorescence 
microscope. Images were acquired every 0.5 s. The video is played at 8 frames/s. 
Cell bodies are located to the left.  
 
Movie 3. In vivo axonal transport of HCT in the sciatic nerve (63X) 
Mice were anaesthetised using isoflurane (National Veterinary Services) and 
AlexaFluor-555 labelled HCT (13 µg) and BDNF (50 ng) were injected 
intramuscularly into the exposed tibialis anterior and gastrocnemius muscles of the 
right hind leg. The mice were allowed to recover and four hours later were re-
anaesthetised and the sciatic nerve of the right leg exposed. The anaesthetised 
mouse was placed on a heated stage in an environmental chamber (both kept at 
37°C) and axonal transport was imaged in the intact sciatic nerve by time-lapse 
confocal microscopy. Images of axons were acquired every 5 s with an invert Zeiss 
LSM 780 using a 63X oil immersion objective. The video is played at 8 frames/s. 
Retrograde carriers are moving from the top right to the bottom left. Scale bar, 20 µm. 
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Movie 4. In vivo axonal transport of HCT in the sciatic nerve (100X) 
Axons were imaged with the 63X objective and a representative area was selected 
for imaging at 100X. Images of the selected axons were acquired every 3.2 s and the 
video is played at 8 frames/s. Retrograde carriers are moving to the left. Scale bar, 
10 µm. 
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Chapter 1. Introduction 
1.1. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by 
the degeneration of upper and lower motor neurons. This degeneration of motor 
neurons leads to progressive muscle paralysis and ultimately death, usually due to 
respiratory failure. The incidence of ALS is approximately 2 per 100,000 people per 
year and the mean age of onset is between 55 and 60 years. However, cases of 
juvenile ALS have been reported, where disease onset occurs before the age of 25. 
Patients with ALS typically survive for 2 to 5 years after symptom onset. 
 
1.1.1. Cognitive impairment in ALS 
It is now clear that at least 50% of ALS patients have evidence of cognitive decline, 
with approximately 15% of patients developing features of frontotemporal dementia 
(FTD) (Ringholz et al., 2005). FTD is characterised by the degeneration of neurons 
in the frontal and temporal lobes and is the second most common cause of 
progressive cognitive impairment after Alzheimer's disease. It is thought by some 
that ALS and FTD may form the two ends of a spectrum of a single 
neurodegenerative disorder (Swinnen and Robberecht, 2014). This is supported by 
the overlapping genetics and pathology of the two diseases. Understanding the 
different forms of ALS and recognising them in patients is a major challenge in the 
field and will certainly impact the development and success of new therapeutic 
strategies.  
 
1.2. Genetics of ALS 
Although the majority of cases of ALS are reported to be sporadic (sALS), 
approximately 5-10% of cases are familial (fALS). The majority of these cases are 
of autosomal dominant inheritance. Clinically, sporadic and familial ALS are 
indistinguishable, therefore studying fALS-associated genes allows us to 
investigate the pathological mechanisms underlying both fALS and sALS.   
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A number of genes have now been unequivocally linked to fALS, the details of 
which are summarised in Table 1. Mutations in some of these genes have also 
been found in a small number of apparently sporadic cases of ALS. 
 
Table 1. Genes identified to carry ALS-causing mutations 
 
Gene Incidence (%) Putative protein 
function 
Reference 
fALS sALS 
Chromosome 9 
open reading 
frame 72 
(C9orf72) 
40 7 DENN Rab GEF (DeJesus-Hernandez 
et al., 2011, Renton et 
al., 2011) 
Superoxide 
dismutase 1 
(SOD1) 
12 1-2 Superoxide 
metabolism 
(Rosen et al., 1993) 
Tar DNA binding 
protein 
(TARDBP) 
4 1 RNA processing (Gitcho et al., 2008, 
Kabashi et al., 2008, 
Sreedharan et al., 
2008) 
Fused in sarcoma 
(FUS) 
4 1 RNA processing (Kwiatkowski et al., 
2009, Vance et al., 
2009) 
Valosin-
containing protein 
(VCP) 
1 1 Proteasome, 
vesicle trafficking, 
autophagy 
(Johnson et al., 2010) 
Sequestosome 1 
(SQSTM1) 
1 <1 Ubiquitination, 
autophagy 
(Fecto et al., 2011) 
Optineurin 
(OPTN) 
<1 <1 Membrane 
trafficking 
(Maruyama et al., 
2010) 
Profilin 1 (PFN1) <1 <1 Cytoskeleton 
dynamics 
(Wu et al., 2012) 
Ubiquilin 2 
(UBQLN2) 
<1 <1 Autophagy, 
proteasome 
(Deng et al., 2011) 
 
(Modified from Renton et al., 2014) 
 
 
The mutations that have had the most significant impact on our understanding of 
ALS are described below. 
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1.2.1. Superoxide dismutase 1 
Superoxide dismutase 1 (SOD1) was the first gene identified as being mutated in 
ALS (Rosen et al., 1993). Population-based studies estimate that mutations in 
SOD1 account for approximately 12% of fALS cases and 1-2% of sporadic cases 
(Chio et al., 2008). SODs are a class of highly conserved enzymes that catalyse 
the conversion of superoxide into oxygen and H2O2. To date, over 180 mutations in 
the SOD1 gene have been identified in ALS (http://alsod.iop.kcl.ac.uk/als) and the 
different mutations display considerable phenotypic heterogeneity, particularly in 
the age of onset and progression of the disease (Andersen et al., 2003). The 
toxicity of mutant SOD1 in ALS is widely thought to result from a toxic gain of 
function rather than a loss of function, as a number of fALS-associated SOD1 
mutants retain their intrinsic enzymatic activity (Gurney et al., 1994) and no 
correlation has been found between intrinsic SOD1 activity and clinical severity 
(Ratovitski et al., 1999). However, measurements in patient samples have revealed 
that overall SOD1 activity is in fact reduced in the majority of SOD1 fALS cases 
compared to healthy controls (Saccon et al., 2013). In addition, although mice 
lacking SOD1 (SOD1-/-) do not develop motor neuron degeneration (Reaume et al., 
1996), they do display progressive denervation of hindlimb muscles (Fischer et al., 
2011). Furthermore, mice carrying the fALS-associated D83G mutation in the 
mouse SOD1 gene, which results in a loss of dismutase activity, not only develop 
the distal axonopathy found in SOD1-/- mice but also develop upper and lower 
motor neuron degeneration (Joyce et al., 2015). These results raise the possibility 
that loss of SOD1 activity may contribute to neuromuscular denervation in ALS and 
that central motor neuron loss and peripheral axonal dysfunction may be mediated 
by different mechanisms.  
 
Transgenic mouse models expressing ALS-associated mutations in SOD1 have 
played a key role in furthering our understanding of the disease and will be 
discussed in detail in Section 1.3. 
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1.2.2. TDP-43 and FUS 
Following the discovery of mutations in SOD1 in 1993, it was another 15 years 
before the next ALS causative mutation was identified. Fuelled by the observation 
that TDP-43 is a major component of the ubiquitinated inclusions that are 
characteristic of ALS (Neumann et al., 2006), mutations in TARDBP (which 
encodes TDP-43) were soon identified in patients with fALS (Gitcho et al., 2008; 
Kabashi et al., 2008; Sreedharan et al., 2008). TDP-43 is a ubiquitously expressed 
RNA-DNA binding protein that has been implicated in transcriptional regulation, 
alternative splicing and microRNA processing (Xu, 2012). Mutations in TARDBP 
are thought to account for approximately 4% of fALS cases and a small percentage 
of sALS cases (Chio et al., 2012). The discovery that TDP-43 is also a component 
of the ubiquitinated inclusions found in FTD patients (Neumann et al., 2006) 
provided one of the first indications that ALS and FTD may be part of a continuous 
spectrum of a single neurodegenerative disorder.  
 
Soon after the discovery of ALS-causing TARDBP mutations, mutations in another 
RNA binding protein, fused in sarcoma (FUS), were also identified in fALS patients 
(Kwiatkowski et al., 2009; Vance et al., 2009). FUS has been proposed to play a 
role in transcriptional regulation, RNA and microRNA processing and mRNA axonal 
transport (Lagier-Tourenne et al., 2010). Its discovery reinforced the idea that 
defects in RNA processing may play a role in ALS pathogenesis (discussed in 
detail in Section 1.5.5).   
 
1.2.3. Hexanucleotide repeat expansion in C9orf72 
The most common mutation associated with fALS has been identified as a 
hexanucleotide repeat expansion (GGGGCC) in a non-coding region of the gene 
C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). This genetic defect 
has also been implicated in sporadic forms of the disease (Renton et al., 2011) and 
FTD (DeJesus-Hernandez et al., 2011). Homology searches have shown that 
C9orf72 encodes a protein that is structurally related to the DENN family of guanine 
nucleotide exchange factors, which regulate the activity of Rab proteins (Levine et 
al., 2013). Rab proteins are part of the Ras superfamily of small GTPases and 
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regulate many aspects of membrane trafficking, including vesicle formation and 
movement, and membrane fusion. C9orf72 has been found to colocalise with Rab 
proteins in human spinal cord motor neurons and siRNA-mediated knockdown of 
C9orf72 in motor neuron cell lines has been shown to disrupt endosomal trafficking 
(Farg et al., 2014). However, it is currently unclear how the hexanucleotide repeat 
expansion affects the normal cellular function of C9orf72 and if this contributes to 
the pathogenic effect of the mutation. It has recently been demonstrated that 
knocking out C9orf72 in neuronal and glial cells does not cause motor neuron 
degeneration or motor deficits in mice (Koppers et al., 2015). Other hypotheses 
have also been proposed to explain the toxicity of the hexanucleotide repeat 
expansion. It has been proposed that the RNA product of the repeat expansion 
forms nuclear foci that sequester key RNA-binding proteins, leading to defects in 
RNA metabolism (Cooper-Knock et al., 2014, Renton et al., 2014). Interestingly, 
the frequency of RNA splicing errors has recently been shown to correlate with 
disease severity in C9orf72 ALS patients (Cooper-Knock et al., 2015). Other 
groups have suggested that the dipeptide repeat proteins, translated from the 
GGGGCC repeat expansion, form toxic aggregates and contribute to motor neuron 
degeneration (Mizielinska et al., 2014).   
 
In addition to the genes known to be causative for ALS (summarised in Table 1), 
mutations in several other genes have also been reported in ALS patients (Table 2, 
next page). For the majority of these genes, more evidence is still required to 
support their involvement in ALS pathogenesis.  
 
Furthermore, a number of susceptibility genes have been identified for sALS, for 
example ITPR2 (van Es et al., 2007) and DPP6 (van Es et al., 2008). It has been 
proposed that mutations in multiple small effect genes, plus gene–environment 
interactions, may underlie many cases of apparently sporadic ALS (Simpson and 
Al-Chalabi, 2006).  
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Table 2. Additional genes associated with ALS 
 
 
Gene Protein function Reference 
Dynactin 1/ p150glued (DCTN1) Axonal transport (Puls et al., 2003) 
Neurofilament heavy chain 
(NF-H) 
Axonal transport (Al-Chalabi et al., 1999) 
Alsin (ALS2) Vesicle trafficking (Hadano et al., 2001) 
Charged multivesicular body 
protein 2B (CHMP2B) 
Vesicle trafficking (Parkinson et al., 2006) 
FIG4 phosphoinositide 5-
phosphatase (FIG4) 
Vesicle trafficking (Chow et al., 2009) 
Vesicle-associated membrane 
protein B (VAPB) 
Vesicle trafficking (Nishimura et al., 2004) 
TANK-binding kinase 1 (TBK1) Membrane trafficking; 
inflammatory signalling 
(Freischmidt et al., 2015) 
Tubulin Alpha 4A (TUBA4A) Cytoskeleton dynamics (Smith et al., 2014) 
Ataxin-2 (ATXN2) Endocytosis; RNA 
translation 
(Elden et al., 2010) 
Heterogeneous nuclear 
ribonucleoprotein A1 
(HNRNPA1) 
RNA metabolism (Kim et al., 2013) 
Heterogeneous nuclear 
ribonucleoprotein A2B1 
(HNRNPA2B1) 
RNA metabolism (Kim et al., 2013) 
Senataxin (SETX) RNA metabolism (Chen et al., 2004) 
Elongator protein 3 (ELP3) RNA metabolism (Simpson et al., 2009) 
Matrin-3 (MATR3) RNA metabolism (Johnson et al., 2014b) 
CHCHD10 Mitochondrial function (Johnson et al., 2014a) 
Angiogenin (ANG) Angiogenesis (Greenway et al., 2006) 
Spastic paraplegia 11 (SPG11)  DNA damage repair (Orlacchio et al., 2010) 
 
(Modified from Renton et al., 2014) 
 
1.3. Mouse models of ALS 
The identification of genetic mutations causative for ALS has been key for the 
development of rodent models of the disease. 
 
The most commonly used and best-characterised model of ALS is a transgenic 
mouse overexpressing the human SOD1 gene carrying the G93A mutation (Gurney 
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et al., 1994). These mice mimic the human disease, showing progressive motor 
neuron loss accompanied by a loss of motor function (as illustrated in Figure 1.1.) 
 
 
 
Figure 1.1. Disease progression in the SOD1G93A mouse model of ALS 
Schematic representation of the appearance of disease signs and motor neuron pathology in 
the SOD1G93A mouse model of ALS, as described in Bilsland et al., 2010. 
 
 
Mice overexpressing fALS-associated G37R and G85R mutant forms of human 
SOD1 have also been developed and are also widely used in ALS research 
(Morrison and Morrison, 1999). A significant concern with the majority of transgenic 
models of the disease is the fact that they overexpress the ALS-associated mutant 
protein at high levels, for example the SOD1G93A mouse expresses the SOD1 
protein at up to 20-fold the endogenous level. In fact, overexpression of wild type 
SOD1 at a similar level has been shown to cause progressive motor neuron death 
in transgenic mice (Graffmo et al., 2013). In order to investigate the effects of 
mutant SOD1 at endogenous levels, Joyce et al. recently identified the SOD1D83G 
mouse, which carries this fALS-associated mutation in the mouse SOD1 gene 
(Joyce et al., 2015). The SOD1D83G mouse develops progressive upper and lower 
motor neuron degeneration between 6 and 15 weeks of age, indicating that fALS-
associated mutations in SOD1 are sufficient to elicit motor neuron degeneration 
when expressed at endogenous levels. 
 
It is important to note that the different mutant SOD1 mouse models show different 
ages of disease onset and rates of disease progression and the results obtained 
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from the different models do not always agree. However, this could reflect 
heterogeneity in the disease caused by different SOD1 mutations rather than a 
limitation of the mouse models themselves. In addition, the disease phenotype of 
mutant SOD1 mice can be strongly affected by genetic background (Mancuso et al., 
2012).  
 
Mouse models based on the ALS-associated genes TDP-43, FUS and VCP have 
also been reported, but so far none have been able to recapitulate the ALS 
phenotype as well as mutant SOD1 transgenic mice (McGoldrick et al., 2013). 
Recently, a mouse model has been reported that expresses expanded C9orf72 
(GGGGCC)66 selectively in the central nervous system (Chew et al., 2015). At six 
months, these mice display cortical neuron and cerebellar Purkinje cell loss, as well 
as behavioural and motor deficits similar to the clinical symptoms of C9orf72 
FTD/ALS patients. However, a detailed longitudinal analysis of motor neuron 
pathology and motor function has not yet been performed in these mice.  
 
1.4. Cell autonomous versus non-cell autonomous 
mechanisms 
Although ALS is defined as a disease of motor neurons, it is now widely accepted 
that non-neuronal cells play a key role in disease pathogenesis. Evidence for this 
comes from cell-type specific expression or deletion of ALS-associated mutant 
genes.  
 
1.4.1. Motor neurons 
It has been demonstrated that expression of mutant SOD1 only in motor neurons is 
not sufficient to cause degeneration. Clement et al. generated chimeric mice with 
different contributions of wild type and SOD1G37R-expressing cells (Clement et al., 
2003). The authors found that mice with mutant SOD1G37R in motor neurons but 
wild type non-neuronal cells did not develop symptoms of ALS. Looking at different 
chimeric mice with different contributions of wild type and SOD1G37R-expressing 
non-neuronal cells, they observed that mice with an increasing contribution of wild 
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type non-neuronal cells survived for longer compared to 100% mutant controls. In 
addition they found that motor neurons expressing mutant SOD1 were more likely 
to survive if they were in proximity to wild type glial cells. 
 
However, it is clear that mutant SOD1 expression in motor neurons does play a key 
role in ALS pathogenesis. By crossing Islet-Cre mice with Lox-SOD1G37R mice, 
Boillee et al. were able to produce a mouse that expressed mutant SOD1 
everywhere except the motor neurons (Boillee et al., 2006). The authors found that 
loss of SOD1G37R in motor neurons delayed disease onset and slowed disease 
progression at an early stage, leading to an increase in survival. 
 
These results indicate that expression of mutant SOD1 in motor neurons plays an 
important role in disease initiation and early progression. However, the fact that 
loss of mutant SOD1 from motor neurons could not prevent the disease in mice 
indicates that non-neuronal cells must also play a role in the pathogenesis. 
 
1.4.2. Astrocytes 
It has been demonstrated in vitro that co-culture of SOD1G93A-expressing 
astrocytes with wild type mouse embryonic stem cell (ES)-derived motor neurons is 
neurotoxic (Di Giorgio et al., 2007). Similar results have also been found using 
patient-derived astrocytes from fALS patients (carrying the SOD1A4V mutation and 
the C9orf72 expansion repeat) and also sALS patients (Meyer et al., 2014, Haidet-
Phillips et al., 2011). However, mice expressing SOD1G86R only in astrocytes (using 
the GFAP promoter sequence) display normal motor neuron physiology (Gong et 
al., 2000). This suggests that mutant SOD1-expressing astrocytes alone may not 
be sufficient to cause motor neuron degeneration in vivo.  
 
In order to determine the role of astrocytes in ALS pathogenesis, Yamanaka et al. 
crossed lox-SOD1G37R mice with cre-GFAP mice, to eliminate expression of mutant 
SOD1 in astrocytes only (Yamanaka et al., 2008). Loss of mutant SOD1 in 
astrocytes was found to have no effect on disease onset, but did cause a small 
slowing of disease progression and an increase in lifespan.  
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1.4.3. Microglia 
Microglia are the innate immune cells of the central nervous system. Boillee et al. 
generated mice that express mutant SOD1 in all cells except microglia and 
macrophages (Boillee et al., 2006). The authors found that loss of microglial mutant 
SOD1 expression had no effect on disease onset or early progression, but did slow 
the progression of the later phase of the disease and extended survival significantly.  
 
Interestingly, delayed microglial activation has been observed in mice that do not 
express mutant SOD1 in astrocytes, even though there was no change in mutant 
SOD1 levels in microglia (Yamanaka et al., 2008). This indicates that there is 
crosstalk between the cells proposed to be involved in ALS and it is likely that a 
complex interaction of both neuronal and non-neuronal cells contributes to disease 
pathogenesis. 
 
1.4.4. Skeletal muscle 
There have been conflicting reports on the effect of muscle-specific expression of 
ALS-associated SOD1 mutants. Dobrowolny et al. demonstrated that selective 
expression of SOD1G93A in mouse skeletal muscle using the myosin light chain 
promoter led to progressive muscle atrophy, reduced muscle strength, impaired 
contractility and mitochondrial dysfunction, but did not cause motor neuron 
degeneration (Dobrowolny et al., 2008). However, Wong and Martin reported that 
muscle-specific expression of either SOD1G93A or SOD1G37R using the human 
skeletal actin promoter resulted in both muscle and motor neuron pathology, similar 
to that seen in ALS patients (Wong and Martin, 2010), suggesting that defects in 
skeletal muscle may play a role in motor neuron degeneration in ALS. However, 
reducing levels of SOD1G93A by over 50% in skeletal muscle has been reported to 
have no effect on disease progression in SOD1G93A mice (Towne et al., 2008). 
These studies indicate that mutant SOD1 is toxic to skeletal muscle and likely plays 
a role in muscle weakness and atrophy in ALS. However, whether skeletal muscle 
dysfunction also contributes to motor neuron pathology still remains unclear. 
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1.5. Pathological mechanisms involved in ALS 
 
At present, the precise cause of motor neuron death in ALS is not fully understood 
and many different mechanisms have been linked to the disease pathogenesis 
(illustrated in Figure 1.2). Difficulties arise in trying to distinguish which 
mechanisms play a causative role in disease pathogenesis, and which are simply 
downstream effects. It is likely that the interaction of multiple pathogenic processes 
is responsible for the dysfunction and ultimate degeneration of motor neurons in 
ALS. 
 
 
 
 
Figure 1.2. Mechanisms proposed to be involved in the pathogenesis of ALS  
A wide range of mechanisms have been reported to be defective in ALS motor neurons, based 
on observations in mouse models of the disease as well as human patient samples. However, 
their exact role in ALS pathogenesis is poorly understood. Reprinted with permission from 
Elsevier (Turner et al., 2013). 
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1.5.1. Oxidative stress 
Oxidative stress is caused by the generation and build-up of reactive oxygen 
species (ROS). ROS cause oxidative damage to proteins, lipids and nucleic acids. 
There have been a number of reports of increased oxidative stress in both sporadic 
and familial ALS patients. Increased levels of markers of lipid peroxidation have 
been found in the cerebrospinal spinal fluid (CSF) and urine of living patients 
(Smith et al., 1998, Simpson et al., 2004, Mitsumoto et al., 2008). Oxidative 
damage to proteins, DNA and lipids has also been observed in ALS spinal cords 
post-mortem (Shaw et al., 1995b, Shibata et al., 2001, Fitzmaurice et al., 1996). In 
addition, expression of ALS-associated mutant forms of TDP-43 in motor neuron 
cell lines has been reported to induce oxidative stress (Duan et al., 2010).  
 
Oxidative damage of mRNA has been reported to be present presymptomatically in 
spinal cords of SOD1G93A mice, whilst damage to proteins, lipids and DNA was not 
observed until later in the disease progression (Chang et al., 2008). Of the mRNAs 
reported to be oxidised in this paper, many encoded proteins previously associated 
with ALS, including SOD1, p150glued (DCTN1) and vesicle-associated membrane 
protein B (VAPB). The authors were also able to demonstrate that vitamin E, which 
has been shown to reduce oxidative stress, delayed disease onset and slowed 
disease progression in SOD1G93A mice. However, vitamin E had no effect on the 
lifespan of the mice. In addition, when high dose vitamin E was administered to 
ALS patients in combination with riluzole, no beneficial effect was found compared 
to riluzole alone (Graf et al., 2005).  
 
1.5.2. Mitochondrial dysfunction  
In addition to their role in producing energy for the cell, mitochondria also play a 
key role in calcium homeostasis and the control of apoptosis. Mitochondrial 
damage has been observed in the SOD1G93A mouse before the onset of symptoms 
(Kong and Xu, 1998). The damage observed has been proposed to be a result of 
mutant SOD1 accumulating in the mitochondria of these mice (Higgins et al., 2002). 
Mitochondrial accumulation of mutant SOD1 has been reported to impair 
mitochondrial function by reducing the activity of the electron transport chain 
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complexes (Ferri et al., 2006). In addition, the calcium buffering capacity of spinal 
cord mitochondria has also been reported to be defective in presymptomatic 
SOD1G93A and SOD1G85R mice (Damiano et al., 2006), and may provide a link 
between mitochondrial dysfunction and calcium-mediated glutamate excitotoxicity, 
another mechanism proposed to be involved in ALS pathogenesis (described in 
detail in Section 1.5.3). Furthermore, the axonal transport of mitochondria has been 
shown to be defective both in vitro (De Vos et al., 2007) and in vivo (Bilsland et al., 
2010) in motor neurons of the SOD1G93A mouse and will be discussed later in 
Section 1.7.2.6.  
 
Attempts to prevent mitochondrial dysfunction pharmacologically have not shown 
promising results in ALS patients to date. Olesoxime, a mitochondrial pore 
modulator that was found to prevent motor neuron death in SOD1G93A mice 
(Sunyach et al., 2012), failed to show any beneficial effects in Phase III trials 
(Lenglet et al., 2014). In addition, dexpramipexole, a drug shown to protect motor 
neurons by stabilising the proton gradients needed for ATP production and 
preventing mitochondrial-dependent apoptosis (Alavian et al., 2012), failed to 
improve function or survival in a Phase III study (Cudkowicz et al., 2013).  
 
1.5.3. Glutamate excitotoxicity 
Glutamate is the main excitatory neurotransmitter in the central nervous system 
(CNS). It exerts its effects through both ionotropic and metabotropic glutamate 
receptors and its excitatory effects are terminated by removal of glutamate from the 
synapse. Glutamate is removed from the synaptic cleft by astrocytes and 
presynaptic neurons via glutamate reuptake transporters, EAAT1, EAAT2, and 
EAAT3 (Arriza et al., 1994). Glutamate excitotoxicity results from excessive 
stimulation of glutamate receptors, usually due to increased levels of glutamate in 
the synapse or increased sensitivity of the neuron to glutamate, for example due to 
increased expression of glutamate receptors. Excessive activation of glutamate 
receptors leads to disruption of neuronal calcium homeostasis and cellular toxicity. 
There are numerous reports providing evidence for glutamate excitotoxicity in ALS. 
Levels of glutamate have been found to be elevated in the CSF of ALS patients 
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(Rothstein et al., 1990). This could be explained by the post mortem observation 
that the number of presynaptic glutamate re-uptake sites is reduced in the spinal 
cord of ALS patients (Shaw et al., 1995a, Rothstein et al., 1995). In addition, 
electrophysiology studies have revealed hyperexcitability of the motor system 
before symptom onset in ALS patients (Vucic and Kiernan, 2006).  
 
Riluzole, the only licensed drug available for ALS, acts to reduce glutamate 
excitotoxicity by a number of mechanisms, including inhibition of repetitive neuronal 
firing (Doble, 1996), inhibition of glutamate release (Wang et al., 2004) and 
stimulation of glutamate transporters (Fumagalli et al., 2008). It is able to increase 
survival of patients by around two months, although it has little effect on slowing 
functional decline (Miller et al., 2003).  
 
1.5.4. Inflammation 
Neuroinflammation is emerging as a common link between many 
neurodegenerative diseases. In SOD1G93A mice, an increased number of activated 
microglia is found in the ventral horn at a presymptomatic stage (Tortarolo et al., 
2003). When activated, microglia alter their gene expression, leading to the 
production and release of several inflammatory mediators, including cytokines, 
chemokines and proteases. Proinflammatory cytokines, such as TNFα and IL-1β, 
have been implicated to play a role in ALS pathogenesis. 
 
Using microarray techniques to examine mRNA expression in the spinal cord of 
SOD1G93A mice, TNFα was found to be one of the earliest inflammatory stimuli to 
be induced (11 weeks, early symptomatic) (Yoshihara et al., 2002). In addition, 
high levels of TNFα are reported in blood samples from sALS patients (Poloni et al., 
2000). However, knocking out TNFα in SOD1G93A mice was found to have no effect 
on disease onset, progression or survival, nor any influence on motor neuron 
degeneration (Gowing et al., 2006).  
 
Interleukin 1-beta (IL-1β) has also been reported to be chronically upregulated in 
mutant SOD1G93A and SOD1G37R transgenic mice (Hensley et al., 2002, Nguyen et 
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al., 2001). However, knocking out IL-1β in SOD1G37R mice was found to have no 
effect on either lifespan or motor neuron degeneration (Nguyen et al., 2001).  
 
These results suggest that TNFα and IL-1β do not play a key role in triggering 
motor neuron death in ALS, but may instead be a consequence of the underlying 
pathology.  
 
1.5.5. RNA processing 
Several genes found to cause fALS encode proteins involved in the regulation of 
RNA transcription and processing, including TDP-43 and FUS. 
 
TDP-43 is a ubiquitously expressed RNA-DNA binding protein that has been 
implicated in transcriptional regulation, alternative splicing and microRNA 
processing. Although normally located in the nucleus, the ALS mutant form is found 
predominantly in the cytoplasm and has been localised to the ubiquitinated 
inclusions that are characteristic of ALS (Neumann et al., 2006). Fibroblasts taken 
from TDP-43-associated ALS patients have been shown to have widespread 
alterations in RNA splicing, indicating that mutant TDP-43 could cause ALS due to 
a loss of its normal function (Highley et al., 2010). This is supported by the 
observation that knocking down TDP-43 in mice leads to progressive motor neuron 
degeneration, motor dysfunction and ultimately paralysis (Yang et al., 2014).  
 
FUS is another RNA-DNA binding protein that has been identified to be mutated in 
ALS (Kwiatkowski et al., 2009; Vance et al., 2009). It has been shown to play a role 
in transcriptional regulation, RNA and microRNA processing and mRNA axonal 
transport (Lagier-Tourenne et al., 2010). Similarly to TDP-43, the nuclear 
localisation of FUS is reported to be lost in ALS, with the protein being found in 
cytoplasmic aggregates in spinal cord motor neurons (Vance et al., 2009). Recent 
evidence has indicated that mutant FUS may cause neurodegeneration due to a 
loss of its normal function and also a toxic gain of function. Qiu et al. demonstrated 
that, in mice expressing FUS carrying the fALS-associated R521C mutation, 
mutant FUS bound to the wild type form of the protein, preventing its interaction 
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with its normal partners (Qiu et al., 2014). In addition, mutant FUS was found to 
form more stable complexes with BDNF RNA and as a result cause BDNF splicing 
defects and impaired BDNF-TrkB signalling.  
 
1.5.6. Protein aggregation 
There are numerous reports of pathological protein aggregates in both mouse 
models of ALS and in fALS and sALS patient samples. Many proteins previously 
associated with the disease through genetics have now been shown to be 
components of these aggregates. 
 
TDP-43 is one of the major protein constituents of the ubiquitin-positive inclusions 
that have been described in ALS (Neumann et al., 2006). In fact, over 95% of ALS 
cases are reported to show cytoplasmic aggregation of TDP-43 (Mackenzie et al., 
2007) and it has been proposed that TDP-43 could be a point of convergence in 
ALS pathogenesis, downstream of many different disease-initiating mechanisms. 
Interestingly, mutant SOD1-associated ALS lacks TDP-43 pathology, suggesting 
that the pathogenesis of SOD1-associated ALS could be distinct from most other 
forms of the disease (Mackenzie et al., 2007). 
 
Redistribution of TDP-43 from the nucleus to the cytoplasm is thought to occur at 
an early stage in ALS pathogenesis (Giordana et al., 2010). However, when 
synthetic peptides were used to block TDP-43 aggregation, Liu et al. found that the 
protein could still mediate cell death when overexpressed in HeLa cells (Liu et al., 
2013). There are also mouse models expressing mutant TDP-43 that develop 
adult-onset motor neuron disease but do not exhibit aggregation of the mutant 
protein (Arnold et al., 2013). These results indicate that aggregation of TDP-43 may 
not be a key mechanism underlying its pathogenic effect. However, the exact role 
of macro-aggregates versus micro-aggregates of TDP-43, as well as soluble 
monomeric and oligomeric forms, still needs to be determined. 
 
ALS-associated SOD1 mutants have also been reported to form aggregates. 
Aggregates have been observed in human ALS spinal cords (Ince et al., 1998) and 
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also in the SOD1G93A mouse model, where high molecular weight complexes 
containing mutant SOD1 appear at an early symptomatic stage and accumulate 
throughout disease progression (Wang et al., 2002). The authors proposed that 
mutations in SOD1 destabilise the protein structure and trigger aggregation. 
Furthermore it has been demonstrated that the propensity of SOD1 to aggregate 
correlates with the clinical severity of the mutations (Pratt et al., 2014). Interestingly, 
it has been shown that mutant SOD1 aggregates contain the dynein motor complex 
and could therefore interfere with retrograde axonal transport (Zhang et al., 2007). 
The role of defects in axonal transport in ALS pathogenesis will be discussed in 
Section 1.7.2.6.  
 
The role of protein aggregation in ALS pathogenesis is still not fully understood. 
Aggregates may act to sequester mutant proteins and limit their deleterious effects. 
Alternatively, aggregates could form as the cell’s protein quality control system is 
overwhelmed and cannot remove mutant, damaged and/or misfolded proteins 
quickly enough. Accumulation of aggregated proteins could then induce cellular 
stress and ultimately contribute to neurodegeneration. This theory is supported by 
the observation that treatment of early symptomatic SOD1G93A mice with 
arimoclomol, which acts to enhance the clearance of protein aggregates, 
significantly improved muscle strength, motor neuron survival and lifespan (Kalmar 
et al., 2008). Arimoclomol is now in Phase II trials for SOD1-positive fALS 
(www.clinicaltrials.gov/ct2/show/NCT00706147).  
 
1.5.7. Axonal transport 
Defects in both retrograde and anterograde axonal transport have been reported in 
ALS and will be described in detail in Section 1.7.2.6. Deficits in axonal transport 
have also been found in many other neurodegenerative diseases, including 
Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and Charcot Marie 
Tooth type 2 (Millecamps and Julien, 2013), suggesting that they may be a key 
pathogenic mechanism in neurodegeneration. 
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1.6. Axonal transport  
Neurons are highly polarised cells, with axons that can extend over a meter away 
from the cell body in large mammals. This unique morphology makes neurons 
particularly dependent on active intracellular transport. Axonal transport plays two 
major roles in neurons:  
 
1) Supply and clearance: delivery of organelles and newly synthesised proteins, 
lipids and RNA to the axon and distal synapses, and removal of faulty ones 
to the soma for degradation; 
2) Long-distance communication between the axon tip and the soma, including 
transport of neurotrophic factors and their receptors, which are essential for 
survival (Chowdary et al., 2012). 
 
Axonal transport can be divided into two classes based on the speed at which 
cargoes move. Vesicles, organelles and mRNA are transported by fast axonal 
transport and move at a speed of 50–200 mm per day (0.5-3 µm/s), whilst 
cytoskeletal proteins, such as neurofilaments and tubulin, and some soluble 
proteins are transported by slow axonal transport and move at a speed of 0.1–3 
mm per day (Maday et al., 2014).  
 
The axonal transport of all cargoes is mediated by two families of ATP-dependent 
motor proteins, kinesins and cytoplasmic dynein, which carry their cargoes along 
microtubule tracks that run the length of the axon. Microtubules impart an intrinsic 
polarity to neurons, with their “plus” ends located at the axon tips and their “minus” 
ends within the cell body. This polarity confers directionality to axonal transport. 
  
1.6.1. Anterograde axonal transport 
Anterograde axonal transport refers to the movement of cargoes from the cell body 
towards the axon tips and is mediated by the kinesin superfamily of motor proteins.  
Kinesin is composed of two heavy chains (115–130 kDa) and two light chains (62–
70 kDa). Structural studies have revealed that kinesin is a rod-shaped protein, with 
two globular heads connected to a tail domain by a long stalk (Figure 1.3).  
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Figure 1.3. The structure of the kinesin-1 motor protein 
Kinesin-1 is a tetramer composed of two light chains (blue) and two heavy chains (orange). The 
motor domains are located in the globular heads at the N terminus of each heavy chain. 
Modified from (Dodding and Way, 2011). Reprinted with permission from John Wiley and Sons. 
 
The globular heads of the kinesin heavy chains (also known as KIFs) comprise the 
motor domains and contain both the ATP and microtubule binding motifs. The 
crystal structure of the motor domain was reported in 1996 (Kull et al., 1996) and it 
is now clear how small conformational changes in the ATP binding pocket lead to 
the motor taking a step (termed a powerstroke) (Vale and Milligan, 2000). The tail 
domains of the KIFs are thought to participate in cargo binding. Kinesin light chains 
(KLCs) localise to the end of the KIF tail domains and are thought to regulate cargo 
binding and the motor’s autoinhibitory mechanism (Vale, 2003). Kinesin-1, also 
known as conventional kinesin, is responsible for the fast axonal transport of most 
vesicles, organelles, proteins and RNA particles and the slow axonal transport of 
cytoskeletal proteins (Maday et al., 2014). Kinesin-2 and kinesin-3 are also 
important for neuronal axonal transport. Kinesin-2 motors have been shown to be 
associated with late endosome-lysosome compartments (Brown et al., 2005), whilst 
kinesin-3 motors carry synaptic vesicle precursors and dense core vesicles (Okada 
et al., 1995, Kiris et al., 2011). 
 
1.6.2. Retrograde axonal transport  
Retrograde axonal transport refers to the movement of cargoes from the axon tips 
back towards the cell body and is mediated by cytoplasmic dynein. Cytoplasmic 
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dynein is composed of two heavy chains (HC) and additional intermediate, light 
intermediate and light chains (Figure 1.4). 
 
 
Figure 1.4. Schematic of dynein-dynactin complex  
Components of the dynein motor and its cofactor dynactin. Dynein interacts with the dynactin 
complex via its intermediate chains (IC). Reprinted with permission from Nature Publishing 
Group (Schliwa and Woehlke, 2003).  
 
 
The dynein heavy chains contain a carboxy-terminal motor domain, comprising the 
ATP and microtubule binding motifs. High-resolution crystal structures of the dynein 
motor domain were reported in 2012 (Kon et al., 2012, Schmidt et al., 2012) and 
have revealed that the motor uses a different mechanism from kinesin to produce a 
powerstroke, involving much larger conformational changes. The amino-terminal 
tails of the heavy chains combine with the additional smaller chains to form the 
cargo-binding domain. Diversity is achieved in the dynein family through different 
combinations of heavy, intermediate, light intermediate and light chains and this is 
thought to underlie the ability of dynein to display cargo-specific transport 
characteristics.  
 
Dynein function is regulated by a multi-subunit cofactor called dynactin (see Figure 
1.4) and consists of eight core subunits: Arp1, Arp11, p62, p150Glued, p50/dynamitin, 
p24, p25 and p27. Arp1, p25 and p27 subunits have been implicated in the 
regulation of cargo binding. A dimer of p150Glued subunits forms a bridge between 
the dynein intermediate chain and microtubules, which is proposed to increase the 
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processivity of the motor complex. In contrast, dynamitin acts to inhibit dynein-
mediated axonal transport by disrupting the dynein-dynactin complex. It is thought 
to do this by causing the release of the p150Glued and p24 subunits (Melkonian et al., 
2007). Dynactin has also been shown to interact with and increase the processivity 
of kinesin-2 (Berezuk and Schroer, 2007).   
 
1.7. Axonal transport defects and neurodegeneration 
Given the key role that axonal transport plays in neurons, it is not surprising that 
defects in transport are deleterious to the health of neurons and that such defects 
have been proposed to be involved in the pathogenesis of neurodegenerative 
diseases.  
 
1.7.1. Genetic evidence 
Evidence of a general relationship between axonal transport deficits and neuronal 
death comes from studies of mice expressing mutations in transport-related genes.  
In 2003, Hafezparast et al. performed an ENU mutagenesis screen in mice, looking 
for mutations that caused progressive locomotor disorders (Hafezparast et al., 
2003). One of the strains identified, legs at odd angles (Loa), was found to carry a 
single point mutation in the gene encoding dynein heavy chain 1 and was reported 
to exhibit a progressive loss of alpha motor neurons. The group were also able to 
demonstrate that embryonic motor neurons from Loa/Loa mice showed a 
significant defect in retrograde axonal transport. It was initially assumed that the 
loss of alpha motor neurons in these mice was responsible for the motor defects 
observed, however subsequent studies showed that the Loa mice also had a 
significant sensory neuropathy (Chen et al., 2007b).  
 
Another mouse that presents motor neuron degeneration in combination with 
axonal transport defects is the Wobbler mouse. Wobbler mice carry a L967Q point 
mutation in the Vps54 gene, a component of the Golgi-associated retrograde 
protein (GARP) complex that has been proposed to regulate endosome to trans-
Golgi network transport. Wobbler mice were found to mimic several features of 
Chapter 1 Introduction 
 39 
human ALS. Motor neuron death begins at around three weeks of age and is 
accompanied by a progressive loss of body weight and muscle strength (Moser et 
al., 2013). Defects in both anterograde and retrograde axonal transport have been 
described in symptomatic Wobbler mice (Mitsumoto et al., 1993). The L967Q 
mutation has been proposed to destabilise Vps54 and the entire GARP complex 
and thereby induce deficits in axonal transport (Karlsson et al., 2013). 
 
Evidence of a link between axonal transport defects and neurodegeneration also 
comes from human genetic studies. Mutations in the genes encoding the molecular 
motors have been linked to neurodegenerative diseases. For example, mutations in 
the dynein heavy chain have been found to cause Charcot Marie Tooth type 2 
(CMT2) and spinal muscular atrophy, whilst mutations in kinesin-1 and 3 cause 
hereditary spastic paraplegia (Maday et al., 2014). In addition, mutations in motor 
adaptor and regulator proteins has also been linked to neurodegenerative diseases. 
ALS has been associated with mutations in the p150glued subunit of dynactin (Puls 
et al., 2003, Munch et al., 2005) and mutations in the late endosomal GTPase 
Rab7 (Verhoeven et al., 2003) have been found in patients with CMT2B. 
 
1.7.2. Functional studies 
The majority of evidence suggesting that axonal transport deficits play an early, 
possibly causative, role in neurodegenerative diseases comes from functional 
rather than genetic studies.  
 
1.7.2.1. Huntington’s Disease 
Huntington’s disease is an autosomal dominant neurodegenerative disease 
associated with a trinucleotide repeat expansion in the gene encoding huntingtin 
(htt). It has been demonstrated in a number of cellular and animal models of the 
disease that pathogenic htt causes inhibition of both anterograde and retrograde 
axonal transport, often before the appearance of other obvious pathological signs 
(Gunawardena et al., 2003, Trushina et al., 2004). Interestingly, this inhibition 
shows the same cell-type specificity as the disease: deficits in the axonal transport 
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of amyloid precursor protein (APP) and brain-derived neurotrophic factor (BDNF) 
were observed in striatal and hippocampal neurons from a mouse model of 
Huntington’s disease (Hdh150Q), but not in the cortical neurons (Her and Goldstein, 
2008). Several mechanisms have been proposed to explain this inhibition of axonal 
transport, including disruption of the huntingtin/HAP1/p150glued complex leading to 
the release of dynein from the microtubules (Li et al., 1998, Gauthier et al., 2004), 
physical blockade of transport by htt aggregates (Sinadinos et al., 2009) and htt-
mediated activation of JNK3 leading to phosphorylation and inhibition of kinesin 
(Morfini et al., 2009).  
 
1.7.2.2. Alzheimer’s Disease 
Alzheimer’s disease (AD) has been linked to mutations in the presenilin and APP 
genes. Mutations in these genes have been reported to alter the proteolytic 
processing of the APP protein, leading to increased production of the Aβ species 
(Scheuner et al., 1996). Smith et al. demonstrated in the Tg2576 mouse model, 
which overexpresses AD-associated mutant APP (K670N/M671L), that axonal 
transport deficits in olfactory receptor neurons are present early in disease 
progression, before the appearance of amyloid plaques (Smith et al., 2007). 
Oligomeric Aβ has been proposed to inhibit fast axonal transport through 
modulation of a number of kinases, including suppression of Akt (Takach et al., 
2015) and activation of casein kinase 2 (Pigino et al., 2009), GSK3β (Vossel et al., 
2015) and p38 MAPK (Guo et al., 2013). In fact, correcting fast axonal transport 
defects by reducing GSK3β activity has been shown to be beneficial in AD 
experimental models (Shaw and Chang, 2013, Vossel et al., 2015). 
 
AD-associated mutations in presenilin-1 have also been shown to induce defects in 
anterograde axonal transport through activation of GSK3β (Pigino et al., 2003). 
Furthermore, the microtubule-associated protein tau, which forms the neurofibrillary 
tangles observed in AD, has been found to play a key role in Aβ-mediated 
activation of GSK3β and subsequent axonal transport defects (Vossel et al., 2015).  
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1.7.2.3. Parkinson’s Disease 
Axonal transport defects have also been proposed to play a role in Parkinson’s 
disease (PD). The disease is characterised by the loss of the neurotransmitter 
dopamine and neuronal degeneration in the substantia nigra pars compacta. The 
most common genetic cause of PD has been shown to be mutations in the leucine-
rich repeat kinase 2 gene (LRRK2) (Zimprich et al., 2004, Paisan-Ruiz et al., 2004). 
Godena et al. recently demonstrated that expression of mutant LRRK2 in rat 
cortical neurons resulted in defects in both retrograde and anterograde 
mitochondrial transport (Godena et al., 2014). Similar results were found in vivo in 
the motor neurons of Drosophila larvae expressing mutant LRRK2. The authors 
proposed that the deficits in axonal transport were due to an aberrant interaction 
between mutant LRRK2 and microtubules. Furthermore, RNAi-mediated 
knockdown of histone deacetylase 6 (HDAC6) was able to restore axonal transport 
and rescue defects in locomotion in LRRK2 mutant flies. HDAC6 knockdown leads 
to increased acetylation of microtubules, allowing for the enhanced recruitment of 
both dynein and kinesin motors (Dompierre et al., 2007). These results provide 
exciting evidence that enhancing axonal transport can prevent neurodegeneration 
and rescue motor phenotypes. 
 
1.7.2.4. Charcot Marie Tooth type 2 
Charcot Marie Tooth is the most common inherited disorder of the peripheral 
nervous system. It is characterised by the degeneration of both motor and sensory 
neurons. Defects in axonal transport have been described in mouse models of 
CMT2 that express mutant forms of the heat shock protein Hsp27. Mice carrying 
the S135F mutation (which is associated with human CMT type 2F) were found to 
develop a CMT2-like phenotype and were shown to have defects in mitochondrial 
transport in DRG neurons dissected from symptomatic mice (d'Ydewalle et al., 
2011). The authors found that treatment with an HDAC6 inhibitor was able to 
correct deficits in axonal transport and also rescue the CMT2 phenotype – 
improving motor performance and reducing denervation in the mice.  
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1.7.2.5. Spinal and bulbar muscular atrophy  
Spinal and bulbar muscular atrophy (SBMA) is a hereditary late-onset 
neurodegenerative disorder, caused by an expansion of a CAG repeat in the first 
exon of the androgen receptor (AR). The disease is characterised by selective loss 
of motor neurons in the spinal cord and bulbar nuclei of the brain stem. Similarly to 
ALS, the mechanism(s) responsible for motor neuron degeneration are still unclear, 
and there have been contradicting views on the role of axonal transport defects in 
disease pathogenesis. In knock-in mice overexpressing the pathogenic form of the 
AR, Kemp et al. reported reduced retrograde axonal transport of cholera toxin 
subunit B (CTB)-labelled endosomes in the sciatic nerve (Kemp et al., 2011). 
However, mice overexpressing wild type AR were also found to exhibit retrograde 
axonal transport defects (Kemp et al., 2011). Later in the same year it was 
demonstrated that if the pathogenic form of AR is expressed at endogenous levels, 
the mice still have significant motor neuron loss but there are no overt retrograde 
transport deficits (Malik et al., 2011). Such findings raise the possibility that 
retrograde axonal transport deficits could be unique to ALS among the motor 
neuron diseases and may therefore have potential as an early biomarker for the 
disease.   
 
1.7.2.6. Amyotrophic Lateral Sclerosis 
There is evidence for both anterograde and retrograde axonal transport defects in 
ALS motor neurons. 
 
Anterograde axonal transport defects 
Defects in the anterograde axonal transport of a number of different cargoes have 
been reported in ALS model systems. Experiments performed in isolated squid 
axoplasm have shown that perfusion of fALS-linked SOD1 mutants (G93A, G85R, 
and H46R) causes a specific inhibition of anterograde axonal transport, with no 
effect on retrograde speeds (Morfini et al., 2013). However, the particular type of 
cargo affected was not identified in these studies. In cortical neurons, transfection 
with SOD1 mutants was found to cause defects in the anterograde axonal transport 
of mitochondria and APP (De Vos et al., 2007).  
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Deficits in anterograde axonal transport have also been reported in transgenic mice 
overexpressing mutant SOD1. In vivo axonal transport studies in the SOD1G93A 
mouse have revealed defects in the anterograde transport of mitochondria in the 
sciatic nerve at a presymptomatic stage (Bilsland et al., 2010). The authors were 
able to demonstrate that overexpression of the wild type form of SOD1 had no 
effect on anterograde axonal transport speeds. Defects in the anterograde axonal 
transport of mRNA have also been reported. Live imaging of Drosophila motor 
neurons revealed that ALS-associated TDP-43 mutants were not transported 
efficiently along axons and displayed a less continuous movement than wild type 
TDP-43 mRNA granules (Alami et al., 2014). Deficits were observed in the 
anterograde direction only. Similar results were also reported in mouse cortical 
neurons and induced pluripotent stem cell-derived human motor neurons carrying 
ALS-causing TDP-43 mutations (Alami et al., 2014).  
 
Retrograde axonal transport defects 
Deficits in retrograde axonal transport have been reported both in vitro and in vivo 
in ALS model systems. In vitro, mutant SOD1 has been shown to induce deficits in 
the retrograde axonal transport of mitochondria, APP and HCT (Kieran et al., 2005, 
De Vos et al., 2007). Bilsland et al. were the first to provide in vivo evidence of 
retrograde axonal transport defects in a mouse model of ALS (Bilsland et al., 2010). 
Using in vivo imaging of the sciatic nerve, they were able to demonstrate a 
significant inhibition in retrograde axonal transport in adult SOD1G93A mice 
compared to wild type controls. A similar defect was also seen in the retrograde 
axonal transport of the p75 neurotrophin receptor (p75NTR) and mitochondria. Of 
particular interest was the observation that retrograde axonal transport defects 
were found in motor but not sensory neurons and were present at a 
presymptomatic stage. Importantly, transgenic mice overexpressing the wild type 
form of SOD1 did not develop defects in retrograde axonal transport.  
 
The early appearance of transport deficits in SOD1G93A mice suggests that they 
may play a crucial role in triggering motor neuron dysfunction and the subsequent 
degeneration observed in ALS. However, the work of Bilsland et al. did not directly 
demonstrate the causal relationship between axonal transport defects and motor 
neuron degeneration. The importance of axonal transport deficits in ALS 
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pathogenesis is in fact still a matter of debate. Marinkovic et al. have proposed that 
axonal transport defects observed in the SOD1G93A mouse are not responsible for 
the degeneration of motor neurons (Marinkovic et al., 2012). In order to investigate 
the causative relationship between deficits in axonal transport and 
neurodegeneration, the group studied transgenic mice expressing the SOD1G85R 
mutation. SOD1G85R mutant mice exhibit progressive weight loss and muscle 
weakness at a preterminal stage, associated with significant denervation of muscle 
fibres. However, analysis of CTB-labelled endosomes in preterminal stage mice did 
not identify any significant deficits in either retrograde or anterograde axonal 
transport in either the intercostal or tibialis nerves. The authors concluded that 
axons are able to degenerate in the absence of axonal transport defects in the 
SOD1G85R mouse, marking the possible dissociation between transport deficits and 
motor neuron loss in ALS. However, the SOD1G85R mouse has not been as 
thoroughly studied as the SOD1G93A model. In addition, the mice demonstrate a 
variable disease progression suggesting that the SOD1G85R mouse could be a less 
reliable model of the human disease. Alternatively, axonal transport defects may 
only play a role in the pathogenesis of specific types of ALS. 
 
These studies highlight the need to demonstrate whether axonal transport defects 
are a true cause of ALS or simply a consequence of the pathology. Identifying 
compounds able to enhance retrograde axonal transport will help answer this 
question and may also shed light on the relative importance of retrograde versus 
anterograde axonal transport defects in ALS.  
 
1.8. Accelerating axonal transport as a therapeutic strategy for 
ALS 
A limited body of evidence already exists that suggests accelerating axonal 
transport could be beneficial in ALS.  
 
Inhibitors of HDAC6 have been described to accelerate anterograde and retrograde 
axonal transport and were mentioned previously in relation to their effects in PD 
and CMT2 mouse models in Sections 1.7.2.3 and 1.7.2.4. Taes et al. tested the 
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effect of deleting the HDAC6 gene in the SOD1G93A mouse model (Taes et al., 
2013). The authors found that loss of HDAC6 extended survival, but had no effect 
on disease onset. They also reported modest increases in motor neuron survival 
and neuromuscular junction innervation. The lack of effect on disease onset and 
modest beneficial effects reported could be due to the fact that HDAC6 also plays a 
major role in axonal regeneration and degradation of misfolded proteins (Simoes-
Pires et al., 2013). This is supported by the fact that knocking out HDAC6 in 
cultured cells has been shown to increase mutant SOD1 aggregation (Gal et al., 
2013). However, these results still provide promising evidence that accelerating 
axonal transport could be beneficial in ALS.  
 
Further genetic evidence for the beneficial effects of accelerating axonal transport 
in ALS comes from crossing SOD1G93A mice with heterozygous Loa mice, which 
carry a point mutation in the dynein heavy chain (Kieran et al., 2005). Primary 
motor neurons derived from Loa/SOD1G93A mice show a complete recovery of the 
retrograde axonal transport defects that are found in SOD1G93A motor neurons. In 
addition, Loa/SOD1G93A mice display delayed disease progression and an increase 
in lifespan compared to SOD1G93A controls. The molecular mechanism by which the 
Loa mutation affects axonal transport in SOD1G93A motor neurons is still unclear; 
especially as homozygous Loa mice display defects in retrograde axonal transport 
(Hafezparast et al., 2003). However, these results provide convincing evidence that 
retrograde axonal transport defects play a critical role in motor neuron 
degeneration in ALS and indicate that pharmacological enhancement of axonal 
transport could be beneficial.  
 
There have been very few studies investigating the effect of pharmacological 
enhancement of axonal transport on ALS pathogenesis. Davunetide (NAP) is an 
eight amino acid peptide that is derived from activity-dependent neuroprotective 
peptide (ADNP). Acute treatment of three-month-old SOD1G93A mice with 10 µg 
NAP was shown to normalise anterograde axonal transport in olfactory neurons to 
wild type speeds (Jouroukhin et al., 2013). The group reported that chronic 
treatment of early symptomatic SOD1G93A mice with 10 µg NAP per day 
significantly increased lifespan compared to saline treated controls (from 129.8 to 
134.2 days). However, the evidence for this minimal increase in survival was not 
Chapter 1 Introduction 
 46 
robust, as the gender and control groups used in the study were not balanced (7 
NAP treated and 4 saline treated females versus 17 NAP treated and 23 saline 
treated males) and a mean increase in survival of four days is unlikely to be 
biologically significant. Furthermore, the therapeutic potential of NAP is limited, as 
peptides are not suited for use as drugs due to their low bioavailability, metabolic 
instability and poor membrane permeability. This study highlights the need to 
identify small molecule drugs able to accelerate axonal transport in motor neurons 
and test them in well-designed preclinical trials. 
 
A final piece of evidence that suggests pharmacological enhancement of 
retrograde axonal transport could be beneficial in ALS comes from studies 
investigating the effects of acetyl-l-carnitine (ALCAR). ALCAR, which we found to 
accelerate retrograde axonal transport in motor neurons in vitro (see Figure 3.5), 
has been shown to be beneficial in the treatment of ALS patients. In a Phase II trial, 
patients treated with 100 mg/day riluzole and 3 g/day ALCAR were compared to 
patients treated with riluzole alone. Addition of ALCAR into the treatment regime 
was found to cause a slowing of functional decline, especially in the first six months, 
and was also seen to increase the median survival by 23 months (Beghi et al., 
2013). ALCAR has been previously described to be neuroprotective in vitro, and 
this was linked to its ability to potentiate aerobic energy metabolism (Forloni et al., 
1994) and enhance glutamate transporter activity, thereby reducing excitotoxicity 
(Jalal et al., 2010). It could be that ALCAR’s enhancing effect on retrograde axonal 
transport also contributes to its beneficial effects in ALS patients.  
 
Interestingly, it has been suggested that defects in mitochondrial axonal transport 
may not play a significant role in ALS pathogenesis. Knocking out syntaphilin, a 
docking receptor for axonal mitochondria, has been shown to increase the number 
of motile mitochondria without affecting the axonal transport of other cargoes. Zhu 
and Sheng crossed these syntaphilin knockouts with SOD1G93A mice. Although 
there was a significant increase in the number of motile mitochondria (shown in 
DRGs cultured from adult SOD1G93A mice), there was no effect on disease 
pathogenesis (Zhu and Sheng, 2011). However, the study did not demonstrate 
whether mitochondrial transport defects in motor neurons had been corrected.  
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This study highlights the need to consider the role of alterations in the axonal 
transport of different cargoes individually, rather than considering the process as a 
whole. This could have important implications when looking to modify axonal 
transport as a therapeutic strategy for ALS and also other neurodegenerative 
diseases.  
 
1.9. Aims of this thesis 
The aims of this PhD project were to: 
 
i. Develop and validate a screen to identify pharmacological enhancers of 
retrograde axonal transport in motor neurons 
ii. Screen a small library of kinase inhibitors for novel enhancers of retrograde 
axonal transport 
iii. Validate the effects of hit compounds on axonal transport in vitro in wild type 
and SOD1G93A motor neurons 
iv. Determine the effect of hit compounds on retrograde axonal transport in vivo 
in early symptomatic SOD1G93A mice 
v. Investigate the mechanism of action of hit compounds 
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Chapter 2. Materials and Methods 
2.1. Materials 
2.1.1. Reagents and media 
Reagents were purchased from Sigma Aldrich unless otherwise stated. Distilled 
water (dH2O), phosphate buffered saline (PBS), Hank’s, penicillin/streptomycin 
(Pen/Strep), SOC medium and ethylenediaminetetraacetic acid (EDTA) were 
provided by Cancer Research UK Laboratory Services. Ciliobrevin A was from 
InterBioScreen, SB-239063 and SB-203580 were supplied by GlaxoSmithKline, 
anisomycin was from Cell Signalling, picropodophyllotoxin was from Tocris and the 
NAP peptide and scrambled control were synthesised by the Cancer Research UK 
Peptide Synthesis service.  
 
2.1.2. Bacterial Strains 
E.coli strain XL1Blue was used for DNA amplification. 
 
2.1.3. Antibodies 
Fluorescently conjugated secondary antibodies for immunofluorescence were 
purchased from Invitrogen and were used at a dilution of 1:400.  
 
HRP-conjugated secondary antibodies for western blotting were from DAKO and 
were used at a dilution of 1:4000. 
 
The primary antibodies that were used in this thesis are listed in Table 3. 
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Table 3. Primary antibodies used 
 
Antigen Antibody Name Supplier Dilution 
Akt 9272 Cell Signalling 1:1000 WB 
p-Akt (Ser473) D9E Cell Signalling 1:1000 WB 
β-actin AC40 Sigma 1:2000 WB 
β-III-tubulin Tuj1 Covance 1:1000 IF 
ERK1/2 9102 Cell Signalling 1:1000 WB 
pERK1/2 
(Thr202/Tyr204) 
9101 Cell Signalling 1:1000 WB 
GAPDH mab374 Millipore  1:5000 WB 
GFP 4E12/8 
CRUK monoclonal 
facility 
1:2000 WB 
p-IGF1R 
(Tyr1161/Tyr1165/ 
Tyr1166) 
ABE332 Millipore 1:1000 WB 
Pan p38 MAPK  9212 Cell Signalling 
1:50 IF 
1:1000 WB 
p-p38 MAPK 
(Thr180/Tyr182) 
4511 Cell Signalling 
1:200 IF 
1:800 WB 
p38 MAPK alpha 9218 Cell Signalling 1:1000 WB 
p38 MAPK beta PA1-41154 Pierce 1:1000 WB 
p38 MAPK gamma 2307 Cell Signalling 1:1000 WB 
p38 MAPK delta 2308 Cell Signalling 1:1000 WB 
p75NTR CRD  
(0.8 mg/ml) 
5410 
Molecular 
Neuropathobiology 
Laboratory, CRUK 
1:4000 IF 
Rab7 sc-376362 Santa Cruz 1:200 IF 
SOD1 ab16831 Abcam 1:2000 WB 
 
IF: immunofluorescence, WB: western blot 
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2.1.4. Primers used 
The following primers were used for genotyping mice. 
Control  IMR 0042 and IMR 0043 
SOD1 mice  IMR 0113 and IMR 0114 
 
Primer sequences: 
Name:  IMR0042 
Sequence: 5'-   CTA GGC CAC AGA ATT GAA AGA TCT   -3' 
 
Name:  IMR0043 
Sequence: 5'-   GTA GGT GGA AAT TCT AGC ATC ATC  -3' 
 
Name:  IMR0113 
Sequence: 5'-   CAT CAG CCC TAA TCC ATC TGA   -3' 
 
Name:  IMR0114 
Sequence: 5'-   CGC GAC TAA CAA TCA AAG TGA   -3' 
 
2.1.5. Sequences of shRNA used 
All shRNA constructs were purchased from GeneCopoeia’s OmicsLink library and 
were expressed using the psi-LVRU6GP vector, under the control of the U6 
promoter. The vector map for all shRNA constructs is shown below: 
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The sequences of individual shRNAs are listed below: 
 
Clone Name Target Target Sequence 
MSH030694-1-LVRU6GP(OS342165) MAPK13 agcttccatgatttctacc 
MSH030694-2-LVRU6GP(OS342166) MAPK13 gacagacctacagaagatc 
MSH030694-3-LVRU6GP(OS342167) MAPK13 aggtccagtacttggtgta 
MSH030694-4-LVRU6GP(OS342168) MAPK13 ccagatcctgaaagtgact 
MSH030695-1-LVRU6GP(OS303957) MAPK14 tgaccggaagaacgttgtt 
MSH030695-2-LVRU6GP(OS303958) MAPK14 atgaccagtcctttgaaag 
MSH030695-3-LVRU6GP(OS303959) MAPK14 agagcctgacctatgatga 
MSH030695-4-LVRU6GP(OS303960) MAPK14 ctgcctttaccatatcagt 
MSH029442-1-LVRU6GP(OS202113) IGF1R tcgagatgaccaatctcaa 
MSH029442-2-LVRU6GP(OS300906) IGF1R gagaggcaataacattgcc 
MSH029442-3-LVRU6GP(OS300907) IGF1R gtccggaaagatgtacttt 
MSH029442-4-LVRU6GP(OS300908) IGF1R caacggattgatcctaatg 
 
2.1.6. Kinase inhibitor libraries 
Table 4 and Table 5 report the kinase inhibitors supplied by GlaxoSmithKline for 
the accumulation assay screen. All compounds were supplied as 10 mM stocks in 
DMSO and stored at -20°C.  
 
2.1.6.1. Preliminary screen 
Table 4. Library of kinase inhibitors used for the preliminary screen 
 
Reference GSK Reg. No. Primary Target 
2A1 GW693481X TGFBR 
2A2 GW572738X JNK 
3A1 GSK200398A EGFR/ErbB2 
3A2 GW651576X EGFR/ErbB2 
A1 SB-239272 p38 MAPK 
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A2 GSK248233A RHO 
A3 GW296115X PDGFR 
A4 GW589961A TIE2/VEGFR2 
A5 GW806742X VEGFR 
A6 GSK586581A IKK 
A7 GW410563A VEGFR 
B1 GW801372X GSK3 
B2 SB-772077-B RHO 
B3 SB-400868-A TGFBR 
B4 SB-220025-A p38 MAPK 
B5 GI261520A EGFR/ErbB2 
B6 GW824645A CDK2 
B7 GSK1023156A PLK 
C1 GW679410X TGFBR 
C2 SB-675259-M GSK3 
C3 GW440139A RET 
C4 GW820759X p38 MAPK 
C5 GW642125X TIE2/VEGFR2 
C6 GW275616X TRKA 
C7 GW406731X RAF 
D1 GW549390X VEGFR 
D2 GW561436X p38 MAPK 
D3 GW768505A TIE2/VEGFR2 
D4 GW856804X TIE2/VEGFR2 
D5 GW461104A EGFR/ErbB2 
D6 GSK180736A RHO 
D7 GW559768X RET 
E1 GW575808A LCK 
E2 GSK319347A IKK 
E3 GW743024X p38 MAPK 
E4 GSK1713088A IGF-1R 
E5 GSK1000163A AKT 
E6 GSK237700A PLK 
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F1 GW632580X CSF 
F2 GW837331X PLK 
F3 SB-358518 GSK3 
F4 GW275944X CDK2 
F5 GSK554170A AKT 
F6 GW513184X GSK3 
G1 GSK317354A RHO 
G2 GW284372X EGFR/ErbB2 
G3 SB-437013 TIE2 
G4 GW305074X RAF 
G5 SB-737198 MSK 
G6 GSK1173862A IGF-1R 
H1 GW819230X GSK3 
H2 SB-744941 MSK 
H3 SB-725317 GSK3 
H4 GSK182497A EGFR/ErbB2 
H5 GR105659X TRKA 
H6 GSK953913A IKK 
 
2.1.6.2. Target Validation Screen  
Table 5. Library of kinase inhibitors used for the target validation screen 
 
Reference GSK Reg. No. Primary Target 
A1 SB-226879 p38 MAPK 
A2 GW775608X p38 MAPK 
A3 GW796921X p38 MAPK 
B1 SB-221466 p38 MAPK 
B2 GW581744X p38 MAPK 
B3 GSK1511931A IGF-1R 
C1 GSK2186269A IGF-1R 
C2 GW607117X p38 MAPK 
C3 SB-223133 p38 MAPK 
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D1 GW618013A p38 MAPK 
D2 SB-242719 p38 MAPK 
D3 GW434756X p38 MAPK 
E1 GSK1326255A IGF-1R 
E2 GW734508X p38 MAPK 
F1 GSK1220512A IGF-1R 
F2 GSK1819799A IGF-1R 
G1 GW769076X p38 MAPK 
G2 GSK2163632A IGF-1R 
H1 GW569293E p38 MAPK 
H2 GW782907X p38 MAPK 
 
2.1.7. Eukaryotic cell lines 
Mouse neuroblastoma N2A cells and Lenti-X 293T (HEK) cells were maintained in 
adherent conditions. Hb9-GFP mouse embryonic stem cells were a gift from 
T.Jessell and H.Wichterle (Columbia University, New York, USA) (Wichterle et al., 
2002). 
 
2.1.8. Animals 
Transgenic mice carrying a human wild-type SOD1 (B6SJLTg[SOD1]2Gur/J; 
SOD1WT) or mutant SOD1G93A (Tg[SOD1-G93A]1Gur) gene were originally obtained 
from Jackson Laboratories. Colonies were maintained at the UCL Institute of 
Neurology Biological Services Unit by breeding male heterozygotes with female 
(C57BL/6 x SJL) F1 hybrids. Animals were housed in a controlled temperature and 
humidity environment and maintained on a 12 h light/dark cycle with access to food 
and water provided ad libitum. 
 
All experiments were carried out under license from the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act 1986 and the GSK Policy 
on the Care, Welfare and Treatment of Animals and were approved by the Institute 
of Neurology Ethical Review Committee. 
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2.2. Methods 
2.2.1. Bacterial cultures 
2.2.1.1. Preparation of chemically competent bacteria 
E.coli XL1Blue were grown in 5 ml Luria Bertani (LB) medium overnight at 37°C, 
then expanded in an additional 500 ml of LB medium. The bacterial cultures were 
incubated at 37°C until an optical density (OD600) of 0.35 was achieved. Bacteria 
were centrifuged at 3000g for 15 min at 4°C using a JA-10 rotor (Beckman) and the 
pellet resuspended in 400 ml ice-cold MgCl2. Cells were harvested by 
centrifugation at 2000g for 15 min at 4°C and the pellet resuspended in 200 ml ice-
cold CaCl2. This suspension was incubated on ice for 20 min. The suspension was 
then centrifuged at 2000g for 15 min at 4°C and the pellet resuspended in 40 ml 
ice-cold 85 mM CaCl2, 15% glycerol and transferred to a 50 ml falcon. Cells were 
then harvested by centrifugation at 1000g for 15 min at 4°C using a GH-3.8 rotor 
(Beckman) and resuspended in 2 ml ice-cold 85 mM CaCl2, 15% glycerol. The final 
OD600 of the suspension was around 200. Finally the suspension was aliquoted and 
stored at -80°C.  
 
2.2.1.2. Bacterial transformation 
For each construct, 10 µl competent bacteria were diluted in 40 µl 100 mM CaCl2, 
20 % glycerol and 1 µl DNA added. The mix was incubated on ice for 30 min and 
then heat shocked at 42°C for 70 seconds. Bacteria were chilled on ice for 2 min 
and then 200 µl SOC medium was added. The bacteria were shaken at 37°C for 
1 h and 10 µl of the culture plated on a pre-warmed LB agar plate containing 
ampicillin (100 µg/ml). Bacteria were grown overnight at 37°C and single colonies 
then picked and expanded in an appropriate volume of LB medium containing 
100 µg/ml ampicillin.  
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2.2.2. Nucleic acid techniques  
2.2.2.1. Isolation of plasmid DNA 
Plasmid DNA was purified from bacterial cultures using either the QIAprep Spin 
Mini Prep kit or Maxi Prep kit according to the manufacturer’s instructions. 
 
2.2.2.2. Nucleic acid quantification 
Isolated DNA was diluted in TE Buffer (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA) 
and its optical density at 260 (OD260) measured using a Nanodrop 
spectrophotometer (Labtech International). 1 unit of OD260 corresponds to 50 mg/ml 
of double-stranded DNA.  
 
2.2.2.3. Extraction of genomic DNA 
Adult mouse ear snips and embryo tails were lysed overnight in 120 µl DirectPCR 
Lysis Reagent (Viagen Biotech) with 0.1 mg/ml Proteinase K in a shaking hot block 
at 55°C. The reaction was then inactivated at 95°C for 30 min.  
 
2.2.2.4. Genotyping PCR 
Genotyping was carried out using MegaMix Blue (Microzone Ltd.), a PCR 
mastermix containing recombinant Taq polymerase. 15 µl MegaMix Blue, 0.25 µl of 
each primer pair and 1 µl genomic DNA was used for each PCR reaction. The 
genotyping PCR programme used is shown below: 
 
Step Function Temperature Time (min) 
1 Denaturation 95°C 3:00 
2 Denaturation 95°C 0:30 
3 Annealing 60°C 0:30 
4 Extension 72°C 0:45 
5 Repeat steps 2 à 4 35 times  
6 Final extension 72°C 2:00 
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An example of the PCR products obtained is shown in Figure 2.1.  
 
 
 
Figure 2.1. Genotyping of SOD1G93A and SOD1WT mice 
The presence of the SOD1 gene was detected using IMR0113 and IMR 0114 primers and seen 
as a product at 236 bp. IMR 0042 and IMR 0043 primers were used as a control for the 
presence of DNA and yield a band at 324 bp. 
 
2.2.2.5. DNA agarose electrophoresis 
Electrophoresis was performed using 2% agarose gels in TBE (90 mM Tris-HCl, 
90 mM boric acid, 2 mM EDTA pH 8.0) with ethidium bromide (0.5 µg/ml). Samples 
were either mixed with 10X DNA loading buffer (10% Ficoll 400, 25% glycerol, 
10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.25% bromophenol blue) or loaded directly 
(genotyping PCR DNA). Samples were electrophoresed at 150 V for 40 min in TBE 
buffer.  
2.2.3. Cell culture techniques 
2.2.3.1. Culture of undifferentiated mouse embryonic stem (ES) cells 
Prior to cell plating, tissue culture flasks were coated in 0.2% fish skin gelatin 
(diluted in distilled water) at room temperature for at least 30 min. Excess gelatin 
was removed just before plating cells. ES cells were maintained at 37°C and 5% 
CO2 in growth medium composed of Glasgow MEM (GMEM), 5% ES-cell tested 
foetal bovine serum (FBS), 5% knockout serum replacement (Gibco), 1% 
GlutaMAX, 0.1 mM β-mercaptoethanol and 1000 units/ml leucocyte inhibitory factor 
(LIF). ES cells were passaged every other day. Growth medium was removed and 
ES cells were trypsinised with 0.05% trypsin/versene for 1 minute at 37°C. Cells 
were resuspended in growth medium and pelleted by centrifugation at 1000 rpm for 
3 min. The cells were resuspended in growth medium and plated. ES cells were fed 
on alternate days.  
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2.2.3.2. Differentiation of mouse ES cells into motor neurons 
ES cells were trypsinised, resuspended in growth medium and counted. 1.2 x 106 
cells were centrifuged at 1000 rpm for 3 min, washed in differentiation medium 
(DFNK), comprising DMEM/F12, Neurobasal, 10% knockout serum replacement, 
1% GlutaMAX and 0.1 mM β-mercaptoethanol, and finally resuspended in 6 ml 
DFNK. Resuspended cells were plated in 50 mm petri dishes and incubated at 
37°C with 5% CO2. 
 
The day after seeding, the forming embryoid bodies were centrifuged at 1000 rpm 
for 3 min, resuspended in 10 ml fresh DFNK and plated in a fresh dish. On the 
following day, embryoid bodies were allowed to settle by gravity and then 
resuspended in fresh DFNK supplemented with 1 µM all-trans retinoic acid (RA) 
and 333 nM sonic hedgehog agonist (SAG). DFNK containing RA and SAG was 
replaced every day until the embryoid bodies were dissociated.  
 
2.2.3.3. Dissociation of embryoid bodies 
Embryoid bodies were allowed to settle and were then washed in PBS. Embryoid 
bodies were resuspended in 1 ml PBS and dissociated by incubation with 10 µl of 
2.5% trypsin in PBS (final concentration 0.025%) for 10 min at 37°C, followed by 
trituration. Once dissociated, the cells were triturated in 1 ml Leibovitz 15 (L-15) 
medium containing 0.1 mg/ml DNase and 0.4% bovine serum albumin (BSA) and 
any fragments were allowed to settle. The supernatant was then transferred to 1ml 
Leibovitz 15 (L-15) medium containing 0.02 mg/ml DNase and 0.4% BSA and 
triturated further if necessary. A 1.5 ml BSA cushion (4% BSA in L-15) was applied 
and the cell suspension centrifuged for 5 min at 1000 rpm. The resulting cell pellet 
was resuspended in 1 ml motor neuron medium (see Section 2.2.3.7) and 
centrifuged at 1000 rpm for 1 min. The resulting pellet was resuspended in 10 ml 
motor neuron medium supplemented with 1 µM retinoic acid and the number of 
cells counted. The cells were then plated on poly-ornithine/laminin coated dishes.  
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2.2.3.4. N2A and HEK cell culture 
N2A and HEK cells were maintained in culture medium (DMEM, 10% horse serum, 
2 mM glutamine) at 37°C in a 5% CO2 incubator. When cells became confluent, the 
medium was removed, the cells washed once with PBS and then detached using 
trypsin. Trypsin was inhibited by addition of culture medium. Resuspended cells 
were centrifuged at 1000 rpm for 3 min at 24°C and then plated in fresh tissue 
culture flasks.  
 
2.2.3.5. Coating of plates, dishes and coverslips for motor neuron cultures 
Plates, dishes and coverslips were coated overnight at 37°C with poly-ornithine 
(1.5 mg/ml diluted in distilled H2O). The poly-ornithine was removed, and laminin 
(3 µg/ml diluted in Neurobasal medium) was added for 4 h at 37°C. Just before 
plating, the laminin was removed and the dishes/coverslips/plates washed with 
Neurobasal medium.  
 
2.2.3.6. Isolation of mouse spinal cord motor neurons 
Motor neurons were isolated from the spinal cords of E11.5-13.5 mouse embryos 
(Arce et al., 1999). Embryos were sacrificed and the spinal cords dissected in 
HBSS containing Penicillin/Streptomycin antibiotics (Pen/Strep). The meninges and 
dorsal horns were removed and the remaining ventral horns minced and collected 
in 500 µl HBSS. Ventral horns from each embryo were collected in separate tubes 
in order to prevent contamination of different genotypes. Ventral horns were 
dissociated by incubation with 0.025% trypsin in PBS for 10 min at 37°C, followed 
by trituration. Once dissociated, the cells were triturated in 1 ml Leibovitz 15 (L-15) 
medium containing 0.1 mg/ml DNase and 0.4% BSA, and then 1ml Leibovitz 15 
(L-15) medium containing 0.02 mg/ml DNase and 0.4% BSA was added. A 1 ml 
BSA cushion (4% BSA in L-15) was applied and the cell suspension centrifuged for 
5 min at 1500 rpm. The resulting cell pellet was resuspended in 100 µl L-15. 500 µl 
motor neuron medium (see Section 2.2.3.7) was then added and the cells 
immediately plated on poly-ornithine/laminin coated dishes. 	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2.2.3.7. Maintenance of primary motor neuron cultures 
Primary motor neurons were maintained at 37°C and 5% CO2 in motor neuron 
medium comprising Neurobasal (Gibco), 2% v/v B27 supplement (Gibco), 2% heat 
inactivated horse serum, 1% GlutaMAX (Invitrogen), 25 µM β-mercaptoethanol, 
10 mg/ml recombinant rat ciliary neurotrophic factor (CNTF; R&D Systems), 
100 pg/ml recombinant rat glial derived neurotrophic factor (GNTF; R&D Systems), 
1 ng/ml recombinant human brain derived neurotrophic factor (BDNF; R&D 
Systems) and Pen/Strep. Motor neurons were maintained in culture for 5-8 days.  
 
2.2.3.8. Preparation of microfluidic chambers 
Microfluidic chambers were prepared at the Cui laboratory (Stanford, CA), as 
previously described (Zhang et al., 2010). Briefly, two compartment microfluidic 
chips were made out of polydimethyl silane (PDMS) and washed with detergent 
followed by distilled water and then sterilized by autoclaving before use. 
Microfluidic devices were constructed by pressing the PDMS chips onto the PLL-
coated coverslips.  
 
2.2.3.9. Primary hippocampal neuron cultures 
Prior to dissection, glass coverslips were coated with 0.2 mg/ml poly-L-lysine 
(diluted in dH2O) overnight at 37°C. Coverslips were then washed in distilled H2O 
and allowed to dry.  
 
E18 wild type rat embryos were sacrificed and their brains extracted. The meninges 
were removed, the brain bisected, the cerebellum removed and the hippocampus 
isolated from each hemisphere of the cerebrum. The hippocampi were collected on 
ice in HBSS containing Pen/Strep.  
 
Hippocampi were incubated with 0.025% trypsin at 37°C for 8 min. The trypsinised 
hippocampi were then centrifuged at 1000 rpm for 5 min, and the supernatant 
removed. The hippocampi were resuspended in hippocampal plating medium 
(Neurobasal, 2% v/v B27 supplement, 0.5 mM glutamine, 25 µM glutamate, 
Chapter 2 Materials and Methods 
 
 61 
1 mM HEPES, 10% heat inactivated FBS and Pen/Strep) and mechanically 
dissociated by trituration. Fragments were allowed to settle, the supernatant 
transferred to a fresh tube and the neurons plated on the cell body side of 
microfluidic chambers and incubated at 37°C with 5% CO2. After 2-4 h the plating 
medium was replaced with differentiation medium (Neurobasal, 2% v/v B27 
supplement, 0.5 mM glutamine, 1 mM HEPEs and Pen/Strep). Once the medium 
had flowed through the microgrooves, differentiation medium was added to the 
axonal side. Hippocampal neurons were maintained in culture for 7-10 days. 
 
2.2.3.10. Primary dorsal root ganglion (DRG) cultures 
Primary DRG cultures were prepared by James Sleigh (Institute of Neurology, 
UCL) as previously described (Malin et al., 2007) but with minor alterations. Briefly, 
≈20 thoracic and lumbar DRG ganglia were dissected from 3 month-old wild-type 
mice in Ca2+/Mg2+-free Hank's Balanced Salt Solution (Life Technologies) 
supplemented with 1% Penicillin-Streptomycin. To produce single cell cultures, 
DRG were enzymatically digested for 10 min in papain solution (60 U papain 
[Worthington 3126], 1 mg/ml L-cysteine, and 0.2 mg/ml NaHCO3 in HBSS) followed 
by 10 min in collagenase/dispase solution (4 mg/ml collagenase type II 
[Worthington 4176] and 4.67 mg/ml dispase II in HBSS). Cells were plated onto 
MatTek dishes coated with 20 µg/ml poly-D-lysine (BD Biosciences) overnight at 
4°C followed by 20 µg/ml laminin for 4-6 h at 37°C. DRG cultures were maintained 
for 48 h in F12 media (Life Technologies) supplemented with 10% FBS, 1% 
Pen/Strep, 20 ng/ml mouse GDNF, and 50 ng/ml mouse nerve growth factor (NGF; 
Peprotech) before imaging. 
 
2.2.4. Harvesting of mouse tissue 
2.2.4.1. Spinal cord collection 
Mice were anaesthetised by i.p. injection of Euthatal (150 mg/kg) and transcardially 
perfused with PBS. Spinal cords were dissected and then snap-frozen in liquid 
nitrogen and stored at -80°C.   
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2.2.4.2. Cryosectioning of sciatic nerves 
Sciatic nerves from both hind legs were dissected and fixed in 4% 
paraformaldehyde (PFA) in PBS for 15 min at room temperature. Sciatic nerves 
were then transferred to 20% sucrose in PBS and incubated overnight at 4°C. 
Samples were then embedded in OCT tissue freezing medium and 20 µm sections 
cut on the cryostat. DAPI was applied for 10 min at room temperature and the 
samples were washed with PBST three times for 5 min each. Samples were then 
post-fixed in 4% PFA in PBS for 30 min at room temperature and mounted using 
Dako fluorescent mounting medium.  
 
2.2.5. Protein techniques 
2.2.5.1. Cell lysate preparation 
Cells were cooled on ice and washed with ice-cold Hanks. Cells were then scraped 
in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS) containing Halt phosphatase and protease inhibitor 
cocktail (1:100, Pierce Biotechnology) and the lysate incubated on ice for 20 min. 
Lysates were then spun at 14000 rpm for 20 min and the pellet discarded. 
 
2.2.5.2. Spinal cord lysate preparation 
Spinal cords were defrosted on ice then homogenised in RIPA buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 2% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM 
EDTA) containing Halt phosphatase and protease inhibitor cocktail. The lysate was 
incubated on ice for 20 min and then spun at 14000 rpm for 20 min and the pellet 
discarded. 
 
2.2.5.3. Protein quantification 
The protein content of cell lysates was determined using the Bio-Rad protein assay 
reagent. Briefly, dilutions of the lysate and BSA standards were made in 200 µl of 
the assay reagent (dilute 1 to 4 in distilled water) in a 96 well NUNC plate. The 
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absorption at 595 nm was then measured using a Fluostar Omega plate reader 
(BMG Labtech). The absorption profile of the BSA standards was used to 
determine the protein concentration of lysates.    
 
The protein content of the spinal cord lysates was determined using the BCA assay 
(Pierce Biotechnology) according to the manufacturer’s instructions using BSA as 
standard.  
 
2.2.5.4. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples were mixed with 5X Laemmli sample buffer (15% SDS, 312.5 mM 
Tris-HCl pH 6.8, 50% glycerol, 16% β-mercaptoethanol, 0.1% bromophenol blue) 
and incubated at 100°C for 4 min. SDS-PAGE was performed using 4–12% 
NuPAGE Bis-Tris gradient gels (Life Technologies) and MOPS buffer (Invitrogen) 
according to the manufacturer's instructions. Gels were run at 60 V for 10 min then 
at 200 V for 60 min.  
 
2.2.5.5. Western blotting 
Proteins were transferred onto methanol-activated polyvinylidene fluoride (PVDF) 
membranes (Millipore) in NuPAGE transfer buffer (Invitrogen) containing 10% 
methanol. Transfers were performed either at room temperature for 3 h at 30V or at 
4°C overnight at 15V. Membranes were blocked in 5% BSA dissolved in Tris-
buffered saline containing 0.5% Tween-20 (TBST) for 1 h at 4°C and then 
incubated with primary antibodies either overnight at 4°C or at room temperature 
for 1 h. Blots were washed 4 times for 5 min each with TBST and then incubated 
with the appropriate HRP-conjugated secondary antibodies (GE Healthcare) diluted 
in 5% milk in TBST. Finally blots were washed 4 times for 5 min each with TBST, 
rinsed once in distilled water and the immunoreactivity detected using Crescendo 
ECL substrates (Millipore) and Fujifilm X-ray films (Fisher Scientific). Films were 
scanned and the intensity of bands analysed using ImageJ software.  
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2.2.5.6. Fluorescent labelling of HCT with AlexaFluor dyes 
1.5 mg HCT protein was diluted in labelling buffer (10 mM HEPES-NaOH pH 7.4, 
250 mM NaCl) containing a 10X molar excess of tris-(2-carboxyethyl)phosphine 
hydrochloride (TCEP). The reaction mixture was incubated for 30 min at 4°C and 
then a 25X molar excess of AlexaFluor 647 C2 Maleimide or AlexaFluor 555 C2 
Maleimide in DMSO (Invitrogen) was added under stirring. The resulting mixture 
was incubated at 4°C overnight in the dark with constant agitation. The labelling 
reaction was stopped by addition of 4 mM reduced glutathione in Tris-HCl (pH 8.0). 
The labelled protein was isolated from free dye using a PD10 desalting column (GE 
Healthcare), equilibrated with ice-cold PBS, according to the manufacturer’s 
instructions and then dialysed over three days against ice-cold dialysis buffer 
(10 mM HEPES-NaOH, 100 mM NaCl, pH 7.4) at 4°C in the dark. Finally the 
labelled protein was concentrated using an Amicon Ultra-0.5 filter device (EMD 
Millipore) according to the manufacturer’s instructions and then aliquoted, snap 
frozen in liquid nitrogen and stored at -80°C.   
 
2.2.5.7. Fluorescent labelling of the p75NTR antibody with AlexaFluor dyes 
p75NTR antibody (α-p75NTR) raised against the extracellular domain of the p75NTR 
(batch 5410, 0.8 mg/ml) (Deinhardt et al., 2007) was dialysed in PBS at 4°C under 
stirring for 48 h to remove glycine present in the storage buffer. The antibody was 
then concentrated using an Amicon Ultra-0.5 filter device (EMD Millipore) according 
to the manufacturer’s instructions until a final concentration of 1 mg/ml was 
achieved. The antibody was then labelled using the AlexaFluor 647 monoclonal 
antibody labelling kit (Life Technologies) according to the manufacturer’s 
instructions. The concentration of the labelled antibody was determined using a 
Nanodrop spectrophotometer (Labtech International) and the antibody then stored 
at 4°C in the dark.  
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2.2.6. Cell-based assays 
2.2.6.1. HCT and α-p75NTR binding assay 
Motor neurons plated on coverslips were cooled on ice for 2 min, the medium 
removed and ice-cold motor neuron medium containing 20 nM AlexaFluor 555-
conjugated HCT and 0.2 µg/ml α-p75NTR antibody added. Motor neurons were then 
incubated at 4°C for 10 min, washed twice with ice-cold Hanks and fixed on ice in 
4% PFA in PBS for 15 min. After fixation, motor neurons were washed once with 
PBS. 
 
2.2.6.2. HCT and α-p75NTR accumulation assay 
For the accumulation assay screening, ES cell-derived motor neurons were plated 
on poly-ornithine/laminin-coated 24 well glass bottom plates (MatTek Corporation) 
and the assay was performed 3 days after dissociation of embryoid bodies. 
 
Motor neurons were cooled on ice for 2 min, the medium removed and fresh motor 
neuron medium containing 20 nM AlexaFluor 555-conjugated HCT and 0.2 µg/ml 
α-p75NTR added. Motor neurons were then incubated at 37°C, 5% CO2 for 2 h.   
 
After 2 h, motor neurons were cooled on ice for 5 min, acid washed on ice with a 
solution of 100 mM citrate-NaOH, 142 mM NaCl (pH 2.0) for 1.5 min, washed twice 
with ice-cold Hanks and then fixed with 4% PFA in PBS for 15 min at room 
temperature. After fixation, motor neurons were washed once with PBS. 
 
2.2.6.3. HCT and α-p75NTR internalisation assay 
Motor neurons were cooled on ice for 2 min, the medium removed and fresh motor 
neuron medium containing 20 nM AlexaFluor 555-conjugated HCT and 0.2 µg/ml 
α-p75NTR added. Motor neurons were then incubated at 37°C, 5% CO2 for 20 min, 
to allow for internalisation of the probes but before axonal transport was significant. 
Motor neurons were then cooled on ice for 5 min, acid washed on ice (as described 
in Section 2.2.6.2) for 1.5 min, washed twice with ice-cold Hank’s and then fixed 
Chapter 2 Materials and Methods 
 
 66 
with 4% PFA in PBS for 15 min at room temperature. After fixation, motor neurons 
were washed once with PBS. 
 
2.2.6.4. Transfection of N2A cells with shRNA 
N2A cells in 6 well plates were transfected with 2.5 µg DNA using Lipofectamine 
3000 according to the manufacturer’s instructions. N2A cells were incubated 
overnight with the transfection mix and then fresh medium was applied. Cells were 
assayed after 3 days.  
 
2.2.6.5. Production of lentiviral shRNA particles 
shRNA constructs directed against p38 MAPKα and δ and scrambled controls were 
purchased from the GeneCopoeia OmicsLink™ shRNA clone collection (all 
constructs were in psi-LVRU6GP plasmids with an eGFP reporter gene). HEK239 
cells were co-transfected with shRNA, packaging, and envelope plasmid vectors 
using Lipofectamine 3000 (Life Technologies) according to the manufacturer’s 
instructions.  Medium containing lentiviral particles was collected every day for 
3 days after transfection. Medium containing viral particles was then concentrated 
using LentiX Concentrator (ClonTech) according to the manufacturer’s instructions 
and the concentrated lentiviral particles resuspended in complete MN medium. 
Lentiviral particles were aliquoted and stored at −80°C until further use. The 
lentivirus titre was determined using the Lenti-X p24 Rapid Titre kit (ClonTech) and 
the concentration was adjusted so that the titre of all lentiviral shRNA preparations 
was equal. 
 
2.2.6.6. Transduction of primary motor neurons 
To transduce primary motor neurons, lentivirus was added to the culture medium 
6 h after plating. The medium was replaced with fresh motor neuron medium 16 h 
after transduction, and motor neurons were assayed 1 week later. 
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2.2.7. Imaging techniques 
2.2.7.1. Immunocytochemistry and confocal imaging of fixed samples on 
coverslips 
Cells on coverslips were fixed in 4% PFA in PBS for 15 min at room temperature. 
Coverslips were then washed with PBS and permeabilised and blocked for 1 h in a 
solution of 5% BSA and 0.1% Triton X-100 in PBS. Primary antibodies were diluted 
in 5% BSA in PBS and incubated overnight at 4°C. Coverslips were washed 3 
times in 5% BSA, then incubated with the appropriate fluorescently conjugated 
secondary antibodies diluted in 5% BSA for 1 h at room temperature. Finally 
coverslips were washed 3 times with PBS, once with water and then mounted 
using Mowiol-488. Coverslips were imaged with either an invert Zeiss LSM 780 
confocal microscope using either the 40X EC Plan-Neofluar oil immersion objective 
with a numerical aperture (NA) of 1.3 or a 63X Plan-Apochromat oil immersion 
objective with an NA of 1.4. Immunofluorescence staining was quantified using 
ImageJ.  
 
2.2.7.2. Immunocytochemistry and confocal imaging of fixed samples in 24 
well glass-bottom plates 
After fixation, motor neurons were blocked and permeabilised using a solution of 
10% goat serum, 2% BSA, 0.25% fish skin gelatin and 0.1% Triton X-100 in PBS 
for 1 h at room temperature. The motor neurons were then stained with AlexaFluor 
647-conjugated donkey anti-rabbit secondary antibody diluted in 10% goat serum, 
2% BSA and 0.25% fish skin gelatin in PBS for 45 min at room temperature. Finally 
motor neurons were washed 3 times with PBS and the plates sealed with parafilm 
and stored in the dark at 4°C until they were imaged.  
 
24 well plates were imaged on an invert Zeiss LSM 510 microscope equipped with 
a 40X Plan-Apochromat oil immersion objective with an NA of 1.4. The Zeiss LSM 
510 had an automated stage that, when used in combination with the Multi Field 
Acquisition (MTS) macro, allowed automated image acquisition to be performed 
overnight. The autofocus function of the MTS macro allowed the focal plane to be 
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determined using the GFP channel (i.e. focusing specifically on the motor neurons) 
and a tile of 36 images was acquired per well.  
 
2.2.7.3. Live in vitro axonal transport assays 
For in vitro assays, motor neurons were plated on poly-ornithine/laminin coated 
35 mm glass bottom MatTek dishes. Assays were performed 3-5 days after 
embryoid body dissociation (ES cell-derived motor neurons) or 5-8 days after 
plating (primary motor neurons). Motor neurons were incubated with either 40 nM 
AlexaFluor 555 or 647-conjugated HCT, 1 µg/ml AlexaFluor 647-conjugated 
α-p75NTR or 100 nM LysoTracker Red DND-99 (Life Technologies) for 25 min at 
37°C, 5% CO2. For samples treated with experimental compounds, the compounds 
were applied at the same time as the HCT or α-p75NTR probe. For control samples, 
DMSO was added at this time. After 25 min, motor neurons were washed once with 
pre-warmed motor neuron medium and then imaged in 2 ml fresh pre-warmed 
motor neuron medium or imaging medium (156 mM NaCl, 10 mM HEPES, 10 mM 
D-glucose, 3 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM KH2PO4, pH 7.35) 
containing the selected compound. MatTek dishes were then placed in an 
environmental chamber heated to 37°C and imaged using either an invert Zeiss 
LSM 510 or 780 confocal microscope with the 63X Plan-Apochromat oil immersion 
objective with a NA of 1.4. Images were acquired every 2-3 seconds at 100X zoom, 
using a resolution of 1024 X 1024 pixels (Movie 1).  
 
Primary hippocampal neurons in two compartment microfluidic chambers were 
incubated with 0.5 nM quantum dot-wheat germ agglutinin (WGA; Life 
Technologies) on the axonal side for 2 h at 37°C, 5% CO2. In drug-treated 
experiment, compound was added for the final 25 min of the incubation. The 
neurons were then washed once with pre-warmed differentiation medium and then 
imaged in fresh pre-warmed differentiation medium, containing compound if 
appropriate, using an invert microscope (Leica DMI6000 B) with a temperature-
controlled stage (Warner Instrument) at a frame rate of 2 frames/second (Xie et al., 
2012) (Movie 2).  
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2.2.7.4. In vivo imaging of axonal transport 
In vivo axonal transport assays were performed in 73 d (± 3 d) old wild type (non-
transgenic) and SOD1G93A mice. A detailed method is described in Section 4.4.1. 
Briefly, mice were anesthetized using isoflurane (National Veterinary Services) and 
AlexaFluor 555-conjugated HCT (13 µg) and BDNF (50 ng) were injected 
intramuscularly (i.m) into the exposed tibialis anterior and gastrocnemius muscles 
of the right hind leg and the wounds then sutured. At this time, mice were also 
injected intraperitoneally (i.p.) with either 100 mg/kg SB-239063 or an equivalent 
volume of vehicle control (1% methyl cellulose [Sigma 274429]). The skin of the 
hind leg was then sutured and the mice were then left to recover from the 
procedure and kept under standard conditions with unlimited food and water supply. 
Four hours later, the mice were re-anesthetized using isoflurane and the sciatic 
nerve of the right leg exposed. The anaesthetised mouse was placed on a heated 
stage in an environmental chamber (both kept at 37°C) and axonal retrograde 
transport was imaged in the intact sciatic nerve by time-lapse confocal microscopy. 
An invert Zeiss LSM 780 with 63X Plan-Apochromat oil immersion objective 
(NA = 1.4) was used to locate the sciatic nerve and visualise labelled axons (Movie 
3). Time lapse images were then acquired at 100X zoom every 3-4 s using a 
resolution of 1024 X 1024 pixels (Movie 4). 
 
2.2.8. Data analysis and quantification 
2.2.8.1. Quantification of the accumulation assay screen 
Confocal images were exported as TIFFs and analysed using the Cell Profiler 
software, developed by Anne Carpenter and Thouis John 
(http://www.cellprofiler.org/), which allows automated analysis of large image 
datasets. The software was instructed to identify cell bodies using the GFP channel 
(motor neurons were Hb9-GFP positive), according to size and intensity constraints. 
This “cell body” mask was then used to isolate the corresponding HCT and 
α-p75NTR signals. Mean staining intensity in the cell body, average number of HCT 
and/or α-p75NTR–labelled vesicles per cell, the size of labelled vesicles and the 
staining intensity in individual vesicles was measured. The resulting data were 
analysed using Microsoft Excel and Prism software. 
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2.2.8.2. Axonal transport tracking 
For HCT, α-p75NTR and lysotracker axonal transport experiments, time-lapse images 
were exported as .avi files and cargoes were manually tracked using Motion 
Analysis software (Kinetic Imaging). Cargoes were only tracked if they crossed the 
entire width of the frame. The speed of individual steps was calculated using an 
Excel kinetic analysis macro developed by Niran Nirmalananthan and the speed 
distribution was obtained using a 0.2 µm/s binning interval.  
 
For axonal transport tracking in primary hippocampal neurons performed at the Cui 
laboratory (Stanford, CA), ImageJ was used to create kymographs and the average 
speed of individual cargoes determined as the distance moved within the 
observation time. 
 
2.2.8.3. Statistical tests 
Statistical analysis was performed using Graphpad Prism software. In order to 
determine the most appropriate statistical test to use, data were tested for normality 
using three tests: D’Agostino & Person omnibus normality test, Shapiro-Wilk 
normality test and KS normality test. If the data were found to be normally 
distributed (the majority of the normality tests giving a positive result), either a 
Student’s t-test (n = 2 groups to compare) or one-way analysis of variance 
(ANOVA) (n > 2 groups to compare), followed by Dunnett’s or Sidak’s multiple 
comparisons test, was used. If the data were not found to be normally distributed, a 
Kruskal-Wallis test was used, followed by Dunn’s multiple comparison test (n > 2 
groups to compare). If there were too few data points to accurately test for 
normality, the data were assumed to be normally distributed. The test used and 
associated p values are indicated in the figure legends.  
 
In order to determine statistical significance of axonal transport data, the average 
speed was calculated by taking the mean of the mean speeds for individual axons 
of each biological replicate and a t-test (n = 2 conditions) or ANOVA (n >2) was 
performed. Error bars on speed profiles represent standard error of the mean 
(SEM).  
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Chapter 3. Identifying novel enhancers of retrograde 
axonal transport 
3.1. Introduction 
The aim of the experiments performed in this Chapter was to develop and perform 
a screen to identify novel enhancers of retrograde axonal transport in motor 
neurons.  
 
Marco Terenzio, a former PhD student in the laboratory, previously performed an 
siRNA screen looking for novel players in the internalisation and trafficking of 
neurotrophin receptors in motor neurons (Terenzio et al., 2014b, Terenzio et al., 
2014a). The read-out for this screen was the intracellular accumulation of the 
binding fragment of tetanus toxin (HCT) and an antibody directed against the 
extracellular domain of the p75 neurotrophin receptor (α-p75NTR). The screen was 
performed in mouse embryonic stem cell (ES)-derived motor neurons that were 
engineered to express GFP under the motor neuron-specific Hb9 promoter, 
allowing easy identification of motor neurons after ES cell differentiation, without 
the need for immunofluorescence. 
 
In this Chapter, I adapted this assay in order to screen a small molecule library of 
kinase inhibitors for novel pharmacological regulators of retrograde axonal 
transport. The accumulation assay was used as a preliminary screen to identify hit 
compounds, whose effects on retrograde axonal transport would then be explored 
in live in vitro axonal transport assays. In this way, relatively large numbers of 
compounds could be screened for their effects on retrograde axonal transport. 
 
3.1.1. Neuronal trafficking of HCT and α-p75NTR 
The binding, internalisation and transport of the two probes used in the screen, HCT 
and α-p75NTR, has been well characterised (Lalli and Schiavo, 2002, Lalli et al., 
2003a, Deinhardt et al., 2006b). The HCT probe used (HCT441, residues 875–1315) 
is a truncated form of the heavy chain of tetanus toxin (Figure 3.1), with a cysteine-
rich tag fused to the amino terminus (Lalli et al., 2003a). This version of HCT has a 
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long shelf life and reduced processing by tissue proteases (Restani et al., 2012). In 
addition, the probe is non-toxic whilst still being efficiently trafficked by neurons, 
and can be easily labelled with fluorophores.  
 
HCT has been shown to bind to nidogens and polysialogangliosides at the 
neuromuscular junction (Rummel et al., 2003, Bercsenyi et al., 2014) and undergo 
clathrin-mediated endocytosis (Deinhardt et al., 2006a). It is transported back to the 
soma in non-acidic endosomes and has been shown to be co-transported in 
signalling endosomes with p75NTR, NGF, TrkB and BDNF (Lalli and Schiavo, 2002, 
Deinhardt et al., 2006b). In its full-length form, tetanus toxin is then transcytosed to 
inhibitory interneurons, where the light chain zinc-endopeptidase mediates synaptic 
silencing through cleavage of VAMP/synaptobrevin, a synaptic SNARE protein 
(Schiavo et al., 1992a, Schiavo et al., 1992b). The axonal transport of HCT is 
therefore thought to be exclusively in the retrograde direction. As HCT has not been 
localised in acidic organelles in the cell body of motor neurons (Lalli and Schiavo, 
2002, Bohnert and Schiavo, 2005), it is thought that it is able to by-pass lysosomal 
targeting and degradation.  
 
 
 
Figure 3.1. The domain structure of tetanus toxin  
Tetanus toxin is composed of two chains: heavy (H) and light (L). The light chain is a zinc-
endopeptidase that cleaves VAMP/synaptobrevin and causes inhibition of neurotransmitter 
release. The H chain is comprised of an N-terminal domain (HN) and a C-terminal domain (HC). 
The HC domain is responsible for the toxin’s neurospecific binding and mediates retrograde 
axonal transport. Modified from (Lalli et al., 2003a). Reprinted with permission from Elsevier.  
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p75NTR is a transmembrane receptor that binds all four members of the 
neurotrophin family - nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). p75NTR is able to form 
heterodimers with a number of co-receptors and interacts with a variety of adapter 
proteins. As a result the receptor is involved in a wide range of physiological 
responses in the nervous system. p75NTR is widely expressed throughout the 
developing nervous system, but in most cells is switched off at adult stages. Two 
exceptions to this are sensory neurons and spinal cord motor neurons, which retain 
a low level of p75NTR expression (Ibanez and Simi, 2012). Like other neurotrophin 
receptors, p75NTR is activated at distal axonal sites and is subsequently internalised 
and retrogradely transported back to the soma where it mediates its effects. The 
internalisation and sorting of p75NTR to the retrograde transport route has been 
shown to be dependent on clathrin-mediated endocytosis and the activity of the 
small GTPases Rab5 and Rab7 (Deinhardt et al., 2006a, Deinhardt et al., 2006b, 
Deinhardt et al., 2007). p75NTR is not thought to be targeted to the lysosome for 
degradation, but has instead been proposed to recycle back to the plasma 
membrane (Deinhardt et al., 2007) and/or be released in exosomes into the 
extracellular medium (Escudero et al., 2014).  
 
HCT and α-p75NTR are therefore ideal probes to use to investigate the effect of 
pharmacological compounds on retrograde axonal transport in motor neurons.  
 
3.1.2. Protein kinases as a therapeutic target 
Protein kinases are a very popular target in current pharmaceutical development as 
they are involved in a huge variety of signalling cascades and have been implicated 
in a multitude of diseases. At present, there are over 30 compounds approved by 
the FDA that target protein kinases and several hundred projects involving protein 
kinases have been registered for clinical trials. Much of the attention of the 
pharmaceutical industry so far has been focused on the use of kinase-targeting 
drugs in the treatment of cancer and chronic inflammatory diseases. 
 
Protein kinases have, however, also been implicated in disorders of the CNS. It has 
been proposed that disease-associated pathological proteins, such as Aβ and 
Chapter 3 Results 
 
 74 
SOD1G93A, mediate their toxic effects through activation of specific kinase cascades 
(Kanaan et al., 2013). Dysregulation of kinase activity is a common feature of a 
number of neurodegenerative diseases, including p38 MAPK in ALS, GSK3β in 
Alzheimer’s disease and JNK3 in Parkinson’s disease, to name but a few (Chico et 
al., 2009). A major problem in targeting protein kinases in the CNS is designing 
inhibitors that are able to cross the blood brain barrier. However, this is an issue 
that the pharmaceutical industry has been addressing for a long time and a number 
of protein kinase inhibitors have now reached clinical trials for CNS disorders 
(Chico et al., 2009). 
 
There is also clear evidence implicating a range of protein kinases in the regulation 
of axonal transport, including GSK3β, Cdk5, JNK3, Akt and p38 MAPK. Protein 
kinases have been shown to directly phosphorylate molecular motors and their 
motor adapter proteins. For example, p38 MAPK and JNK3 have been shown to 
phosphorylate kinesin-1 directly, reducing the efficiency with which kinesin-1 moves 
along axonal microtubules and therefore inhibiting anterograde axonal transport 
(Morfini et al., 2009, Morfini et al., 2013). Cyclin dependent kinase 5 (Cdk5), on the 
other hand, has been shown to positively regulate retrograde axonal transport 
through phosphorylation of the dynein-associated protein Ndel1 and reduction of its 
inhibitory effect on dynein activity (Pandey and Smith, 2011). 
 
Given the role of protein kinases in both the regulation of axonal transport and 
neurodegeneration, we decided to screen a library of kinase inhibitors in search of 
novel enhancers of retrograde axonal transport.  
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3.2. Validating the accumulation assay as a screen for novel 
modulators of retrograde axonal transport 
Based on previous work in the laboratory, our hypothesis was that the 
accumulation of HCT and α-p75NTR in the cell body of motor neurons would act as a 
read-out for the efficiency of retrograde axonal transport. Robust axonal transport is 
only detected in vitro following 20-30 minutes incubation with probes such as HCT 
and α-p75NTR, therefore it was decided to assess accumulation in the cell body after 
two hours. Firstly, it was necessary to determine whether the somal accumulation 
of HCT and α-p75NTR in motor neurons was a suitable assay to screen compounds 
for their effects on retrograde axonal transport. To this end, the assay was 
performed in ES-derived motor neurons in the presence of known inhibitors and 
enhancers of retrograde axonal transport, as well as in primary SOD1G93A motor 
neurons in which defects in retrograde axonal transport have been described 
(Kieran et al., 2005, Bilsland et al., 2010). 
 
3.2.1. Determining the sensitivity of the accumulation assay to changes in 
retrograde axonal transport speed 
In order to determine whether the accumulation assay was sensitive to decreases 
in axonal transport efficiency, I performed the assay in the presence of known 
inhibitors of retrograde axonal transport. Erythro-9-(2-hydroxy-3-nonyl)adenine 
(EHNA) is an established inhibitor of cytoplasmic dynein, that acts to inhibit the 
ATPase activity of the motor (Penningroth et al., 1982). Treatment of motor 
neurons with 1 mM EHNA has previously been shown to cause a significant 
inhibition of the retrograde axonal transport of HCT-containing endosomes (Figure 
3.2A) (Lalli et al., 2003b, Deinhardt et al., 2007, Terenzio et al., 2014b). Incubation 
of ES-derived motor neurons with 1 mM EHNA together with HCT and α-p75NTR 
was found to cause a decrease in the staining intensity of both probes in the cell 
body (Figure 3.2B-D), indicating that the sensitivity of this assay is sufficient to 
detect reductions in retrograde axonal transport efficiency. However, EHNA is not a 
selective inhibitor of cytoplasmic dynein. It has also been reported to cause 
morphological and functional changes to the actin cytoskeleton (Schliwa et al., 
1984), inhibit cyclic GMP-stimulated phosphodiesterase activity (Mery et al., 1995) 
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and potently inhibit adenosine deaminase (Woodson et al., 1998). It therefore 
cannot be ruled out that its effects on the somatic accumulation of HCT and 
α-p75NTR may be a consequence of one or more of these off-target effects. 
 
 
 
Figure 3.2. Inhibition of retrograde axonal transport by EHNA is detected by the 
accumulation assay 
(A) Treatment of motor neurons with 1 mM EHNA has been previously shown to cause a 
significant inhibition of the retrograde axonal transport of HCT (Lalli et al., 2003b). Reprinted with 
permission from the Company of Biologists. (B, C) Treatment of ES-derived motor neurons with 
1 mM EHNA causes a significant decrease in the accumulation of HCT in the cell body 
compared to the DMSO control. Results are expressed as a percentage of the DMSO control 
(DMSO n = 191 cell bodies, EHNA n = 161 cell bodies; 4 independent experiments). (D, E) 
Treatment of ES-derived motor neurons with 1 mM EHNA causes a significant decrease in the 
accumulation of α-p75NTR in the cell body compared to the DMSO control. Results are 
expressed as a percentage of the DMSO control (DMSO n = 223 cell bodies, EHNA n = 181 cell 
bodies; 4 independent experiments). **** p< 0.0001 (unpaired Student’s t test). Error bars 
represent SEM. Scale bar, 10 µm. 
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To further investigate the relationship between the inhibition of cytoplasmic dynein 
and the somatic accumulation of HCT and α-p75NTR, we also investigated the 
effects of ciliobrevin A, a more specific inhibitor of dynein ATPase activity 
(Firestone et al., 2012). In vitro axonal transport assays revealed that treatment of 
ES-derived motor neurons with 100 µM ciliobrevin A caused an almost complete 
disruption of axonal transport (Figure 3.3A). However, when the concentration was 
lowered to 50 µM, a sufficient number of cargoes could be tracked to allow speed 
analysis to be performed. 50 µM ciliobrevin A was found to cause a significant 
inhibition of the retrograde axonal transport of HCT-labelled carriers (p = 0.045), as 
shown by the shift of the speed distribution curve to the left (Figure 3.3B).  
 
 
 
Figure 3.3. Ciliobrevin A inhibits retrograde axonal transport in motor neurons 
(A) The effect of 100µM ciliobrevin A on HCT axonal transport. MNs in mass culture were 
incubated with AlexaFluor 555-conjugated HCT and treated with 100µM ciliobrevin A (or DMSO 
control) after the appearance of motile fluorescent carriers. Corresponding kymographs are 
presented and below each a scheme showing manually drawn lines tracing the movement of 
retrograde carriers (in red). Retrograde carriers were moving to the right. Arrowheads report 
when 100µM ciliobrevin A or DMSO was added. (B) Speed profiles of HCT carriers in MNs 
treated with DMSO (black squares) or 50 µM ciliobrevin A (red diamonds) (DMSO: 55 carriers, 
10 axons; 50 µM ciliobrevin A: 46 carriers, 8 axons; 3 independent experiments). 
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Importantly, the inhibition of retrograde axonal transport by ciliobrevin A was also 
mirrored by the reduced accumulation of HCT and α-p75NTR in the soma of ES-
derived motor neurons (Figure 3.4).  
 
 
 
 
 
Figure 3.4. Ciliobrevin A reduces the accumulation of HCT and α-p75NTR in the cell body of 
ES-derived motor neurons  
(A, B) Treatment of ES-derived motor neurons with 100 µM ciliobrevin A causes a significant 
decrease in the accumulation of HCT in the cell body compared to the DMSO control. Results 
are expressed as a percentage of the DMSO control (DMSO n = 212 cell bodies, Ciliobrevin A n 
= 229 cell bodies; 4 independent experiments). (C, D) Treatment of ES-derived motor neurons 
with 100 µM ciliobrevin A causes a significant decrease in the accumulation of α-p75NTR in the 
cell body compared to the DMSO control. Results are expressed as a percentage of the DMSO 
control (DMSO n = 253 cell bodies, Ciliobrevin A n = 250 cell bodies; 4 independent 
experiments). **** p< 0.0001 (unpaired Student’s t test). Error bars represent SEM. Scale bar, 
10 µm. 
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In contrast to inhibitors of axonal transport, very few specific enhancers of 
retrograde axonal transport are available. Acetyl-L-carnitine (ALCAR) has been 
previously reported to enhance both slow (Di Giulio et al., 1995) and fast retrograde 
axonal transport in diabetic rats (Kano et al., 1999). However, the effects of ALCAR 
had not been previously tested in mouse motor neuron cultures. I therefore tested 
ALCAR in our in vitro axonal transport assays in mouse ES-derived motor neurons. 
When motor neurons were incubated with 1 mM ALCAR, HCT-labelled endosomes 
were transported at faster speeds (p = 0.063; Figure 3.5A). This subtle increase in 
transport efficiency could also be detected using the accumulation assay (Figure 
3.5B-E).   
 
Since EHNA, ciliobrevin A and ALCAR were applied to the motor neurons at the 
same time as HCT and α-p75NTR, it was possible that the results seen in the 
accumulation assay were due to an alteration in the binding of the probes, rather 
than the compounds’ effects on retrograde axonal transport efficiency. To control 
for this, I assessed the effect of all three compounds on binding of the probes to 
ES-derived motor neurons (Figure 3.6). EHNA was found to cause a significant 
inhibition of the binding of both HCT and α-p75NTR. However, as ciliobrevin A had no 
inhibitory effect on binding, it appears that the accumulation assay is indeed 
sensitive to reductions in axonal transport efficiency. In addition the effects of 
ALCAR on binding did not mimic the results seen in the accumulation assay. These 
findings support the use of the accumulation assay to identify likely modifiers of 
retrograde axonal transport.  
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Figure 3.5. ALCAR causes a subtle enhancement of axonal transport speed in motor 
neurons that can be detected by the accumulation assay  
(A) Speed profiles of HCT carriers in MNs treated with control medium (black squares) or 1 mM 
ALCAR (green triangles) (No drug: 53 carriers, 10 axons; 1 mM ALCAR: 61 carriers, 8 axons; 3 
independent experiments). (B, C) Effects of 1 mM ALCAR on accumulation of HCT in the cell 
body of ES-derived MNs compared to the no drug (water treated) control. Results are 
expressed as a percentage of the no drug control (No drug n = 192 cell bodies, ALCAR n = 193 
cell bodies; 4 independent experiments). (D, E) Effects of 1 mM ALCAR on accumulation of α-
p75NTR in the cell body of ES-derived MNs compared to the no drug (water treated) control. 
Results are expressed as a percentage of the no drug control (No drug n = 125 cell bodies, 
ALCAR n = 153 cell bodies; 4 independent experiments). *** p< 0.001 **** p< 0.0001 (unpaired 
Student’s t test). Error bars represent SEM. Scale bars, 10 µm. 
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Figure 3.6. Testing the effect of ALCAR, EHNA and ciliobrevin A on HCT and α-p75NTR 
binding 
(A) The effect of 1 mM ALCAR, 1 mM EHNA and 100 µM ciliobrevin A on the binding of HCT 
and α-p75NTR to ES-cell derived motor neurons. ES-derived MNs were cooled on ice and then 
incubated with AlexaFluor 555-conjugated HCT and α-p75NTR antibody +/- drug. MNs were then 
washed with ice-cold Hanks, fixed on ice and stained for α-p75NTR. The amount of HCT and α-
p75NTR was quantified as the mean staining intensity per pixel. Scale bars, 10 µm. (B) 
Quantification of HCT binding. Results are expressed as a percentage of the control (No drug n 
= 134 cell bodies, ALCAR n = 127, DMSO n = 118, EHNA n = 125, ciliobrevin A n = 112; 3 
independent experiments). ** p < 0.01 (unpaired Student’s t test). **** p< 0.0001, NS = non 
significant (one-way ANOVA followed by Dunnett’s multiple comparisons test). Error bars 
represent SEM. (C) Quantification of α-p75NTR binding. Results are expressed as a percentage 
of the control (No drug n = 118 cell bodies, ALCAR n = 128, DMSO n = 125, EHNA n = 140, 
ciliobrevin A n = 106; 3 independent experiments). NS = non significant (unpaired Student’s t 
test). * p < 0.05 ****, p< 0.0001 (one-way ANOVA followed by Dunnett’s multiple comparisons 
test). Error bars represent SEM. 
 
 
A final step in validating the accumulation assay was to confirm whether the assay 
was sensitive enough to detect retrograde axonal transport defects in primary 
SOD1G93A motor neurons (Kieran et al., 2005). Primary wild type (non-transgenic) 
and SOD1G93A motor neuron cultures were incubated with HCT for two hours, as 
previously described, and we were able to detect a significant decrease in 
accumulation in SOD1G93A motor neurons compared to the wild-type controls 
(Figure 3.7). 
 
 
 
 
 
Figure 3.7. Deficits in retrograde axonal transport in SOD1G93A motor neurons can be 
detected by the accumulation assay  
Defective retrograde axonal transport in SOD1G93A MNs is observed as a decrease in 
accumulation of HCT in the cell body. Primary MNs from E13 SOD1G93A embryos were 
incubated with AlexaFluor 555-conjugated HCT for 2 h. Cells were then acid-washed and fixed. 
The amount of HCT was quantified as the mean staining intensity per pixel in the cell body. 
Results are expressed as a percentage of the wild type control (WT n = 161 cell bodies, 
SOD1G93A = 156 cell bodies; 3 independent experiments). **** p< 0.0001 (unpaired Student’s t 
test). Error bars represent SEM. Scale bar, 10 µm. 
Chapter 3 Results 
 
 83 
3.2.2. Scaling up the accumulation assay for use as a medium through-put 
screen      
In order to adapt the accumulation assay for screening a small library of 
compounds it was necessary to establish automated protocols of image acquisition 
and analysis. 
 
To this aim, it was decided to perform the accumulation assay in 24-well glass 
bottom plates (MatTek Corporation). This would allow fixing and staining in situ, 
avoiding the use of individual coverslips, while providing a large enough surface 
area per well to avoid clumping of the ES-derived motor neurons as seen in 96-well 
plates. Glass-bottom plates also allowed the use of confocal microscopy. 
 
The Zeiss LSM 510 inverted confocal microscope has an automated stage that, 
when used in combination with the Multi Field Acquisition (MTS) macro, allows 
automated image acquisition from a 24-well plate to be performed overnight. The 
autofocus function of the MTS macro allows the focal plane to be determined using 
the GFP channel (i.e. focussing specifically on the motor neurons) and a tile of 36 
images can be acquired for each well using a 40X objective. 
 
The confocal images were then fed into the Cell Profiler software, developed by 
Anne Carpenter and Thouis John (http://www.cellprofiler.org/), which allows 
automated analysis of large image datasets (Figure 3.8). The software can be 
instructed to identify cell bodies using the GFP channel and both size and intensity 
constraints. It can then use this “cell body” mask to isolate the corresponding HCT 
and α-p75NTR signals and make a number of measurements, including mean 
staining intensity, average number of HCT and/or α-p75NTR–labelled vesicles per 
cell, the size of these vesicles and the staining intensity of individual vesicles. 
However, the ability of the software to distinguish individual vesicles is limited, due 
to the restricted resolution of the microscope images. The detection settings were 
optimised such that the software could sensitively detect the known changes in 
mean staining intensity and number of HCT and/or α-p75NTR-labelled vesicles after 
EHNA and ALCAR treatment.  
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Figure 3.8. Automatic image analysis using Cell Profiler software 
Images are loaded as single RGB images. The Cell Profiler software uses the GFP channel to 
identify motor neuron cell bodies and create a mask. Using this mask the HCT and α-p75NTR 
receptor signals are isolated and the software can measure the mean staining intensity of each 
probe within each cell body. Cell Profiler can also create a mask of the vesicles and use this to 
count the number and staining intensity of individual vesicles. The cell body mask has been 
superimposed on top of the HCT vesicle mask in this instance in order to make the identification 
of vesicles within cell bodies clearer.  
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In order to confirm that the use of automated image acquisition and analysis did not 
reduce the sensitivity of the assay, I compared the two approaches (manual versus 
automated) side-by-side. As shown in Figure 3.9, the automated approach 
produced very similar results and was therefore suitable to be used when 
screening the library of kinase inhibitors provided by GlaxoSmithKline.  
 
 
 
 
 
Figure 3.9. Comparison of the results obtained from manual and automated image 
acquisition and analysis 
The results of the accumulation assay were compared when the protocol was performed 
manually (as described previously) or using automated image acquisition and analysis. n ≥ 25 
cell bodies; n = 3 repeats. **** p < 0.0001, ** p < 0.01 (unpaired Student’s t test). Error bars 
represent SEM. 
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3.3. Identification and validation of lead compounds 
To identify compounds that may be enhancing retrograde axonal transport, 56 
compounds (listed in Table 4) were screened at a concentration of 2 µM using the 
accumulation assay. These compounds were all derived from a kinase inhibitor 
library supplied by GlaxoSmithKline. The library was composed of previously 
published compounds, which targeted 24 different kinases that had been previously 
implicated in the regulation of axonal transport and/or that had been proposed to 
play a role in neurodegeneration. For the preliminary screen, accumulation was 
quantified using two of the Cell Profiler measurements described in Section 3.2.2 – 
the mean staining intensity of HCT and α-p75NTR in each motor neuron cell body 
and the average number of HCT or α-p75NTR-labelled vesicles per cell body. The 
screen was performed blind and in triplicate for each compound.  
 
3.3.1. Preliminary screening results 
Active compounds were defined as those that increased the mean staining intensity 
of HCT and/or α-p75NTR by at least three standard deviations above the DMSO 
control level, which was taken as 100% (represented as a yellow rectangle; Figure 
3.10A). Four active compounds were identified on this basis – A1, A4, C3 and E4 
(Figure 3.10B). In addition, four more compounds were included (C1, C2, D1 and 
D3), as they sat on or close to the significance boundary. Therefore, in total, eight 
active compounds were selected, representing a primary hit rate of 14%. 
 
These active compounds were then confirmed, based on data collected about the 
average number of labelled vesicles per cell (Figure 3.10D and E). By comparison 
of the two data sets, six of the active compounds were confirmed as causing an 
increase in both the mean staining intensity and the number of vesicles per cell, for 
HCT and/or α-p75NTR. These were compounds A1, A4, C3, D1, D3 and E4. 
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Figure 3.10. Chemical screening for the identification of enhancers of HCT and α-p75NTR 
accumulation in the cell body of ES-derived motor neurons 
(A) Summary of preliminary screening results shown as an XY plot of the normalized mean 
staining intensity values for α-p75NTR vs HCT.  Active compounds were defined as those able to 
increase accumulation of α-p75NTR and/or HCT by at least 3-times the standard deviation 
(represented by the yellow rectangle). The negative control (EHNA) is shown in red. (B) The 8 
active compounds that were selected. (C) Summary of preliminary screening results shown as 
an XY plot of the normalized average number of vesicles per cell body values for α-p75NTR vs 
HCT. The negative control (EHNA) is shown in red. (D) Average number of vesicles per cell 
body data for the 8 active compounds identified in (B). Error bars represent SD. n ≥ 25 cell 
bodies per repeat; n = 3 repeats. 
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3.3.2. Identification of lead compounds 
In order to validate the six active compounds, a dose-dependence study of their 
effect in the accumulation assay was performed. In addition to the previously tested 
concentration of 2 µM, the assay was also performed at five-fold lower (0.4 µM) 
and five-fold higher (10 µM) concentrations. All compounds were found to have a 
dose-dependent effect on accumulation between 0.4 µM and 2 µM. However, with 
the exception of C3, a concentration of 10 µM appeared to be either toxic to ES-
derived motor neurons or had an inhibitory effect on the accumulation of HCT and 
α-p75NTR (Figure 3.11). 
 
 
 
Figure 3.11. Dose-dependent effects of the active compounds 
Concentration-response curves for the six active compounds. The screening assay was 
repeated at 0.4 µM, 2 µM and 10 µM and the amount of HCT and α-p75NTR accumulating was 
quantified as the mean staining intensity per pixel in the cell body. n ≥ 25 cell bodies per repeat; 
n = 3 repeats. Error bars represent SEM. 
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To further validate the six active compounds, the accumulation assay was repeated 
once more at the screening concentration of 2 µM in order to achieve three 
independent experimental repeats. Variability between the three repeats was found 
to be low, and all six compounds were confirmed as enhancers of HCT and 
α-p75NTR accumulation in the cell body, with compounds A1, C3 and E4 showing 
the strongest effects (Figure 3.12). 
 
 
 
Figure 3.12. Summary of screening assay repeats for active compounds 
Summary of the three runs of the screening assay at 2 µM. Results shown as an XY plot of the 
average mean staining intensity values for α-p75NTR vs HCT for the 6 active compounds at a 
screening concentration of 2 µM. n ≥ 75 cell bodies per experiment; n = 3 independent 
experiments. Error bars represent SD. 
 
 
 
Based on the screening data and subsequent validation experiments, A1, C3 and 
E4 were chosen as the three lead compounds to be investigated further.  
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3.3.3. Validation of lead compounds  
In order to validate the lead compounds, A1, C3 and E4 were tested for their 
effects on HCT accumulation in SOD1G93A primary motor neurons (Figure 3.13). All 
three compounds were found to correct the deficits in accumulation observed in 
SOD1G93A motor neurons. 
 
 
 
 
Figure 3.13. Validation of the lead compounds in SOD1G93A motor neurons 
Effects of 2 µM A1, C3 and E4 on accumulation of HCT in the cell body of primary motor 
neurons from E13 SOD1G93A embryos (DIV6). The amount of HCT accumulating was quantified 
as the mean staining intensity per pixel in the cell body, using ImageJ. Results are expressed 
as a percentage of the wild type level (WT n = 33 cell bodies, SOD1G93A n = 38, SOD1G93A + A1 
n = 30, SOD1G93A + C3 n = 33, SOD1G93A + E4 n = 32; 1 independent experiment). Error bars 
represent SEM.  
  
 
 
Of course, one drawback of our screening assay is that the intracellular 
accumulation of the probes will also be affected by compounds that target 
pathways upstream or downstream of axonal transport, such as the binding, 
internalisation, recycling or degradation of HCT and α-p75NTR.  
 
In order to determine whether the lead compounds were affecting the 
internalisation of HCT and α-p75NTR, the accumulation assay protocol was modified, 
such that accumulation in the cell body was assessed before significant axonal 
transport had begun. Using this modified protocol, we found that treatment of motor 
neurons with A1 and C3 enhanced the internalisation of α-p75NTR (Figure 3.14B), 
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but had no effect on the internalisation of HCT (Figure 3.14A). Compound E4 had 
no effect on the internalisation of either probe.  
 
 
 
 
 
Figure 3.14. Effects of lead compounds on the internalisation of HCT and α-p75NTR 
Effects of 2 µM A1, C3 and E4 on the internalisation of HCT (A) and α-p75NTR (B) in the cell body 
of ES-derived motor neurons. The assay was performed using the same methodology as the 
accumulation assay, except the incubation time with HCT and α-p75NTR was reduced to 20 
minutes. The amount of HCT and α-p75NTR accumulating was quantified as the mean staining 
intensity per pixel in the cell body, using ImageJ (DMSO n = 241 cell bodies, A1 n = 240 cell 
bodies, C3 n = 238 cell bodies, E4 n = 217 cell bodies; 3 independent experiments). Results are 
expressed as a percentage of the DMSO control. **** p 0.0001, NS = non significant (Kruskal-
Wallis test followed by Dunn’s multiple comparisons test). Error bars represent SEM. 
 
 
 
In order to confirm whether any of the lead compounds were truly enhancers of 
retrograde axonal transport, we next performed live in vitro axonal transport assays 
(an example of which is shown in Movie 1 on the CD provided). 
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3.4. In vitro axonal transport assays 
All the compounds in our kinase inhibitor library were supplied in DMSO and 
therefore the first necessary step was to demonstrate that DMSO itself had no 
effect on retrograde axonal transport speeds in ES-derived motor neurons in vitro 
(as shown in Figure 3.15). 
 
 
Figure 3.15. DMSO has no effect on retrograde axonal transport in motor neurons 
Speed profiles of HCT carriers in untreated and DMSO treated ES-derived motor neuron 
cultures (untreated: 24 carriers, 2 axons, DMSO: 20 carriers, 3 axons; n = 1). 
 
Having established this, I went on to investigate the effects of each compound on 
the axonal transport of HCT and α-p75NTR in both ES-derived and primary motor 
neurons. 
 
3.4.1. Investigating the effects of compound A1 on axonal transport 
After completing the preliminary screening and validation assays, compound A1 
was revealed to be an inhibitor of p38 mitogen-activated protein kinase (p38 
MAPK) (Boehm et al., 2001).  
Structure
Assay GSK1713088A GW440139A GW440139B SB-­‐2 9272
hc_intensity_summary 110.8246937 101.0161833 103.6526406
hc_vesicle_number_summary 161.7681376 96.67489429 124.302703
p75_intensity_summary 144.1545722 121.9956197 113.0873849
P75_vesicle_number_summary 299.9189243 154.8863007 128.9057692
ALK	  Human	  Filt	  Bind	  -­‐	  2.5	  nM	  1	  Hr	  Endpoint	  -­‐	  pIC50	  (Summary	  Results) 7.94
Insulin	  Receptor	  (Activated	  Catalytic)	  Human	  Enzyme	  HTRF	  -­‐	  pIC50	  Summary	  (Abse5) 7.9 5
IGF1R	  Human	  Inhibitor	  -­‐	  Activated	  Catalytic	  -­‐	  HTRF	  -­‐	  pIC50	  Summary	  (Abse5) 7.6
CLK2	  Human	  Inhibition	  IMAP	  -­‐	  pIC50	  Summary	  (Abse5) 7.3 5
ALK5	  (TGFBR1)	  -­‐	  FP	  -­‐	  pIC50	  Full	  Curve	  Summary	  (Abse5) 5 7.7 7.1
RIP3	  ATP	  Binding	  Inhibition	  Ligand	  (GSK2691657A)	  FP	  HTS	  -­‐	  pIC50	  Summary	  (Abse) 8.7 8.4 5.3
VEGFR2	  (KDR)	  -­‐	  HTRF	  -­‐	  pIC50	  Full	  Curve	  Summary	  (Abse5) 8.4 8.6
ActRIIB	  (ACVR2B)	  Human	  Binding	  FP	  	  -­‐	  pIC50	  Summary	  (Abse5) 8.2 8.5
RET	  Kinase	  Inhibition	  Human	  HTRF	  -­‐	  pIC50	  Summary	  (Abse) 8
RIPK2	  Human	  Inhibition	  SPA	  -­‐	  pIC50	  Summary	  (Abse5) 7.9 7.7
RIPK2	  Human	  Inhibition	  FP	  -­‐	  pIC50	  Summary	  (Abse5) 7.1 8.4 5.2
EGFR	  (HER1)	  Wild-­‐Type	  Human	  30	  min	  Preinc.	  HTRF	  -­‐	  pIC50	  Summary	  (Abse5) 7.7
ActRIIA	  (ACVR2A)	  Human	  Binding	  FP	  -­‐	  pIC50	  Summary	  (Abse5) 7.3 6.1
Cytochrome	  P450	  2D6	  Human	  -­‐	  FLINT	  -­‐	  pIC50	  Summary	  (Abse5) 5.7 8.1
LCK	  Human	  IMAP	  pIC50	  Summary	  (Abse5) 5.3 6.4 7.9
SYK	  Human	  Inhibition	  Ramos	  B	  Cell	  Lysate	  FLINT	  -­‐	  pIC50	  Summary	  (Abse5) 5.8 7.5
RIP3	  Human	  Kinase	  -­‐	  Inhib	  ADP	  Glo	  -­‐	  Luminescence	  -­‐	  pIC50	  Summary	  (Abse) 9
BTK	  Human	  HTRF	  -­‐	  pIC50	  -­‐	  ATP	  Preactivated	  Low	  ATP@Km	  Summary	  (Abse5) 8.4
RIPK2	  Human	  Inhibition	  AlphaLISA	  -­‐	  pIC50	  Summary	  (Abse5) 7.7
p38/CSBP	  IC50	  Kinase	  Binding	  -­‐	  FP	  (HW)	  (Summary	  Results) 186.5
p38	  Kinase	  Binding	  -­‐	  IC50	  -­‐	  Competitive	  Radioligand	  Binding 8.05
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Figure 3.16. The chemical structure of the p38 MAPK inhibitor compound A1 
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When tested at the screening concentration of 2 µM in in vitro axonal transport 
assays, compound A1 was found to have no effect on retrograde axonal transport 
speeds in either ES-derived motor neurons (p = 0.514; Figure 3.17) or wild type 
primary motor neurons (p = 0.930; Figure 3.18A).  
 
 
 
Figure 3.17. Treatment of ES-derived motor neurons with 2 µM A1 has no effect on 
retrograde axonal transport 
Speed profiles of HCT carriers in ES-derived motor neuron cultures treated with either DMSO or 
2 µM A1 (DMSO: 56 carriers, 9 axons, A1: 54 carriers, 14 axons; n = 4 independent 
experiments). 
 
 
In contrast, when tested in primary motor neurons derived from SOD1G93A embryos, 
compound A1 was able to correct defects in the retrograde axonal transport of HCT 
(SOD1G93A versus SOD1G93A + 2 µM compound A1: p = 0.013; Figure 3.18B). 
Deconvolution of the speed distribution profiles shown in Figure 3.18A and B 
highlights a marked reduction in the fastest (1.41 µm/s) speed component in 
SOD1G93A motor neurons and a corresponding increase in the frequency of 
intermediate speed carriers (0.56 µm/s), when compared to wild type controls 
(Figure 3.18C). However, when treated with compound A1, SOD1G93A motor 
neurons had a speed carrier distribution indistinguishable from wild type controls (p 
= 0.853). Similarly for α-p75NTR, treatment with 2 µM compound A1 was found 
normalise retrograde axonal transport in primary SOD1G93A motor neurons (WT 
versus SOD1G93A + 2 µM compound A1: p = 0.468, SOD1G93A versus SOD1G93A + 
2 µM compound A1: p = 0.013; Figure 3.18D). 
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These results indicate that compound A1 is able to specifically rescue SOD1G93A-
induced deficits in retrograde axonal transport in primary motor neurons. 
 
 
 
Figure 3.18. The effect of compound A1 on the axonal transport in primary motor 
neurons 
(A) Speed profiles of HCT carriers in wild type + DMSO (black squares) and wild type + 2 µM A1 
(light blue triangles) motor neuron cultures. Comparison of the curves reveals that compound 
A1 has no effect on wild type axonal transport speeds (wild type:  94 carriers, 13 axons; wild 
type + 2 µM A1: 108 carriers, 11 axons; 4 independent experiments). (B) Speed profiles of HCT 
carriers in wild type, SOD1G93A and SOD1G93A + 2 µM A1 motor neuron cultures. Comparison of the 
curves reveals SOD1G93A motor neurons treated with compound A1 (blue triangles) have a similar 
speed distribution to wild type cultures (black squares) (wild type:  94 carriers, 13 axons; SOD1G93A: 
126 carriers, 14 axons; SOD1G93A + 2 µM A1: 121 carriers, 16 axons; 4 independent experiments). 
(C) Deconvolution analysis of the in vitro speed profiles (as previously described in Bilsland et 
al., 2010) demonstrating that there are three defined speed components: 0 µm/s (slow), 0.56 
µm/s (intermediate), and 1.41 µm/s (fast). Defects in axonal transport in SOD1G93A motor 
neurons can be explained by a reduction in the number of “fast” moving carriers, and an 
increase in the number of “intermediate” speed carriers. Treatment of SOD1G93A motor neurons 
with 2 µM A1 corrects the distribution of carriers back to that of wild type. (D) Compound A1 
also restores retrograde axonal transport of the α-p75NTR in SOD1G93A motor neurons. Speed 
profiles of α-p75NTR carriers in wild type, SOD1G93A and SOD1G93A + 2 µM A1 motor neuron 
cultures (wild type:  118 carriers, 6 axons; SOD1G93A: 85 carriers, 6 axons; SOD1G93A + 2 µM 
A1: 96 carriers, 8 axons; 3 independent experiments).  
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3.4.2. Investigating the effects of compound C3 on axonal transport 
Compound C3 was revealed to be an inhibitor of the RET tyrosine kinase (Graham 
Robinett et al., 2007). RET is a transmembrane receptor for glial-derived 
neurotrophic factors (GDNFs) - GDNF, neurturin, artemin and persephin (Mulligan, 
2014).  
 
 
Figure 3.19. The chemical structure of the RET inhibitor compound C3 
 
 
When motor neurons treated with 2 µM C3 were examined in closer detail during in 
vitro axonal transport assays, the compound was observed to be neurotoxic – 
causing severe blebbing of axons (Figure 3.20A). Furthermore, when the dose was 
lowered to a non-toxic concentration (0.5 µM), compound C3 was found to have no 
effect on retrograde axonal transport in ES-derived (data not shown) or wild type 
primary motor neurons (Figure 3.20B). As a result, compound C3 was excluded 
from further analysis.  
 
 
 
Figure 3.20. Compound C3 has no effect on retrograde axonal transport speeds 
(A) Compound C3 is toxic at 2 µM, causing blebbing of axons. Scale bar, 10 µm. (B) Speed 
profiles of HCT carriers in wild type motor neurons treated with either DMSO or 0.5 µM C3. n = 1. 
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3.4.3. Investigating the effects of compound E4 on axonal transport 
Compound E4 was revealed to be an inhibitor of the insulin-like growth factor 1 
receptor (IGF1R) (Chamberlain et al., 2009).  
 
 
Figure 3.21. The chemical structure of the IGF1R inhibitor compound E4 
 
Similarly to compound C3, further analysis of motor neurons treated with 2 µM E4 
revealed blebbing of axons (Figure 3.22A). However, when the dose was lowered 
to a non-toxic concentration, compound E4 was found to accelerate the axonal 
transport of HCT-labelled endosomes in ES-derived motor neurons (p = 0.029; 
Figure 3.22B).  
 
 
 
Figure 3.22. Treatment of ES-derived motor neurons with compound E4 accelerates 
axonal transport   
(A) Compound E4 is toxic at 2 µM, causing blebbing of axons. Scale bar, 10 µm. (B) Speed 
profiles of HCT carriers in wild type motor neurons treated with either DMSO or 0.5 µM E4 
(DMSO: 10 axons, 84 carriers, E4: 10 axons, 89 carriers; n = 3 independent experiments).  
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Compound E4 also had a similar accelerating effect on the axonal transport of HCT 
in both wild type (p = 0.0003; Figure 3.23A) and SOD1G93A (SOD1G93A versus 
SOD1G93A + 0.5 µM compound E4: p = 0.108; Figure 3.23B) primary motor neurons. 
Deconvolution of the wild type speed distribution profiles shown in Figure 3.23A 
highlights a marked reduction in the intermediate and fast (1.41 µm/s) speed 
components and a corresponding increase in the frequency of very fast speed 
carriers (2.24 µm/s), when motor neurons are treated with 0.5 µM E4 (Figure 
3.23C). For SOD1G93A motor neurons treated with 0.5 µM E4 (Figure 3.23B), there 
is a large increase in the frequency of fast speed carriers and a corresponding 
decrease in intermediate speed carriers, compared to DMSO treated controls.   
 
 
 
Figure 3.23. Compound E4 accelerates the axonal transport of HCT in both wild type and 
SOD1G93A motor neurons 
(A) Speed profiles of HCT carriers in wild type + DMSO (black squares) and wild type + 0.5 µM 
E4 (dark green triangles) motor neuron cultures. Comparison of the curves reveals that 
compound E4 accelerates axonal transport in wild type motor neurons (wild type:  153 carriers, 
13 axons; wild type + 0.5 µM E4: 165 carriers, 13 axons; n = 4 independent experiments). (B) 
Speed profiles of HCT carriers in wild type + DMSO, SOD1G93A + DMSO and SOD1G93A + 0.5 µM E4 
motor neuron cultures. Comparison of the curves reveals SOD1G93A motor neurons treated with 
compound E4 (light green triangles) have accelerated axonal transport compared to DMSO treated 
SOD1G93A controls (red diamonds). Wild type:  136 carriers, 12 axons; SOD1G93A: 96 carriers, 13 
axons; SOD1G93A + 0.5 µM E4: 136 carriers, 8 axons; n = 4 independent experiments. (C) 
Deconvolution analysis of the in vitro speed profiles demonstrating that there are four defined 
speed components: 0 µm/s (slow), 0.56 µm/s (intermediate), 1.41 µm/s (fast) and 2.24 µm/s 
(very fast).  
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Finally, compound E4 was also found to accelerate the retrograde axonal transport 
of α-p75NTR. This was observed in both wild type (p = 0.241; Figure 3.24A) and 
SOD1G93A (SOD1G93A versus SOD1G93A + 0.5 µM compound E4: p = 0.004; Figure 
3.24B) motor neurons. These results suggest that compound E4 may act as a 
general enhancer of retrograde axonal transport in motor neurons. 
 
 
 
Figure 3.24. Compound E4 accelerates the axonal transport of α-p75NTR in both wild type 
and SOD1G93A motor neurons 
(A) Speed profiles of α-p75NTR carriers in wild type + DMSO (black squares) and wild type + 0.5 
µM E4 (dark green triangles) motor neuron cultures. Comparison of the curves reveals that 
compound E4 accelerates axonal transport in wild type motor neurons (wild type:  118 carriers, 
6 axons; wild type + 0.5 µM E4: 134 carriers, 8 axons; n = 3 independent experiments). (B) 
Speed profiles of α-p75NTR carriers in wild type + DMSO, SOD1G93A + DMSO and SOD1G93A + 0.5 
µM E4 motor neuron cultures. Comparison of the curves reveals SOD1G93A motor neurons treated 
with compound E4 (light green triangles) also have accelerated axonal transport compared to 
DMSO treated SOD1G93A controls (red diamonds) (wild type:  118 carriers, 6 axons; SOD1G93A: 85 
carriers, 6 axons; SOD1G93A + 0.5 µM E4: 128 carriers, 12 axons; n = 3 independent experiments).  
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3.5. Target Validation Screening 
Compound A1 (an inhibitor of p38 MAPK) and compound E4 (an inhibitor of 
IGF1R) were selected for further investigation. In order to confirm that their effects 
on retrograde axonal transport were due to inhibition of their target kinases, and not 
due to off-target effects, additional screening was performed. The new compound 
library (detailed in Table 5) was composed of structurally diverse p38 MAPK and 
IGF1R inhibitors. Screening was performed using the same methodology as 
previously described (Section 3.3).  
 
As before, hit compounds were defined as those that increased the mean staining 
intensity of HCT and α-p75NTR by at least three standard deviations above the 
DMSO control level, which was taken as 100% (yellow rectangle; Figure 3.25A). Hit 
compounds were further confirmed based on data about the average number of 
vesicles per cell (Figure 3.25B).   
 
Four inhibitors of p38 MAPK (2-A3, 2-C3, 2-D3 and 2-H2; highlighted in blue) were 
found to cause a significant increase in the mean staining intensity of both probes 
in the cell body – mimicking the results seen for compound A1. These four 
compounds also caused an increase in the number of vesicles per cell body and 
were therefore taken forward into in vitro axonal transport assays (see Section 
4.2.1). Only one IGF1R inhibitor, 2-C1 (highlighted in green), caused a significant 
increase in both HCT and α-p75NTR accumulation. However two other compounds, 
2-G2 and 2-B3 (also highlighted in green), caused large increases in α-p75NTR 
accumulation and were therefore also chosen to investigate further (see Section 
5.2.1). 
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Figure 3.25. Target validation screening of additional p38 MAPK and IGF1R inhibitors  
(A) Results of the target validation screening shown as an XY plot of the normalised mean 
staining intensity values for α-p75NTR vs HCT.  Active compounds were defined as those able to 
increase accumulation by at least three-times the standard error (represented by the yellow 
rectangle). The negative control (EHNA) is shown in red. Lead compounds are highlighted in 
blue (p38 MAPK inhibitors) and green (IGF1R inhibitors). (B) Target validation screening results 
shown as an XY plot of the normalised average number of vesicles per cell body values for α-
p75NTR vs HCT. The negative control (EHNA) is shown in red. Lead compounds are highlighted 
in blue (p38 MAPK inhibitors) and green (IGF1R inhibitors). Error bars represent SEM. n ≥ 25 
cell bodies per repeat, n = 3 repeats. 
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3.6. Discussion 
Deficits in axonal transport have not only been described in ALS, but also in many 
other neurodegenerative diseases (Millecamps and Julien, 2013), including 
Huntington’s, Alzheimer’s, Parkinson’s and Charcot Marie Tooth type 2 (see 
Section 1.7.2). Furthermore, accelerating axonal transport using histone 
deacetylase 6 (HDAC6) inhibitors has been shown to be neuroprotective in vivo in 
both Parkinson’s disease (Godena et al., 2014) and Charcot Marie Tooth type 2 
(d'Ydewalle et al., 2011). The identification of pharmacological enhancers of axonal 
transport is therefore relevant to understanding the pathogenesis of many 
neurodegenerative diseases, including ALS.  
 
However, we still have much to learn about the role that axonal transport defects 
play in neurodegeneration. In most cases, it still remains to be shown whether 
axonal transport defects play a key role in triggering neuronal death. In addition, it 
is now clear that axonal transport cannot be considered as a single process. It is 
necessary to try and distinguish the role of anterograde versus retrograde axonal 
transport defects, the presence and contribution of axonal transport defects in 
different neuronal types and the role of different types of cargo, for example, 
signalling endosomes, RNA, mitochondria, late endosomes/lysosomes and 
autophagosomes. The identification of pharmacological modifiers of axonal 
transport with cargo-, neuron- and/or direction-specific effects will enable us to 
investigate these questions in detail.  
 
Modifiers of axonal transport have the potential to become novel therapeutic agents 
for the treatment of several neurodegenerative diseases. It is therefore of interest 
to screen large libraries of compounds to identify new enhancers of axonal 
transport. However, this is not a straightforward task. The most robust way to test a 
compound for its effects on axonal transport is to perform live in vitro or in vivo 
transport assays. Given that a typical in vitro assay takes around two hours to 
complete, and in vivo assays a minimum of six hours, it is not feasible to use such 
assays in a pharmaceutical drug discovery setting, where tens of thousands of 
compounds would typically be screened. For this reason, my project began with the 
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aim of developing a cell-based assay suitable for screening medium-size libraries 
of compounds for their effects on retrograde axonal transport.  
 
3.6.1. The accumulation assay as a screen for enhancers of retrograde 
axonal transport efficiency 
In this Chapter, I have described the development and validation of the 
accumulation assay, which utilises the accumulation of HCT and α-p75NTR in the cell 
body of motor neurons as a read-out for axonal transport efficiency. These probes 
were chosen as their axonal transport has been previously well characterised by 
our laboratory (Lalli and Schiavo, 2002, Lalli et al., 2003a, Deinhardt et al., 2006b). 
We decided to use two probes rather than one as it allowed twice the amount of 
data to be collected without any increase in the time taken to perform the assay, 
and would help validate hit compounds. It also allowed us to potentially identify any 
differences in the regulation of the axonal transport and sorting of the two probes. 
 
I was able to demonstrate that the accumulation of HCT and α-p75NTR in mouse ES-
derived motor neurons was sensitive to both the inhibition and acceleration of 
retrograde axonal transport caused by known modifiers of axonal transport. The 
accumulation assay was successfully adapted to allow for the screening of larger 
numbers of compounds, without any significant loss in sensitivity or increase in 
variability. The use of glass-bottom plates improved the efficiency of the assay, 
whilst automated microscopy allowed plates to be imaged unmonitored overnight in 
order to save time. In addition, automated image analysis software allowed large 
image datasets to be quickly and easily analysed, whilst avoiding bias.  
 
3.6.1.1. Limitations of the accumulation assay 
The use of mouse ES-derived motor neurons 
The accumulation assay was performed in mouse ES-derived motor neurons that 
were engineered to express GFP under the motor neuron-specific promoter Hb9 
(Wichterle et al., 2002). These cells are well suited for use in screening assays, as 
mouse ES cells can be differentiated into motor neurons in a relatively short period 
of time (6 days compared to 28 days for motor neurons derived from pluripotent 
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human stem cells (Hu and Zhang, 2009)) and unlike primary neurons, there is 
almost no limitation on how many cells you can produce. In addition, a higher purity 
of motor neurons is achieved than with primary cultures.  
 
However, mouse ES-derived motor neurons do have their disadvantages. From our 
experience culturing these cells in the laboratory, the quality and quantity of motor 
neurons produced can be very variable. The ES cells are very sensitive to changes 
in timings and media composition and therefore great care must be taken to adhere 
to strict protocols, keep the same suppliers and check for any changes in ingredient 
composition. In addition, there have been questions raised whether these mouse 
ES-derived motor neurons are fully developed and functional neurons, especially 
when assayed after just 3 DIV, as in our experiments. Indeed, it has been 
demonstrated that mouse ES-derived motor neurons are only able to fire repetitive 
trains of action potentials after 3 - 7 DIV (Miles et al., 2004, Bryson et al., 2014). In 
addition, when co-cultured with chick myotubules, ES-derived motor neurons do 
not form functional synapses until 6 DIV (Miles et al., 2004). It is therefore clear that 
the motor neurons we use in our assay are not fully functional. However axonal 
transport is observed to be robustly established at 3 DIV (see Section 3.2.1). In 
addition, the survival of ES-derived motor neurons in vitro drops significantly after 3 
DIV (from 62% at 3 DIV, to 8% at 9 DIV) (Bryson et al., 2014). Therefore to ensure 
sample sizes were large enough for our screening purposes, we chose to assay 
our ES-derived motor neurons after 3 DIV.  
 
The use of Hb9-GFP motor neurons is well suited for our particular screening 
assay as it eliminates the need for additional manipulations of the cells 
(immunocytochemistry), allows the microscope to autofocus on the motor neuron 
layer rather than underlying glial cells and allows our automated image analysis 
software to easily identify motor neurons. As the GFP signal is strongest in the 
soma and weaker in neurites, the analysis software can easily isolate cell bodies 
based on fluorescence intensity. It is worth noting that HB9 plays a key role in early 
motor neuron development and its expression peaks around E11 (Arber et al., 
1999). This again suggests that the Hb9-GFP motor neurons assayed in our screen 
are not fully mature. However, since our results in ES-derived motor neurons can 
be reproduced both in primary motor neurons and in vivo (Sections 3.4 and 4.4.2), 
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it appears that the accumulation assay is able to produce reliable, physiologically 
relevant results.  
 
Design of the assay 
The most obvious limitation of the accumulation assay is the fact that it will not only 
detect compounds that alter axonal transport, but also those that affect other 
processes, such as the binding, internalisation, recycling or degradation of HCT and 
α-p75NTR. It is therefore likely to generate a number of “false positives” when used 
to identify modifiers of axonal transport. However, the rationale behind using the 
accumulation assay was that it would act as a preliminary screen, to identify 
compounds that were likely to be affecting axonal transport, and that subsequent 
live in vitro axonal transport assays would always be necessary to validate hit 
compounds.  
 
Accumulation of HCT and α-p75NTR was assessed in the cell body of motor neurons 
after two hours incubation with the probes. Robust axonal transport of the probes 
begins after approximately 30 minutes, and therefore the two hour time point was 
chosen as it would allow sufficient time for compounds to have a significant effect 
on axonal transport. This reasoning was validated when EHNA, ciliobrevin A and 
ALCAR were tested in the accumulation assay and their effects on axonal transport 
could be sensitively detected (Figure 3.2, Figure 3.4 and Figure 3.5). However, the 
assay could be improved by applying the probes as a “pulse”, for example for 15 
minutes, and then allowing them to accumulate for a further two hours in the 
presence of the compound to be tested. This would eliminate any effects of the 
compounds on the binding of the probes, hopefully making the assay more 
sensitive to changes in axonal transport.  
 
Another limitation of the assay was that the probes were applied to motor neurons 
in mass culture. It is clear that a proportion of the HCT and α-p75NTR accumulating 
in the soma will simply be a result of the probes binding and being internalised in 
situ, rather than a result of retrograde transport along the axon. One way to 
overcome this would be to culture motor neurons in microfluidic devices (Restani et 
al., 2012), which would allow the fluidic isolation of cell bodies and axon terminals. 
In this way, the probes could be applied selectively to the axon terminals and any 
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HCT and α-p75NTR accumulating in the cell bodies must have been delivered by 
retrograde axonal transport. The only exception to this would be if motor neurons 
released HCT and/or α-p75NTR and it was taken up by other motor neurons (rather 
than interneurons as is the case in vivo). However, the use of microfluidic devices 
is not yet suited for use in screening assays, as the preparation is time consuming 
and expensive and such devices are not available in a format suitable for 
automated microscopy.  
 
The assays described in this Chapter were performed in 24 well glass bottom 
plates and the screening library provided by GSK contained only 56 compounds. It 
was therefore possible to handle the number of 24 well plates required to perform 
the assay in triplicate. However, such a plate format would not be suitable for 
screening typical pharmaceutical compound libraries. If the assay were to be used 
for high throughput screening, 96 well or even 384 well plates would have to be 
utilised. In fact, microscopy-based survival assay screens have already been 
successfully performed using mouse ES-derived motor neurons in 384 well plates 
(Yang et al., 2013). It should therefore be possible to scale up the accumulation 
assay in this way. However, a significant amount of work would be required to 
optimise the motor neuron cultures, for example to prevent clustering of the cells at 
the centre of the well (more likely with a reduced plating volume), and to achieve a 
high enough frequency of GFP-positive cells such that sufficient n numbers are 
reached with automated image acquisition.  
 
Automated microscopy and analysis of results 
Imaging of screening plates was performed using a confocal microscope with an 
automated stage and an autofocus function. This allowed plates to be imaged 
unattended and often overnight in order to save time. Confocal microscopy was 
used as it allowed sufficient resolution for individual endosomes to be visualised in 
the cell body. However, it was not possible to optimise the autofocus function of the 
microscope to ensure that every image of every well was in focus. This is most 
likely an inherent problem of neuronal cultures, where neuronal cell bodies are 
large and often at different heights due to variations in the underlying glial layer. 
Therefore in order to acquire in-focus, comparable images, a Z stack of four 
images was acquired at each location. In this way the optimal image could be 
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selected for analysis. However, in combination with acquiring images with a high 
enough resolution to see individual endosomes, this increased the imaging time 
significantly, with one 24 well plate taking up to 10 hours to fully image. It also 
added another step to the analysis process – selection of the optimal image from 
each Z stack – that could not be automated. Again, such a protocol would not be 
suitable for screening much larger libraries of compounds. To solve this problem, 
automated fluorescence imaging (using systems such as the Cellomics ArrayScan 
or Opera Phenix™) could be utilised rather than confocal microscopy. This would 
allow much faster image acquisition. Although it is unlikely that individual 
endosomes could be visualised using such a system, it is likely that robust staining 
intensity data could still be collected. 
 
Image datasets were analysed using Cell Profiler – a free image analysis software 
that allows you to build customised analysis pipelines. In this way, a pipeline could 
be developed that identified cell bodies based on size constraints and the intensity 
of the Hb9-GFP signal, and then measured the intensity of the HCT and α-p75NTR 
staining within the identified cell bodies. This part of the pipeline worked very nicely, 
and could sensitively and reproducibly detect changes in accumulation caused by 
EHNA, ciliobrevin A and ALCAR. The pipeline was also set up to identify individual 
vesicles within the cell bodies and determine the number of vesicles per cell body. 
Unfortunately, as can be seen in Figure 3.8, the software was not always able to 
accurately identify single endosomes. This problem was particularly obvious when 
there were large numbers of vesicles accumulated, as they tend to cluster and it is 
difficult to teach the software to recognise individual endosomes within a cluster. 
Increasing the resolution and magnification of the images acquired would help 
improve this, but it would not be conducive for screening purposes. The vesicle 
number data acquired from our screen did correlate with the staining intensity 
results (for example, E4 caused the largest increase in accumulation judged by 
both parameters), indicating it is a sensitive measure of HCT and α-p75NTR 
accumulation. However, due to the limited sensitivity of this parameter, I would 
recommend only using this data to help validate hits from the staining intensity 
results, rather than as a primary source for selecting hit compounds.  
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3.6.2. Identification and validation of lead compounds 
3.6.2.1. Preliminary screening 
Limitations of the protocol 
The accumulation assay was successfully used to identify three active compounds 
in the preliminary screen – A1, C3 and E4. When tested in in vitro axonal transport 
assays, two of these compounds were found to alter the retrograde axonal 
transport of HCT and α-p75NTR. This indicates that the accumulation assay is an 
effective way to screen compounds for their effects on axonal transport in motor 
neurons.  
 
A limitation of our preliminary screen was the lack of a positive control in the 
screening plates. At the start of the Chapter, we were able to demonstrate that 
ALCAR causes a small acceleration of retrograde axonal transport and that this 
can be detected by the accumulation assay (see Section 3.2.1). It would have been 
a useful control in our screening plates, in order to confirm that the screening 
conditions, microscope settings and data analysis protocol were optimal for 
identifying enhancers of axonal transport and also to quantitatively compare the 
effects on accumulation of any active compounds with the known effect of ALCAR 
on accumulation and transport.  
 
Consideration of the results 
The preliminary screening identified A1 as an active compound and it was 
subsequently shown to correct SOD1G93A-induced deficits in retrograde axonal 
transport in primary motor neurons. Interestingly, compound A1 actually had no 
effect on retrograde axonal transport speeds in wild type motor neurons. 
Considering compound A1 was identified in the accumulation assay using wild type 
ES-derived motor neurons, this was a somewhat surprising result. It appears that, 
by chance, compound A1 affects the somatic accumulation of HCT and α-p75NTR 
through a mechanism unrelated to its effect on axonal transport in SOD1G93A motor 
neurons and this is why it was identified as a hit in the accumulation assay. When 
we assessed the effects of the compounds on the internalisation of the probes, 
compound A1 caused a small but significant increase in the internalisation of 
α-p75NTR, but not HCT (Figure 3.14). p38 MAPK has been previously implicated in 
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the regulation of growth factor receptor internalisation (Zwang and Yarden, 2006) 
and early endocytic membrane trafficking by Rab5 (Cavalli et al., 2001). However, 
these studies found that activated p38 MAPK enhances internalisation, rather than 
inhibits it, and therefore cannot explain our results.  
 
Another point worth noting is the observed toxicity of compounds C3 and E4 when 
tested in live in vitro axonal transport assays at the screening concentration of 2 µM. 
This is most likely due to the fact that the compounds inhibit key neurotrophic 
(RET; C3) and growth factor receptors (IGF1R; E4). However it is hard to explain 
why this toxicity was not observed initially in the accumulation assay, as all of our 
screening plates were checked for overt signs of toxicity. It could be that the 
presence of axonal blebbing was not visible unless viewed at 63X or 100X as used 
for in vitro axonal transport assays. Alternatively it could be that the culturing 
conditions used for axonal transport assays (MatTek dishes versus 24-well plates) 
make the neurons more sensitive to the toxic effects of these compounds. These 
results highlight the fact that if the accumulation assay were to be used to screen 
more compounds, especially if it were used for larger libraries, it would be 
necessary to check for motor neuron toxicity in parallel. 
 
It is also possible that some of the compounds in our screening assay were 
incorrectly eliminated as false negatives. This is an inherent problem with 
screening, as only a limited number of compounds can be taken forward for further 
testing. We initially identified six active compounds, based on the staining intensity 
and vesicle number data (see Figure 3.10 and Figure 3.11). After performing dose 
response analysis and additional repeats at the screening concentration, only three 
of these compounds were chosen for further investigation. Interestingly the three 
remaining compounds (A4, D1, D3) were later revealed to have the same target - 
vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR-2 has not been 
linked to the regulation of axonal transport previously. However, the receptor 
activates a number of downstream kinases including p38 MAPK and PKC, both of 
which have been shown to negatively regulate fast axonal transport (Ozsarac et al., 
2003, Morfini et al., 2013) and could explain why VEGFR-2 inhibitors were 
identified in our screen.  
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3.6.2.2. Target validation screening 
Additional inhibitors of p38 MAPK and IGF1R were screened using the 
accumulation assay to validate these kinases as the targets of A1 and E4 
respectively (Figure 3.25). Four p38 MAPK inhibitors and three IGF1R inhibitors 
were selected as hit compounds and their effects on axonal transport are described 
in the following Chapters. A limitation of this screen was the bias towards inhibitors 
of p38 MAPK (see Table 5 in Materials and Methods). This was a reflection of 
GlaxoSmithKline’s interests. 
 
It should be noted that not all the p38 MAPK or IGF1R inhibitors that were 
screened had the same effect. In fact, the majority of compounds did not have a 
significant effect on the accumulation of either probe. This is not entirely surprising, 
as the inhibitors had only been previously tested in in vitro kinase assays and/or in 
efficacy assays in standard cell lines. It is therefore possible that these compounds 
have reduced permeability through the motor neuron plasma membrane, are 
degraded by motor neurons or the screening concentration of 2 µM is not high 
enough to yield significant kinase inhibition.  
 
There are also some compounds, however, that appear to have the opposite effect 
on accumulation of the probes compared to our lead compounds A1 and E4. It 
could be that these compounds are toxic to motor neurons, or that their off-target 
effects alter accumulation in a way that obscures any effect on axonal transport. 
There also appears to be a trend in increasing effect on HCT accumulation with the 
IGF1R-targeted inhibitors 2-B3, 2-G2 and 2-C1 (shown in green in Figure 3.25). It 
would be interesting to look into the chemical and pharmacological profiles of these 
compounds and try to determine what underlies this effect. This result also 
highlights the fact that it may be possible to identify compounds able to specifically 
enhance the axonal transport of just one of the probes. Colocalisation studies in 
our laboratory have previously shown that HCT and α-p75NTR are transported in the 
same signalling endosomes (Lalli and Schiavo, 2002, Deinhardt et al., 2006b). 
However, the present results suggest there could be different mechanisms 
regulating their retrograde axonal transport.  
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3.6.3. Further applications of the accumulation assay 
Deficits in axonal transport have been described in several neurodegenerative 
diseases (Millecamps and Julien, 2013) and therefore the identification of novel 
pharmacological enhancers of retrograde axonal transport could be useful for a 
number of CNS pathologies, in addition to ALS. The accumulation assay could be 
applied to different neuronal types in order to identify potential novel therapeutics 
and to understand the role of axonal transport defects in other neurodegenerative 
diseases. For example, in Huntington’s disease, mutant htt has been shown to 
induce defects in both retrograde and anterograde axonal transport (Morfini et al., 
2009, Her and Goldstein, 2008, Zala et al., 2008). Identifying novel enhancers of 
retrograde axonal transport in striatal and hippocampal neurons could therefore 
potentially allow the role of anterograde versus retrograde defects to be 
distinguished in Huntington’s disease.  
 
It would also be very interesting to perform the accumulation assay in both mouse 
ES-derived motor neurons expressing ALS-associated mutations and ALS patient 
iPSC-derived motor neurons. A number of different ALS patient–specific iPSCs 
have now been successfully differentiated into spinal cord motor neurons, including 
those with disease-causing mutations in SOD1 (Alami et al., 2014, Chen et al., 
2014), TDP43 (Egawa et al., 2012, Devlin et al., 2015), VCP (Patani et al., 2012) 
and C9orf72 (Sareen et al., 2013, Devlin et al., 2015). In addition, some of these 
iPSC-derived motor neurons have already been utilised in screening assays 
(Egawa et al., 2012) and could therefore help generate more disease-relevant hits 
than assays performed in mouse cell lines. However, preliminary work is required 
to determine whether ES-derived motor neurons expressing ALS-associated 
mutations and ALS patient iPSC-derived motor neurons display defects in axonal 
transport.  
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Chapter 4. Inhibition of p38 MAPK rescues axonal 
transport defects in SOD1G93A mice 
4.1. Introduction 
Results presented in Chapter 3 suggest that inhibition of p38 MAPK is able to 
restore defects in retrograde axonal transport that are observed in motor neurons 
derived from the SOD1G93A mouse model of ALS.  
 
p38 MAPK is a member of the mitogen-activated protein kinase family of 
serine/threonine kinases, which also includes extracellular signal-regulated kinases 
(ERKs) and c-Jun-N-terminal kinases (JNKs) (see Figure 4.1). p38 MAPK is 
activated in response to inflammation and stressful stimuli, for example tumour 
necrosis factor-α (TNFα), interleukin 1 (IL1), heat shock and UV irradiation. The 
kinase is involved in a wide variety of cellular processes, including phosphorylation 
of cytoskeletal proteins, biosynthesis of cytokines and nitric oxide, protein 
degradation and endocytosis (Cuadrado and Nebreda, 2010).  
 
There are four p38 MAPK isoforms: α (MAPK14), β (MAPK11), γ (MAPK12) and δ 
(MAPK13), all of which are widely expressed in mammalian tissues. However, p38 
MAPKα and β are considered to be the major isoforms expressed in the central 
nervous system (Morfini et al., 2013). There is some overlapping substrate 
specificity between the four isoforms and a degree of functional redundancy has 
been hypothesised (Cuenda and Rousseau, 2007).  
 
4.1.1. The p38 MAPK signalling cascade 
All isoforms are activated by phosphorylation at Thr180 and Tyr182 in the 
activation loop. Phosphorylation induces a conformational change that removes 
steric blocking of the active site and stabilizes the activation loop in an open 
conformation, allowing substrate binding (Cuenda and Rousseau, 2007). For all 
four isoforms, this phosphorylation is mediated by the upstream kinase (MAPKK) 
MKK6. In addition, p38 MAPK α, γ and δ are also phosphorylated by MKK3 and 
p38 MAPK α and δ can also be phosphorylated by MKK4, an activator of JNK 
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(Cuadrado and Nebreda, 2010). All of these MKKs are in turn activated by 
upstream kinases (MAPKKKs), such as ASK1 (Bendotti et al., 2005) (illustrated in 
Figure 4.1).  
 
 
 
Figure 4.1. The mitogen-activated protein kinase (MAPK) signalling cascade  
MAPK cascades are comprised of a MAPK kinase kinase (MAPKKK) which, when activated by 
phosphorylation, phosphorylates a MAPK kinase (MAPKK). This MAPKK goes on to 
phosphorylate and activate its target MAPK. In mammals, there are three families of MAPKs: 
the extracellular signal-regulated kinases 1 and 2 (ERK1/2), the c-Jun amino-terminal kinases 
(JNKs) and the p38 MAPKs. Modified from (Pierce et al., 2002). Reprinted with permission from 
the Nature Publishing Group. 
 
 
p38 MAPK signalling is terminated by the activity of a number of phosphatases. 
These enzymes dephosphorylate Thr180 and Tyr182 in the activation loop and 
return p38 MAPK to its resting conformation. This termination of signalling can be 
mediated by generic serine/threonine phosphatases, such as protein phosphatase 
2A and 2C, and/or generic tyrosine phosphatases, such as striatal enriched 
tyrosine phosphatase (STEP). Dephosphorylation can also be mediated by a family 
of dual-specificity phosphatases that are able to dephosphorylate both phospho-
tyrosine and phospho-threonine residues (Cuadrado and Nebreda, 2010). 
 
4.1.2. Downstream targets 
p38 MAPK is implicated in the regulation of a wide variety of cellular processes. 
Therefore it is not surprising that it has been shown to phosphorylate a plethora of 
downstream targets. As well as activating downstream kinases such as 
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MAPAPK2/3, MNK1/2 and MSK1/2 (Cuadrado and Nebreda, 2010), p38 MAPK 
also phosphorylates a variety of non-kinase cytoplasmic and nuclear proteins 
directly (see Figure 4.2). It is of particular interest to note that p38 MAPK has been 
shown to phosphorylate proteins involved in endocytic trafficking, including Rho-
GDI (Cavalli et al., 2001) and the Rab5 effector EEA1 (Mace et al., 2005). p38 
MAPK has also been demonstrated to phosphorylate the microtubule-associated 
protein tau (Reynolds et al., 2000).   
 
 
 
Figure 4.2. Downstream targets of p38 mitogen-activated protein kinase 
p38 MAPK has been shown to phosphorylate a wide range of downstream targets, including 
both cytoplasmic and nuclear proteins. Illustration reproduced with permission from Cell 
Signaling Technology, Inc. (www.cellsignal.com). 
 
 
 
The aim of this Chapter was to determine the role of p38 MAPK in inducing 
retrograde axonal transport deficits in the SOD1G93A mouse model of ALS.  
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4.2. In vitro validation of p38 MAPK as the target kinase 
 
The results of the preliminary screening assay and in vitro axonal transport 
experiments described in 0 suggest that inhibitors of p38 MAPK are able to rescue 
deficits in retrograde axonal transport in vitro in SOD1G93A motor neurons.  
 
In this Chapter, p38 MAPK is validated as the target kinase responsible for the 
observed effects on axonal transport and its activity in SOD1G93A motor neurons is 
investigated both in vitro and in vivo. In addition, the effects of p38 MAPK inhibition 
on retrograde axonal transport in vivo are investigated. 
 
4.2.1. Confirming the hits of the validation screen 
In order to confirm that the effects of compound A1 were due to inhibition of p38 
MAPK and not due to off-target effects, additional inhibitors were screened in ES-
derived motor neurons using the accumulation assay (described in Section 3.5). 
Four active compounds were identified (2-A3, 2-C3, 2-D3, 2-H2) and tested in live 
in vitro axonal transport assays in primary SOD1G93A motor neurons. All four 
compounds were found to mimic the effect of compound A1, restoring retrograde 
axonal transport in SOD1G93A motor neurons (Figure 4.3; SOD1G93A versus 
SOD1G93A + 2 µM compound 2-A3: p = 0.010, SOD1G93A versus SOD1G93A + 2 µM 
compound 2-C3: p = 0.047, SOD1G93A versus SOD1G93A + 2 µM compound 2-D3: 
p = 0.053, SOD1G93A versus SOD1G93A + 2 µM compound 2-H2: p = 0.020).  
 
To further validate p38 MAPK as the target, we next investigated the effect of 
activating p38 MAPK on retrograde axonal transport in wild type motor neurons. 
Live in vitro axonal transport assays were performed in the presence of 0.5 µg/ml 
anisomycin, an established activator of p38 MAPK (Figure 4.4A). Activation of p38 
MAPK in primary wild type motor neurons was found to significantly inhibit the 
retrograde axonal transport of HCT-labelled carriers (p = 0.0003; Figure 4.4B).  
Chapter 4 Results 
 
 116 
 
 
Figure 4.3. Structurally diverse inhibitors of p38 MAPK also correct retrograde axonal 
transport defects in SOD1G93A motor neurons 
Speed profiles of HCT carriers in wild type + DMSO (black squares), SOD1G93A + DMSO (red 
diamonds) and SOD1G93A motor neurons treated with 2 µM of each of the hit p38 MAPK compounds 
(blue triangles): 2-A3 (A), 2-C3 (B), 2-D3 (C), 2-H2 (D). Wild type: 74 carriers, 8 axons; SOD1G93A: 
119 carriers, 7 axons; SOD1G93A + 2 µM 2-A3: 120 carriers, 7 axons; SOD1G93A + 2 µM 2-C3: 117 
carriers, 8 axons; SOD1G93A + 2 µM 2-D3: 166 carriers, 9 axons; SOD1G93A + 2 µM 2-H2: 94 carriers, 
7 axons. 3 independent experiments.  
 
 
 
 
Figure 4.4. Activation of p38 MAPK inhibits retrograde axonal transport of HCT  
(A) Treatment of wild type motor neuron cultures with 0.5 µg/ml anisomycin for 30 min causes a 
substantial activation of p38 MAPK. (B) Speed profiles of HCT carriers in primary wild type 
motor neuron cultures treated with either DMSO (black squares) or 0.5 µg/ml anisomycin (red 
diamonds). Anisomycin causes a shift to slower transport speeds (DMSO treated:  77 carriers, 8 
axons; 76 Anisomycin treated: carriers, 8 axons; 3 independent experiments). 
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4.2.2. Determining the effects of p38 MAPK inhibition on the retrograde 
axonal transport of late endosomes/lysosomes and autophagosomes 
Up until this point, the effect of p38 MAPK inhibition had only been studied using 
HCT and α-75NTR (cargoes of signalling endosomes). It was therefore interesting to 
investigate whether p38 MAPK was responsible for defects in the axonal transport 
of other cargoes. To this end, we performed in vitro axonal transport assays in 
primary motor neurons using Lysotracker™. Lysotracker™ is a fluorescent dye that 
labels all acidic organelles (late endosomes/lysosomes and autophagosomes) and 
therefore allows both retrograde and anterograde axonal transport to be analysed. 
The direction of transport was determined in these experiments by co-incubation 
with HCT. The results with Lysotracker™ indicate that there is a defect in the 
retrograde axonal transport of acidic organelles in SOD1G93A motor neurons (Figure 
4.5A; p = 0.145). As in our experiments investigating the axonal transport of 
signalling endosomes, we found that treatment of SOD1G93A motor neurons with 
2 µM A1 was able to correct deficits in Lysotracker™ retrograde transport (Figure 
4.5B; SOD1G93A versus SOD1G93A + 2 µM compound A1: p = 0.026). 
 
 
 
Figure 4.5. Compound A1 rescues defects in the retrograde axonal transport of 
Lysotracker™ in SOD1G93A motor neurons 
(A) Retrograde speed profiles of Lysotracker™-labelled carriers in wild type (black squares) and 
SOD1G93A (red diamonds) motor neuron cultures. (B) Retrograde speed profiles of Lysotracker™-
labelled carriers in wild type + DMSO (black squares), SOD1G93A + DMSO (red diamonds) and 
SOD1G93A + 2 µM A1 (blue triangles) motor neuron cultures (wild type: 85 carriers, 12 axons; 
SOD1G93A: 30 carriers, 15 axons; SOD1G93A + 2 µM A1: 39 carriers, 13 axons; 5 independent 
experiments).  
 
 
The anterograde axonal transport of mitochondria and RNA has also been 
previously shown to be defective in ALS (Alami et al., 2014, Bilsland et al., 2010) 
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and p38 MAPK has been suggested to be responsible for mutant SOD1-induced 
defects in anterograde axonal transport in squid axoplasm (Morfini et al., 2013).  
 
However, in our in vitro axonal transport assays using Lysotracker™, we could not 
detect any deficit in anterograde axonal transport (Figure 4.6; p = 0.698). This 
suggests that axonal transport defects in ALS are both cargo and direction-specific. 
 
 
 
Figure 4.6. The anterograde axonal transport of Lysotracker™ is not defective in 
SOD1G93A motor neurons 
Speed profiles of Lysotracker™-labelled carriers moving in the anterograde direction in wild type 
(black squares) and SOD1G93A (red diamonds) motor neuron cultures (wild type + DMSO: 44 
carriers, 14 axons; SOD1G93A + DMSO: 45 carriers, 15 axons; 5 independent experiments).  
 
 
 
4.2.2.1. p38 MAPK is activated in motor neurons isolated from SOD1G93A 
mice 
The ability of inhibitors of p38 MAPK to rescue defects in retrograde axonal 
transport in SOD1G93A motor neurons, whilst having no effect on transport speeds 
in wild type motor neurons, suggests that the kinase is specifically activated in 
SOD1G93A motor neurons.  
 
Indeed, p38 MAPK has been previously shown to be activated in motor neurons of 
adult SOD1G93A mice (Tortarolo et al., 2003, Dewil et al., 2007, Morfini et al., 2013). 
However, given the effect of compound A1 in our in vitro axonal transport assays, it 
was important to assess the levels of phosphorylated p38 MAPK in primary 
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SOD1G93A motor neurons. Immunofluorescence analysis revealed increased levels 
of phospho-p38 MAPK in motor neurons overexpressing human SOD1G93A (Figure 
4.7A), whilst overexpression of the wild type form of the human SOD1 protein 
(SOD1WT) had no effect (Figure 4.7B). 
 
 
 
Figure 4.7. p38 MAPK activation can be seen by immunofluorescence in primary 
SOD1G93A motor neurons 
(A) Immunofluorescence staining using an antibody directed against phosphorylated p38 MAPK 
reveals an increase in phopsho-p38 MAPK levels in SOD1G93A motor neurons compared to wild 
type controls. (B) As a control, motor neurons overexpressing wild type SOD1 were compared 
with wild type motor neurons. p38 MAPK is not activated in these motor neurons. Scale bars, 10 
µm.  
 
 
Western blot analysis of lysates made from primary motor neuron cultures 
confirmed that there was a small but significant increase in phospho-p38 MAPK 
levels in SOD1G93A motor neurons compared to wild type controls and also 
confirmed that 2 µM compound A1 caused a significant inhibition of p38 MAPK 
activity in SOD1G93A motor neurons (Figure 4.8A). In addition, we confirmed that 
overexpression of wild type human SOD1 (SOD1WT) was not responsible for the 
increased levels of phospho-p38 MAPK in these cultures (Figure 4.8B).  
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Figure 4.8. p38 MAPK is activated in primary SOD1G93A motor neurons 
(A) Top Western blot showing activation of p38 MAPK in SOD1G93A motor neuron cultures 
compared to wild type controls. Compound A1 normalises phospho-p38 MAPK in SOD1G93A 
cultures to wild type levels. Bottom Western blot quantification reveals a 1.5 fold increase in 
phospho-p38 MAPK levels in SOD1G93A motor neuron cultures compared to wild type cells, and 
confirms the normalisation of p38 MAPK activity by compound A1 (n = 3 independent 
experiments). ** p< 0.01, *** p < 0.001 (One-way ANOVA followed by Sidak’s multiple 
comparison test). (B) Top Western blot showing p38 MAPK activity in motor neurons 
overexpressing the SOD1WT protein. Bottom Western blot quantification detected no significant 
difference in phospho-p38 MAPK levels between wild type cultures and motor neurons 
overexpressing SOD1WT (n = 3 independent experiments). Non-significant using unpaired 
Student’s t test. Error bars represent SEM.  
 
 
 
Western blot analysis was also performed on lysates of spinal cords collected from 
adult SOD1G93A and SOD1WT mice. Pre-symptomatic (36 d), early symptomatic 
(73 d), symptomatic (96 d) and late symptomatic (115 d) SOD1G93A mice were 
chosen so that phospho-p38 MAPK levels could be directly correlated with the in 
vivo axonal transport defects previously described by our laboratory (Bilsland et al., 
2010). Phospho-p38 MAPK levels were found to be increased in the spinal cord of 
pre-symptomatic SOD1G93A mice, whilst SOD1WT controls showed no increase 
compared to wild type mice (Figure 4.9). Phospho-p38 MAPK levels were observed 
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to be highest in early symptomatic SOD1G93A mice - the age at which in vivo axonal 
transport defects are most severe (Bilsland et al., 2010).  
 
 
 
Figure 4.9. p38 MAPK is activated in an age-dependent manner in the spinal cord of adult 
SOD1G93A mice 
Western blot showing levels of phospho-p38 MAPK in spinal cord lysates from wild type, 
SOD1G93A and SOD1WT overexpressing mice. Phospho-p38 MAPK levels are increased in pre-
symptomatic (36 d) and early symptomatic (73 d) SOD1G93A mice. Spinal cords from SOD1WT 
overexpressing mice show no change in phospho-p38 MAPK levels compared to wild type 
controls (n = 1 animal per condition). 
 
 
 
Finally, the intracellular localisation of phospho-p38 MAPK was investigated in vitro 
in primary SOD1G93A motor neurons. The punctate staining of phospho-p38 MAPK 
(as seen in Figure 4.7) suggested that the kinase might be located on endosomes. 
However phospho-p38 MAPK was not found to colocalise with either HCT or Rab7 
(Figure 4.10A and B). This was in agreement with previous data from our 
laboratory characterising the composition of HCT-labelled endosomes using mass 
spectrometry (Solène Debaiseux, UCL Institute of Neurology). Furthermore, there 
was no colocalisation with AlexaFluor 488-conjugated wheat germ agglutinin 
(WGA; Figure 4.10C), which binds to sialic acid and N-acetylglucosaminyl residues 
and therefore labels all membranous compartments. To date, the intracellular 
location of activated p38 MAPK remains unclear.  
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Figure 4.10. Activated p38 MAPK does not colocalise with endocytic markers  
Primary SOD1G93A motor neurons were fixed and co-stained for phospho-p38 MAPK and HCT  
(A), Rab7 (B) or WGA (C). No colocalisation was found with any of the markers tested. Scale 
bars, 10 µm.  
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4.3. Identification of the p38 MAPK isoform responsible for 
axonal transport deficits in SOD1G93A motor neurons 
As there are four isoforms of p38 MAPK (α, β, γ and δ), it was important to 
distinguish which isoform(s) is responsible for the axonal transport defects 
observed in SOD1G93A motor neurons.  
 
 
 
Figure 4.11. All four p38 MAPK isoforms are expressed in primary motor neurons 
Lysates of primary wild type and SOD1G93A motor neurons were subjected to western blotting 
using isoform-specific antibodies. Mouse brain lysate was loaded as an antibody control for p38 
MAPKβ. 
 
 
 
All four isoforms were found to be expressed in primary motor neuron cultures 
(Figure 4.11), therefore both genetic knockdown and pharmacological inhibition 
approaches were utilised in order to determine which isoform was affecting 
retrograde axonal transport.  
 
4.3.1. Knockdown of p38 MAPK isoforms in N2A cells and primary motor 
neurons 
p38 MAPKα (also known as MAPK14) is strongly expressed in both embryonic and 
adult motor neurons and has been previously shown to inhibit anterograde axonal 
transport in isolated squid axoplasm (Morfini et al., 2013). To investigate whether 
p38 MAPKα is responsible for the defects in retrograde axonal transport observed 
in mouse primary SOD1G93A motor neurons, we ordered four shRNAs targeted 
against different sequences within the MAPK14 mRNA. The shRNA constructs 
contained an eGFP reporter gene, to allow easy identification of 
transfected/transduced cells. The shRNA constructs were first tested in N2A cells, 
in order to determine which caused the most efficient knockdown of p38 MAPKα. 
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Figure 4.12. Testing MAPK14 shRNA constructs in N2A cells 
(A) N2A cells were transfected with four different shRNA constructs against MAPK14 (p38 
MAPKα), as well as a scrambled control. GFP indicates expression of the construct. (B) 
Quantification of the western blot in (A) showing knockdown of p38 MAPKα in N2A cells with 
different shRNA constructs. n = 1. (C) N2A cells transfected with either scrambled shRNA (top) 
or MAPK14 shRNA construct 1 (bottom) were stained with an antibody against p38 MAPK. GFP 
indicates transfected cells. Scale bars, 10 µm.  
 
 
 
N2A cells were transfected with the shRNA constructs using Lipofectamine™ and 
lysates were prepared. Western blot analysis revealed that shRNA 1 caused the 
strongest knockdown of p38 MAPKα (Figure 4.12A and B), and this was confirmed 
by immunofluorescence (Figure 4.12C).  
 
The MAPK14 shRNA 1 construct was therefore used to produce lentiviral particles, 
along with the scrambled construct as a control, so that we could knockdown p38 
MAPKα in our primary motor neuron cultures.  
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Figure 4.13. Knocking down p38 MAPKα in primary motor neuron cultures 
(A) Lysates were made from motor neurons transduced with increasing amounts of lentivirus 
expressing either scrambled or MAPK14 shRNA. Western blotting with an antibody specific for 
p38 MAPKα reveals a dose-dependent knockdown with the MAPK14 shRNA but not when 
scrambled shRNA is used. GFP indicates expression of the shRNA construct. (B) Quantification 
of the blots shown in (A). Levels of p38 MAPKα are normalised to the loading control GAPDH. n 
= 1. 
 
 
 
 
Lentiviral transduction of primary motor neurons with increasing amounts of 
MAPK14 shRNA was found to cause a dose-dependent reduction in p38 MAPKα 
protein levels, whilst scrambled shRNA had no effect (Figure 4.13). These results 
were also confirmed by immunofluorescence in primary motor neuron cultures 
(Figure 4.14).  
 
Our lentiviral shRNA vectors could therefore be used to determine the effect of 
knocking down p38 MAPKα on retrograde axonal transport in primary motor 
neurons.  
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Figure 4.14. Immunofluorescence reveals knockdown of p38 MAPKα in motor neurons 
(A) Comparison of non-transduced primary motor neurons with those transduced with MAPK14 
shRNA. Motor neurons were stained with an antibody against pan p38 MAPK. GFP marks 
transduced motor neurons. Representative images were acquired from motor neurons on the 
same coverslip. (B) Comparison of non-transduced primary motor neurons with those 
transduced with a scrambled shRNA construct. Motor neurons were stained with an antibody 
against pan p38 MAPK. GFP expression indicates transduced motor neurons. Representative 
images were acquired from motor neurons on the same coverslip. Scale bars, 10 µm.  
 
 
Firstly, an important control experiment was to determine whether transfection of 
primary motor neurons with the scrambled shRNA control had any effect on axonal 
transport speeds. This experiment was performed in both wild type and SOD1G93A 
motor neurons using the HCT probe and 1 µl of the scrambled shRNA lentiviral 
vector. Scrambled shRNA was found to have no effect on retrograde axonal 
transport in either genotype (Figure 4.15; wild type untreated versus wild type + 
scram shRNA: p = 0.624, SOD1G93A versus SOD1G93A + scram shRNA: p = 0.449).  
 
We therefore investigated the effect of knocking down p38 MAPKα in both wild type 
and SOD1G93A primary motor neurons (Figure 4.16). 
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Figure 4.15. Transduction with scrambled shRNA has no effect on retrograde axonal 
transport in primary motor neurons 
(A) Speed profiles of HCT carriers in untreated wild type motor neurons (green circles) and wild type 
motor neurons transduced with 1 µl scrambled shRNA lentivirus (black squares). Comparison of the 
curves reveals that scrambled shRNA constructs have no effect on retrograde axonal transport 
speeds (wild type untreated: 62 carriers, 5 axons; wild type + scrambled shRNA: 89 carriers, 17 
axons; 3 independent experiments). (B) Speed profiles of HCT carriers in untreated SOD1G93A motor 
neurons (green circles) and SOD1G93A motor neurons transduced with 1 µl scrambled shRNA 
lentivirus (red diamonds). Comparison of the curves reveals that the scrambled shRNA construct 
(green triangles) has no effect on axonal transport speeds (SOD1G93A untreated: 45 carriers, 7 
axons; SOD1G93A + scrambled shRNA: 104 carriers, 24 axons; 4 independent experiments). 
 
 
 
 
Figure 4.16. The effect of knocking down p38 MAPKα on retrograde axonal transport in 
primary wild type and SOD1G93A motor neurons 
(A) Speed profiles of HCT-labelled signalling endosomes in wild type motor neurons transduced with 
1 µl scrambled shRNA lentivirus (black squares) or 1 µl MAPK14 shRNA lentivirus (blue triangles). 
Comparison of the curves reveals that knocking down MAPK14 in wild type motor neurons has no 
enhancing effect on axonal transport (wild type + scrambled shRNA: 89 carriers, 17 axons; wild type 
+ MAPK14 shRNA: 62 carriers, 14 axons; 4 independent experiments). (B) Speed profiles of HCT-
labelled signalling endosomes in wild type motor neurons transduced with 1 µl scrambled shRNA 
lentivirus (black squares), SOD1G93A motor neurons transduced with 1 µl scrambled shRNA 
lentivirus (red diamonds) and SOD1G93A motor neurons transduced with 1 µl MAPK14 shRNA 
lentivirus (blue triangles). Comparison of the curves reveals that knocking down MAPK14 in 
SOD1G93A motor neurons (blue triangles) accelerates axonal transport to wild type speeds (black 
squares) (wild type + scrambled shRNA: 89 carriers, 17 axons; SOD1G93A + scrambled shRNA: 104 
carriers, 24 axons; SOD1G93A + MAPK14 shRNA: 99 carriers, 20 axons; 4 independent 
experiments). 
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In wild type motor neurons, p38 MAPKα knockdown caused a small, but non-
significant, slowing of retrograde axonal transport speeds (p = 0.257; Figure 4.16A). 
On the other hand, knocking down p38 MAPKα in SOD1G93A motor neurons was 
able to effectively restore axonal transport speeds to physiological wild type levels 
(WT + scram shRNA versus SOD1G93A + MAPK14 shRNA: p = 0.194, SOD1G93A + 
scram shRNA versus SOD1G93A + MAPK14 shRNA: p = 0.0003; Figure 4.16B). 
This result mimics those seen previously using pharmacological inhibitors of p38 
MAPK (Figure 3.18) and suggests that p38 MAPKα is responsible for SOD1G93A-
induced defects in retrograde axonal transport.  
 
In order to demonstrate that the results of our knockdown experiments were 
specific to p38 MAPKα, we also ordered an shRNA clone set targeted against p38 
MAPKδ (MAPK13). Again the four shRNA constructs were tested in N2A cells, in 
order to determine which produced the most efficient knockdown. Western blot 
analysis revealed that MAPK13 shRNA 3 could reduce p38 MAPKδ levels by ~60% 
(Figure 4.17) and this construct was therefore chosen to produce lentiviral particles.  
 
 
 
Figure 4.17. Testing MAPK13 shRNA constructs in N2A cells 
(A) N2A cells were transfected with four different shRNA constructs against MAPK13 (p38 
MAPKδ), as well as a scrambled control. GFP indicates expression of the construct. (B) 
Quantification of the western blot in (A) showing knockdown of p38 MAPKδ in N2A cells with 
different shRNA constructs. n = 1. 
 
 
Lentiviral transduction of primary motor neurons with MAPK13 shRNA caused a 
dose-dependent reduction in the levels of p38 MAPKδ (Figure 4.18). However, 
knockdown of p38 MAPKδ in SOD1G93A motor neurons had no effect on retrograde 
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axonal transport speeds (p = 0.097; Figure 4.19), indicating that p38 MAPKα alone 
is responsible for the deficits seen in ALS motor neurons. 
 
 
 
Figure 4.18. Lentiviral-mediated knockdown of p38 MAPKδ in primary motor neurons 
(A) Western blot showing lentivirus-mediated knockdown of p38 MAPKδ. GFP indicates 
expression of the shRNA construct. GAPDH acts as a loading control. B) Quantification of the 
western blot in (A). p38 MAPKδ levels were quantified relative to the GAPDH loading control. n 
= 1. 
 
 
 
 
 
 
Figure 4.19. Knockdown of p38 MAPKδ has no effect on retrograde axonal transport 
speeds in SOD1G93A motor neurons 
Speed profiles of HCT carriers in SOD1G93A motor neurons transduced with scrambled shRNA 
(red diamonds) and SOD1G93A motor neurons transduced with MAPK13 shRNA (green 
triangles). Comparison of the curves reveals that knockdown of p38 MAPK delta has no effect 
on axonal transport speeds (SOD1G93A + scrambled shRNA: 46 carriers, 10 axons; SOD1G93A + 
MAPK13 shRNA: 101 carriers, 12 axons; 3 independent experiments). 
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4.3.2. Pharmacological inhibition of p38 MAPK alpha corrects defects in 
axonal transport 
In order to confirm the results of our p38 MAPKα knockdown experiments, we 
acquired two isoform-specific p38 MAPK inhibitors from GlaxoSmithKline. 
SB-203580 is an established inhibitor of p38 MAPKα and β that has been 
demonstrated to prevent SOD1G93A-induced motor neuron death in vitro (Dewil et 
al., 2007). When tested at 2 µM in our in vitro axonal transport assays, we found 
that SB-203580 was able to correct SOD1G93A-induced deficits in retrograde axonal 
transport (WT + DMSO versus SOD1G93A + 2 µM SB-203580: p = 0.149, SOD1G93A 
+ DMSO versus SOD1G93A + 2 µM SB-203580: p = 0.008; Figure 4.20A). However, 
SB-203580 is also known to inhibit JNK 2/3 (Coffey et al., 2002). In order to 
demonstrate that inhibition of JNK 2/3 is not involved in the restoration of axonal 
transport, we also tested SB-239063, a second-generation p38 MAPKα and β 
inhibitor with greatly reduced activity towards JNK 2/3. As with SB-203580, 
SB-239063 could rescue retrograde axonal transport in SOD1G93A motor neurons 
(WT + DMSO versus SOD1G93A + 2 µM SB-239063: p = 0.273, SOD1G93A + DMSO 
versus SOD1G93A + 2 µM SB-239063: p = 0.017; Figure 4.20).  
 
 
 
Figure 4.20. Pharmacological inhibition of p38 MAPKα corrects defects in retrograde 
axonal transport in SOD1G93A motor neurons in vitro  
(A) Speed profiles of HCT carriers in wild type motor neurons treated with DMSO (black 
squares), SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor 
neurons treated with 2 µM SB-203580 (blue triangles). Comparison of the speed profiles 
reveals SOD1G93A motor neurons treated with 2 µM SB-203580 have a similar speed distribution 
to wild type cultures (black squares) (wild type: 50 carriers, 8 axons; SOD1G93A: 56 carriers, 7 
axons; SOD1G93A + 2 µM SB-203580: 75 carriers, 10 axons; 3 independent experiments). (B) 
Speed distribution profiles of HCT carriers in wild type motor neurons treated with DMSO (black 
squares), SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor 
neurons treated with 2 µM SB-239063 (blue triangles). Comparison of the speed profiles 
reveals SOD1G93A motor neurons treated with 2 µM SB-239063 have a similar speed distribution 
curve to wild type cultures (wild type: 84 carriers, 8 axons; SOD1G93A: 56 carriers, 5 axons; 
SOD1G93A + 2 µM SB-239063: 85 carriers, 9 axons; 3 independent experiments). 
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SB-239063 has been demonstrated to be suitable for in vivo use (see Figure 4.26). 
We therefore performed a limited dose response with this compound in vitro in 
order to gain a better understanding of the concentration required to correct 
SOD1G93A-induced transport deficits. This, in combination with pharmacokinetic 
analysis, described in Figure 4.26, would allow us to pick a suitable dose to be 
tested in axonal transport assays in vivo.  
 
In vitro axonal transport assays were therefore performed in SOD1G93A motor 
neurons with either a ten-fold lower (0.2 µM) or ten-fold higher (20 µM) 
concentration of SB-239063 to that previously tested. 0.2 µM SB-239063 was able 
to effectively restore axonal transport in SOD1G93A motor neurons to wild type 
levels (WT + DMSO versus SOD1G93A + 0.2 µM SB-239063: p = 0.996, SOD1G93A + 
DMSO versus SOD1G93A + 0.2 µM SB-239063: p = 0.003; Figure 4.21A). In addition, 
20 µM did not appear to be toxic, causing no axon blebbing or obvious decrease in 
motor neuron survival, and was also able to rescue deficits in transport (WT + 
DMSO versus SOD1G93A + 20 µM SB-239063: p = 0.610, SOD1G93A + DMSO 
versus SOD1G93A + 20 µM SB-239063: p = 0.021; Figure 4.21B).  
 
 
 
Figure 4.21. In vitro axonal transport dose-response tests with SB-239063  
(A) Speed profiles of HCT carriers in wild type motor neurons treated with DMSO (black 
squares), SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor 
neurons treated with 0.2 µM SB-239063 (blue triangles). Comparison of the curves reveals 
SOD1G93A motor neurons treated with 0.2 µM SB-239063 have a similar speed distribution to 
wild type cultures (wild type: 59 carriers, 12 axons; SOD1G93A: 47 carriers, 12 axons; SOD1G93A 
+ 0.2 µM SB-239063: 57 carriers, 10 axons; 4 independent experiments). (B) Speed distribution 
profiles of HCT carriers in wild type motor neurons treated with DMSO (black squares), 
SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor neurons 
treated with 20 µM SB-239063 (blue triangles). Comparison of the speed profiles reveals 
SOD1G93A motor neurons treated with 20 µM SB-239063 have a similar speed distribution curve 
to wild type cultures (wild type: 55 carriers, 8 axons; SOD1G93A: 37 carriers, 11 axons; SOD1G93A 
+ 20 µM SB-239063: 36 carriers, 7 axons; 3 independent experiments). 
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4.4. Testing the effect of p38 MAPK alpha inhibition on axonal 
transport in vivo in the SOD1G93A mouse 
Having established the effect of p38 MAPKα inhibition on retrograde axonal 
transport in primary SOD1G93A motor neurons in vitro, it was important to confirm 
our findings at a more disease-relevant stage. Since the most severe in vivo axonal 
transport defects were observed in SOD1G93A mice at an early symptomatic stage, 
we decided to test whether SB-239063 could rescue retrograde axonal transport 
defects at this stage of the disease.  
 
4.4.1. Establishing the in vivo axonal transport protocol 
A method for imaging axonal transport in the exposed sciatic nerve of live 
anaesthetised mice had been previously established in our laboratory by Lynsey 
Bilsland (Bilsland et al., 2010) but was no longer in current use when I arrived in 
the laboratory. Therefore, in collaboration with Bernadett Kalmar (UCL Institute of 
Neurology), we set about re-establishing and optimising the protocol, so that it 
could be used to test the effect of our kinase inhibitors in vivo.  
 
 
Figure 4.22. Intramuscular injection of fluorescently labelled HCT into the tibialis anterior 
and gastrocnemius muscles  
(A) Incisions are made through the skin above the tibialis anterior and gastrocnemius muscles 
in one hind leg to expose the muscles. (B) Position of the needle required for injection of the 
probe into the exposed tibialis anterior muscle. (C) Position of the needle required for injection 
of the fluorescently labelled probe into the exposed gastrocnemius muscle. 
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In the first step of the protocol, AlexaFluor 555-conjugated HCT and BDNF are 
injected into the tibialis anterior and gastrocnemius muscles of one hind leg (Figure 
4.22). BDNF acts to increase the internalisation of the probe by the nerve (Roux et 
al., 2006). In order to determine the optimal incubation time before imaging the 
sciatic nerve, we collected nerves at 2, 4, 6 and 24 hours after i.m. injection of HCT, 
as well as a nerve from a non-injected animal as a control. Sectioning and imaging 
of the nerves revealed that after 4 hours there were a significant number of HCT-
labelled axons (Figure 4.23). At 6 hours, although there was an increase in the 
number of labelled axons, the background increased significantly. 4 hours post-
injection was therefore chosen as the optimal time for imaging. We also noted that 
labelling in the nerve persisted for at least 24 hours (Figure 4.23). 
 
 
Figure 4.23. Time-dependent accumulation of fluorescently labelled HCT in the sciatic 
nerve 
AlexaFluor 555-labelled HCT was injected i.m. into the tibialis anterior and gastrocnemius 
muscles of anaesthetised mice. Sciatic nerves were then collected at 2, 4, 6 and 24 h, fixed and 
sectioned. HCT-labelled endosomes can be seen to appear at 4 h and persist in the sciatic 
nerve until 24 h. Scale bars, 100 µm. 
 
 
 
In order to image the sciatic nerve using a confocal microscope, surgery must be 
performed to remove surrounding tissue and expose the underlying nerve (Figure 
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4.24). This is a relatively simple surgery, taking a maximum of 10-15 minutes, but 
requires careful attention to ensure the sciatic nerve is not damaged nor 
contaminated with blood or hair that would impede imaging.  
 
 
 
Figure 4.24. Surgical exposure of the sciatic nerve for in vivo imaging 
(A) An incision is made through the skin between the knee and hip joints to expose the 
underlying muscle and nerves. (B) The skin around the operating field is removed and the 
sciatic nerve is visible underneath the muscle, beneath the femur (black arrow). (C) The muscle 
is carefully removed to reveal the underlying sciatic nerve. (D) The sciatic nerve is separated 
from the surrounding tissue using a pair of curved forceps. (E) A small piece of plastic is 
inserted beneath the sciatic nerve to separate it from underlying tissues, facilitating imaging of 
the nerve.  
 
 
Once the nerve is exposed, we developed a technique of placing a small piece of 
plastic underneath the nerve (Figure 4.24E). This facilitates locating the nerve 
underneath the microscope as the nerve is separated from the underlying tissue.  
 
For confocal imaging, the anaesthetised mouse is placed on a custom-made stage 
with a small imaging window (Figure 4.25A). The imaging window is covered with a 
glass coverslip and the sciatic nerve is placed carefully on top of the coverslip, 
directly above the 63X objective (Figure 4.25B).  
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Figure 4.25. In vivo imaging of the exposed sciatic nerve using confocal microscopy 
(A) The exposed sciatic nerve is carefully positioned on the glass coverslip, directly above the 
microscope objective. (B) Correct positioning of the anaesthetised mouse on the microscope 
stage. (C) Initial imaging of the sciatic nerve using the 63X objective shows clearly labelled 
endosomes within axons. A representative collection of axons is chosen to be monitored. Scale 
bar, 10 µm. (D) Imaging of a collection of axons using the 100X objective allows sufficient time 
and spatial resolution for individual endosomes to be tracked. Scale bar, 10 µm.  
 
 
 
Using this protocol, we were able to acquire high-resolution images of individual 
endosomes within the sciatic nerve (63X, Figure 4.25C, Movie 3). Zooming in at 
100X allows time-lapse movies to be acquired (Figure 4.25D, Movie 4) and the 
speed of axonal transport of individual endosomes to be analysed. 
 
 
4.4.2. Testing the effect of SB-239063 on axonal transport in vivo 
In order to determine the optimal dose to test in our in vivo axonal transport assays, 
GlaxoSmithKline performed pharmacokinetic analysis with SB-239063. The 
concentration of SB-239063 was determined in the brain, spinal cord and muscle 
after i.p. injection at either 30 mg/kg or 100 mg/kg. The 100 mg/kg dose allowed for 
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circulating concentrations similar to those tested in our in vitro axonal transport 
assays and was therefore chosen as the first dose to be tested in vivo. 
 
 
 
Figure 4.26. Pharmacokinetics of SB-239063  
(A) Mice were administered SB-239063 i.p. at either 30 mg/kg or 100 mg/kg. The free 
concentration in the brain, spinal cord and muscle was determined after 1 h. ^ based on fraction 
unbound in mouse brain. ^^ based on fraction unbound in mouse blood. (B) Predicted brain free 
concentration profiles with twice-daily i.p. dosing at 0 and 8 hours for 30 mg/kg and 100 mg/kg. 
This work was performed by the GlaxoSmithKline DMPK team in Singapore.  
 
 
 
Early symptomatic mice were injected with 100 mg/kg SB-239063 i.p. at the same 
time as the HCT probe was injected i.m. into the tibialis anterior and gastrocnemius 
muscles. The sciatic nerve was then imaged four hours later (Figure 4.27A). 
Treatment of SOD1G93A mice with SB-239063 was observed to accelerate 
retrograde axonal transport compared to untreated SOD1G93A controls, restoring 
transport to physiological wild type levels (WT versus SOD1G93A + 100 mg/kg 
SB-239063: p = 0.744, SOD1G93A versus SOD1G93A + 100 mg/kg SB-239063: 
p = 0.004; Figure 4.27B). Deconvolution of the speed distribution profiles shown in 
Figure 4.27B highlights a marked reduction in the fastest (2.39 µm/s) speed 
component in SOD1G93A mice and a corresponding increase in the frequency of 
intermediate speed carriers (1.24 µm/s), when compared to wild type controls 
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(Figure 4.27C). However, when treated with SB-239063, SOD1G93A mice had a 
speed carrier distribution very similar to wild type. 
 
 
 
Figure 4.27. SB-239063 corrects retrograde axonal transport defects in vivo in the 
SOD1G93A mouse  
(A) Mice were anaesthetised and AlexaFluor 555-conjugated HCT was injected i.m. into the 
tibialis anterior and gastrocnemius muscles. At the same time, 100 mg/kg SB-239063 or vehicle 
control was injected i.p. Mice were allowed to recover for 4 h, then re-anaesthetised and axonal 
transport imaged in the exposed sciatic nerve. (B) Retrograde axonal transport in single axons 
of the sciatic nerve was assessed in 73 d wild type (black squares), SOD1G93A (red diamonds) 
and SOD1G93A mice treated with 100 mg/kg SB-239063 (blue triangles). SOD1G93A mice 
displayed a significant impairment in retrograde transport, whilst SOD1G93A mice treated with 
100 mg/kg SB-239063 showed transport speeds similar to those of wild type mice. Wild type: 
161 carriers, n (animals) = 4; SOD1G93A: 185 carriers, n = 5; SOD1G93A + 100 mg/kg SB-239063: 
238 carriers, n = 4. (C) Deconvolution analysis of the in vivo speed profiles demonstrating there 
are three defined speed components: 0.0 (paused), 1.24 (intermediate), and 2.39 (fast). Defects 
in axonal transport in the sciatic nerve of early symptomatic SOD1G93A mice can be explained by 
a reduction in the number of “fast” moving carriers and an increase in the number of 
“intermediate” speed carriers. Treatment of SOD1G93A mice with 100 mg/kg SB-239063 corrects 
the distribution of carriers back to that of wild type. 
 
 
 
Our in vivo axonal transport results highlight SB-239063 as a tool to test whether 
deficits in retrograde axonal transport play a role in disease progression in the 
SOD1G93A mouse. However, 100 mg/kg is a very high dose to test in a chronic 
dosing study, especially when you consider the amount of drug that would 
ultimately be required to treat a human patient. We therefore tested different 
concentrations of SB-239063 to identify a lower effective dose and found that at 
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10-mg/kg the compound was still able to correct deficits in axonal transport in vivo 
(Figure 4.28A). In addition, we identified 0.3 mg/kg as a non-effective dose (Figure 
4.28B) that could be used as a control in chronic dosing studies to allow us to 
better understand the relationship between the effects of p38 MAPK inhibition on 
axonal transport and its effects on disease progression. 
 
 
 
Figure 4.28. Dose-dependent effects of SB-239063 on axonal transport in vivo  
(A) Retrograde transport in single axons of the sciatic nerve was assessed in 73 d wild type 
(black squares), SOD1G93A (red diamonds) and SOD1G93A mice treated with 10 mg/kg 
SB-239063 (blue triangles). SOD1G93A mice treated with 10 mg/kg SB-239063 showed transport 
speeds similar to those of wild type mice (wild type: 161 carriers, n (animals) = 4; SOD1G93A: 
185 carriers, n = 5; SOD1G93A + 10 mg/kg SB-239063: 35 carriers, n = 1). (B) Retrograde 
transport in single axons of the sciatic nerve was assessed in 73 d wild type (black squares), 
SOD1G93A (red diamonds) and SOD1G93A mice treated with 0.3 mg/kg SB-239063 (blue 
triangles). SOD1G93A mice treated with 0.3 mg/kg SB-239063 showed transport speeds similar 
to those of SOD1G93A mice (wild type: 161 carriers, n (animals) = 4; SOD1G93A: 185 carriers, 
n = 5; SOD1G93A + 10 mg/kg SB-239063: 42 carriers, n = 1). 
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4.5. Discussion 
Previous work from our laboratory has demonstrated that retrograde axonal 
transport is defective both in vitro and in vivo in SOD1G93A motor neurons. In this 
Chapter, I was able to demonstrate that structurally diverse inhibitors of p38 MAPK 
are able to correct deficits in retrograde axonal transport in vitro in SOD1G93A motor 
neurons. In addition, we found that activation of p38 MAPK in wild type motor 
neurons inhibits retrograde axonal transport. Together these data support the 
conclusion that p38 MAPK is a negative regulator of retrograde axonal transport. 
  
p38 MAPK has been previously implicated in ALS pathogenesis. Our results 
support these past studies which demonstrate that p38 MAPK is activated in a 
disease-dependent manner in SOD1G93A mice (Dewil et al., 2007, Tortarolo et al., 
2003, Veglianese et al., 2006) and that this pathological activation is responsible 
for axonal transport defects induced by SOD1G93A (Morfini et al., 2013).  
 
Using both pharmacological and genetic approaches, we were able to show that 
p38 MAPKα is responsible for the retrograde axonal transport defects observed in 
vitro in SOD1G93A motor neurons. One of the p38 MAPKα/β specific inhibitors 
tested, SB-239063, was suitable for use in vivo and we were therefore able to 
demonstrate that inhibition of p38 MAPKα could also correct retrograde axonal 
transport defects in early symptomatic SOD1G93A mice. These findings therefore 
provide the basis for a longer-term study to determine the role of p38 MAPKα-
induced axonal transport defects in ALS disease progression.  
 
4.5.1. Anterograde versus retrograde axonal transport defects  
The work in this Chapter has focused primarily on correcting deficits in retrograde 
axonal transport. However, it is important to recognise that defects in anterograde 
axonal transport have also been reported in ALS (Bilsland et al., 2010, Morfini et al., 
2013, Alami et al., 2014). There is still much to be understood about the specific 
roles of both anterograde and retrograde axonal transport in neurodegeneration. 
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The analysis of anterograde axonal transport in motor neurons is more challenging 
than for retrograde axonal transport, due to difficulties in finding a suitable cargo to 
label and track. Anterograde axonal transport is typically followed in hippocampal, 
striatal and cortical neurons by expressing fluorescently tagged anterograde 
cargoes, for example BDNF-mCherry and APP-yellow fluorescent protein (YFP) 
(Her and Goldstein, 2008). However, this approach relies on transfection of 
neurons using reagents such as Lipofectamine™ or Nucleofection™. The efficiency 
of these transfection techniques in motor neurons is typically too low to be used for 
axonal transport studies. There is also the additional problem that these 
transfection procedures can induce morphological changes and cell death 
(Deinhardt and Schiavo, 2005), which could affect the efficiency of axonal transport.  
 
 
 
Figure 4.29. Cargoes transported by fast axonal transport  
Schematic illustrating cargoes that are transported by anterograde (left), bidirectional (middle) 
and retrograde (right) fast axonal transport. Reprinted with permission from Elsevier (Maday et 
al., 2014). 
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We therefore considered analysing the anterograde axonal transport of cargoes 
that are transported bidirectionally (see Figure 4.29), as there are a number of 
probes available that allow easy labelling of these cargoes. Since the anterograde 
axonal transport of both mitochondria and mRNA has been reported to be defective 
in ALS (Bilsland et al., 2010, Alami et al., 2014), these cargoes were considered 
first. 
 
Live imaging protocols for mitochondrial axonal transport are well established both 
in vitro and in vivo (Bilsland et al., 2010, Misgeld et al., 2007, De Vos and Sheetz, 
2007), due to the well-documented relationship between mitochondrial defects and 
neurodegenerative disease (Johri and Beal, 2012). However, it has been shown 
that reversing mitochondrial trafficking deficits does not prevent neuronal death and 
disease progression in the SOD1G93A mouse (Zhu and Sheng, 2011). In addition, 
the axonal transport of mitochondria is differentially regulated from that of other fast 
axonal transport cargoes (Zala et al., 2013) and has very different transport 
characteristics (De Vos and Sheetz, 2007). Mitochondria were therefore not a 
suitable cargo to use to determine whether our compounds affected anterograde 
and retrograde axonal transport in the same way in SOD1G93A motor neurons.  
 
Next we attempted to image anterograde axonal transport using the SYTO RNA 
Select™ dye to label mRNA. Although the labelling was very good, few motile 
cargoes were seen and as a result it was not possible to achieve high enough n 
numbers to reliably analyse anterograde axonal transport.  
 
Finally we tested Lysotracker™, which labels acidic organelles, such as late 
endosomes/lysosomes and autophagosomes. With Lysotracker™ there was a 
much larger number of brightly labelled, motile carriers, moving in both directions. It 
was therefore deemed the best probe to use to study anterograde axonal transport 
in our SOD1G93A motor neurons.  
 
Surprisingly, in our in vitro axonal transport assays using Lysotracker™ we were 
only able to detect defects in retrograde axonal transport. The anterograde axonal 
transport of Lysotracker™ in SOD1G93A motor neurons was identical to wild type. 
This suggests that anterograde and retrograde axonal transport may be 
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differentially regulated and may not always be in equilibrium. At first glance, our 
results also appear to disagree with previous work by Morfini et al., demonstrating 
that ALS-associated SOD1 mutants (including SOD1G93A) induce defects in 
anterograde axonal transport (Morfini et al., 2013). However, it is important to note 
that Morfini et al. analysed the axonal transport of all types of vesicles (using 
differential interference contrast (DIC) microscopy) whilst our analysis of 
anterograde axonal transport focused on Lysotracker™-labelled organelles only.  
 
In ALS model systems, retrograde axonal transport defects have now been 
described for acidic organelles (late endosomes/lysosomes and autophagosomes), 
signalling endosomes (HCT and α-p75NTR) (Kieran et al., 2005, Bilsland et al., 2010), 
mitochondria (Bilsland et al., 2010) and APP-labelled vesicles (De Vos et al., 2007). 
These results support the hypothesis that defective retrograde axonal transport 
plays a significant role in motor neuron degeneration in ALS.  However, as shown 
by work investigating the role of mitochondrial axonal transport in ALS (Zhu and 
Sheng, 2011), it is possible that defects in the axonal transport of different cargoes 
are mediated by different mechanisms and may also play different roles in disease 
progression. It is therefore important that we investigate the axonal transport of 
these cargoes individually in order to fully understand their contribution to 
neurodegeneration in ALS.  
 
4.5.2. p38 MAPKα is responsible for defects in axonal transport in SOD1G93A 
motor neurons 
In this Chapter, we were able to demonstrate using genetic knockdown that p38 
MAPKα is the isoform responsible for retrograde axonal transport defects in 
SOD1G93A motor neurons. One shortcoming of our approach is that our lentiviral 
vectors transduced both glial cells and motor neurons; therefore we do not know 
whether p38 MAPKα is acting via a cell autonomous or non-autonomous 
mechanism. This question could be addressed in the future by building lentiviral 
vectors with neuron-specific promoters (Hioki et al., 2007).  
 
Previous experiments in isolated squid axoplasm have reported that addition of 
recombinant p38 MAPKα induces defects in anterograde axonal transport only, 
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with no effect on retrograde transport (Morfini et al., 2013). These contrasting 
results are difficult to explain, but could represent differences in the biological 
systems used (squid axoplasm versus mouse primary motor neurons). It could be 
that squid axoplasm is not an accurate model of the mammalian axonal transport 
system. Unfortunately, as we were unable to detect defects in the anterograde 
axonal transport of Lysotracker™ in mouse SOD1G93A motor neurons, we were not 
able to test whether our p38 MAPK inhibitors could also correct defects in 
anterograde axonal transport.  
 
In order to help understand the role of p38 MAPKα-mediated axonal transport 
defects in ALS disease progression, we identified a pharmacological inhibitor of the 
kinase that is able to restore retrograde axonal transport to wild type levels in early 
symptomatic SOD1G93A mice. It would also be interesting to address this question 
in vivo using a genetic approach. Knocking out p38 MAPKα results in embryonic 
lethality (E11.5-12.5) mainly due to placental insufficiency (Mudgett, 1998). 
However, MAPK14 lox/lox mice are available (Nishida et al., 2004) and therefore it 
should be possible to generate motor neuron-specific p38 MAPKα knockout mice. If 
these mice are viable, they could be crossed with SOD1G93A mice to determine the 
effects of motor neuron-specific p38 MAPKα knockout on both axonal transport and 
disease progression. However, it is likely that knocking out p38 MAPKα during 
development will have deleterious effects. To avoid potential problems with 
knocking out p38 MAPKα, gene therapy could be used to knockdown p38 MAPKα 
in adult mice instead. For example, pre- or early symptomatic SOD1G93A mice could 
be treated with adeno-associated viral (AAV) vectors encoding shRNA against p38 
MAPKα. Preferential targeting of motor neurons with AAV vectors has been 
previously described in adult mice using intrathecal delivery and the cmv promoter 
(Dirren et al., 2015). 
 
In contrast to our results using pharmacological inhibitors, lentivirus-mediated 
knockdown of p38 MAPKα in wild type motor neurons was found to have a small 
inhibitory effect on retrograde axonal transport (Figure 4.16). This suggests that, at 
basal levels, activated p38 MAPKα may play a role in axonal transport regulation 
and/or maintaining normal neuronal function and indicates that too great a degree 
of p38 MAPKα inhibition in vivo may be deleterious. 
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4.5.3. p38 MAPK is a negative regulator of axonal transport 
In this Chapter, we have demonstrated that p38 MAPK is responsible for defects in 
the retrograde axonal transport of signalling endosomes and acidic organelles in 
SOD1G93A motor neurons. The question that remains to be answered is how p38 
MAPK exerts its effects on axonal transport. Both direct (phosphorylation of motors 
and/or their adaptor proteins) and indirect mechanisms have been proposed. 
 
4.5.3.1. Phosphorylation of motors and motor adaptor proteins 
Work performed using isolated squid axoplasm has demonstrated that p38 MAPKα 
inhibits anterograde axonal transport through direct phosphorylation of kinesin-1 
(Morfini et al., 2013). The authors demonstrated that p38 MAPKα-mediated 
phosphorylation of kinesin heavy chain KIF5c reduced the efficiency with which the 
motor moved along axonal microtubules in cultured hippocampal neurons.  
 
p38 MAPK-mediated inhibition of retrograde axonal transport could potentially be 
explained by a similar model, in which one or more subunits of cytoplasmic dynein 
are directly phosphorylated. Dynein has been previously shown to be regulated by 
phosphorylation (Dillman and Pfister, 1994, Mitchell et al., 2012, Kumar et al., 2000, 
Runnegar et al., 1999). Although p38 MAPK has not yet been demonstrated to 
phosphorylate neuronal dynein, another member of the MAP kinase family, ERK1/2, 
has. In hippocampal and cortical neurons, the dynein intermediate chain IC-1 was 
reported to be phosphorylated by ERK1/2 in response to neurotrophin stimulation 
(Mitchell et al., 2012). Inhibition of ERK1/2 was found to reduce the association of 
dynein with TrkB-containing endosomes and cause a reduction in the number of 
motile endosomes in the retrograde direction in hippocampal neurons.  
 
There are also reports that dynein motor activity can be negatively regulated by 
phosphorylation. Phosphorylation of residues in the light, intermediate and heavy 
chains of cytoplasmic dynein have all been reported to reduce the ATPase activity 
of the motor and binding of the motor to microtubules (Kumar et al., 2000, 
Runnegar et al., 1999). Although the kinase(s) responsible were not identified, this 
mechanism of regulation would explain the inhibitory effect of p38 MAPK on 
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retrograde axonal transport in ALS. However, it remains to be seen if p38 MAPK 
does indeed phosphorylate any of the dynein subunits and if so, what effect this 
has on the motor’s activity.  
 
The activity of dynein adaptor proteins can also be regulated by phosphorylation. 
For example, phosphorylation of Ndel1 by Cdk5 stimulates the retrograde axonal 
transport of acidic organelles (Pandey and Smith, 2011), whilst phosphorylation of 
huntingtin (htt) at serine 421 by Akt has been shown to cause the preferential 
recruitment of kinesin-1 to BDNF-containing vesicles and an acceleration of their 
anterograde axonal transport (Colin et al., 2008). The authors of this latter study 
speculate that htt phosphorylation may act as a switch between anterograde and 
retrograde axonal transport. p38 MAPK has been shown to increase the expression 
of serum- and glucocorticoid-induced kinase (SGK), which, like Akt, also 
phosphorylates htt at Ser421 (Rangone et al., 2004). Inhibition of p38 MAPK could 
therefore indirectly lead to reduced SGK-mediated htt phosphorylation and 
preferential retrograde axonal transport. However, a mechanism based on 
translation would not explain the acute effects we have observed in our in vitro 
axonal transport assays.  
 
It is clear that future work must focus on determining whether p38 MAPK 
phosphorylates components of the axonal transport machinery. Mass spectrometry 
analysis of changes in the phosphorylation state of proteins (Mann et al., 2002) 
between wild type and SOD1G93A samples could help elucidate the effector 
protein(s) responsible for p38 MAPK’s effect on axonal transport. Differential 
phosphorylation analysis including SOD1G93A samples treated with one of our p38 
MAPK inhibitors that are active in axonal transport assays could help decipher 
which phosphorylated proteins may be involved in p38 MAPK-mediated inhibition of 
retrograde axonal transport.  
 
4.5.3.2. Indirect mechanisms of p38 MAPK-mediated axonal transport 
inhibition  
One mechanism by which p38 MAPK could indirectly inhibit axonal transport is 
through the phosphorylation of neurofilaments. Neurofilaments are a type of 
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intermediate filament, found specifically in neurons and are thought to provide 
structural support for axons, regulate axon diameter and act as a scaffold for the 
docking of various axoplasmic components (Yuan et al., 2012). They are 
composed of three major subunits: light (NF-L), medium (NF-M) and heavy (NF-H). 
Neurofilament subunits are synthesised in the cell body of neurons and transported 
via slow axonal transport to the axon where they are incorporated into the existing 
neurofilament network.  
 
Under normal conditions, phosphorylation of the subunits regulates both their 
transport along the axon and their assembly into neurofilaments (Yuan et al., 2012, 
Miller et al., 2002). However, aberrant hyperphosphorylation is thought to slow their 
transport and induce bundling, leading to large accumulations of neurofilaments in 
the cell body and proximal axons (Miller et al., 2002). Interestingly, slowing of 
neurofilament axonal transport (through 35S labelling of NF-L) is considered an 
early pathological feature in mutant SOD1 mice (Williamson and Cleveland, 1999, 
Zhang et al., 1997). In addition, accumulations of phosphorylated neurofilaments 
have been reported in motor neurons of patients with both familial and sporadic 
ALS as well as in the SOD1G93A mouse model at a presymptomatic stage (Bendotti 
et al., 2004, Ackerley et al., 2004, Tortarolo et al., 2003). 
 
p38 MAPKα is known to phosphorylate the tail domains of NF-M and H (Ackerley et 
al., 2004). Phosphorylation of these domains has been demonstrated to regulate 
the axonal transport of neurofilaments by regulating their attachment to motor 
proteins (Miller et al., 2002). Aberrant activity of p38 MAPK could therefore cause 
the release of neurofilaments from their motors, resulting in the accumulation of 
phosphorylated neurofilaments. The role of p38 MAPK in hyper-phosphorylating 
neurofilaments in ALS is also supported by the fact that the kinase colocalises with 
phosphorylated neurofilaments in the cell bodies and proximal axons of motor 
neurons in spinal cord sections from SOD1G93A mice (Tortarolo et al., 2003). 
 
The mechanism by which hyperphosphorylated neurofilaments could disrupt axonal 
transport is not fully understood. It is possible that phosphorylation-induced slowing 
of neurofilament axonal transport leads to the formation of accumulations that 
cause a general blockade of transport along the axon. Alternatively, the loss of 
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structural support to the axon that is normally provided by neurofilaments could 
reduce axonal transport efficiency. Such hypotheses would explain why p38 MAPK 
has been reported to induce both retro- and anterograde axonal transport defects 
in ALS. It is also interesting to note that deletion of the tail domains of NF-M and 
NF-L, which are phosphorylated by p38 MAPK, delays disease onset, increases 
lifespan and increases the number of surviving motor neurons in SOD1G93A mice 
(Lobsiger et al., 2005). In addition, riluzole, the only drug approved for the 
treatment of ALS, has been shown to prevent glutamate-induced slowing of 
neurofilament transport in primary rat cortical neurons (Stevenson et al., 2009). The 
authors found that this correlated with reduced phosphorylation of the NF-M/NF-H 
tail domains and a reduction in the level of activated p38 MAPK.  
 
An alternative explanation for the inhibitory effect of p38 MAPK on axonal transport 
focuses on the fact that p38 MAPK phosphorylates the microtubule-associated 
protein tau. Tau binds and stabilises microtubules and its activity is regulated by 
phosphorylation. p38 MAPK has been shown to directly phosphorylate tau at 
several sites, including Thr231, Ser235 and Ser356 (Reynolds et al., 2000). 
Phosphorylation at these three sites has been demonstrated to reduce the 
association of tau with microtubules (Cho and Johnson, 2004). If aberrantly 
activated, p38 MAPK could destabilise microtubules and thereby cause a disruption 
in axonal transport. Indeed, hyperphosphorylated tau has been reported in the 
SOD1G37R mouse model of ALS before disease onset (Farah et al., 2003).  
 
Davunetide (NAP), an eight amino acid peptide that is derived from activity-
dependent neuroprotective peptide (ANDP) has been demonstrated to reduce tau 
hyperphosphorylation by two-fold in SOD1G93A mice (Jouroukhin et al., 2013). 
Interestingly, the authors were also able to demonstrate that treatment of SOD1G93A 
mice with davunetide could rescue defects in anterograde axonal transport in 
olfactory neurons (Jouroukhin et al., 2013). These results support the idea that 
hyperphosphorylated tau could be responsible for axonal transport defects in ALS. 
However, no significant difference was observed in neurodegeneration between 
SOD1G93A mice with normal tau levels and those with reduced tau levels (Taes et 
al., 2010). In addition, there is no association of polymorphisms in the gene 
encoding tau (MAPT) with human ALS (Taes et al., 2010). 
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An alternative explanation relates to the fact that phosphorylation of tau at Thr231 
and Ser235 has also been reported to reduce α-tubulin acetylation (Cho and 
Johnson, 2004). The degree of acetylation of microtubules has been demonstrated 
to affect the binding of motor proteins and therefore axonal transport. Increasing 
α-tubulin acetylation using histone deacetylase 6 (HDAC6) inhibitors has been 
shown to accelerate the microtubule-based transport of BDNF in mouse striatal 
cells (Dompierre et al., 2007). This increase in trafficking was found to be due to an 
increase in the recruitment of both dynein and kinesin motor complexes to the 
microtubules. Phosphorylation of tau by p38 MAPK could therefore cause a 
reduction in the association of motors with the microtubules and inhibit axonal 
transport as a result. Deletion of the HDAC6 gene in SOD1G93A mice has been 
shown to extend survival and maintain motor axon integrity, correlating with an 
increase in α-tubulin acetylation in the spinal cord and sciatic nerve (Taes et al., 
2013). However there are no reports of reduced α-tubulin acetylation in ALS motor 
neurons to date, suggesting that this may not be the mechanism underlying the 
defects in axonal transport.     
 
A shortcoming of these proposed indirect mechanisms of p38 MAPK-mediated 
inhibition of axonal transport is the fact that they would be expected to inhibit all 
types of transport. However, we were not able to detect defects in anterograde 
axonal transport in our experiments with Lysotracker™. 
 
4.5.4. p38 MAPK is aberrantly activated in SOD1G93A mice 
In this Chapter, I was able to demonstrate that p38 MAPK is activated in SOD1G93A 
motor neurons both in vitro and in vivo. In adult mouse spinal cords, we found that 
the aberrant activation of p38 MAPK correlated with the appearance and worsening 
of in vivo retrograde axonal transport defects (Bilsland et al., 2010). Our results 
agree with data that has been previously published on p38 MAPK activation in ALS. 
A limitation of our analysis was the use of western blotting and whole spinal cord 
lysates to assess phospho-p38 MAPK levels. However, Dewil et al. have previously 
shown using immunofluorescence that p38 MAPK is activated in the motor neurons 
and microglia of the SOD1G93A spinal cord, but not in astrocytes (Dewil et al., 2007). 
Abnormally activated p38 MAPK is also found in motor neurons of sporadic ALS 
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patients (Bendotti et al., 2004). To date, the pathological activation of p38 MAPK 
has only been demonstrated in mutant SOD1-mediated ALS. In the future, it will be 
interesting to examine whether p38 MAPK is activated in other forms of fALS and 
whether this also correlates with the presence of axonal transport defects. 
 
It still remains to be determined what causes the pathological activation of p38 
MAPK in mutant SOD1-mediated ALS. Analysis of SOD1G93A spinal cords reveals 
that the upstream kinases MKK3/6, MKK4 and ASK1 are all activated 
presymptomatically, indicating that the whole p38 MAPK cascade is activated 
(Veglianese et al., 2006). This is supported by the observation that 
pharmacological inhibition of ASK1 can rescue defects in anterograde axonal 
transport induced by SOD1G93A in squid axoplasm assays (Song et al., 2013).  
 
p38 MAPK could be activated due to a gain-in-function of SOD1G93A that we have 
not yet been able to understand. Alternatively, a number of pathways that activate 
p38 MAPK have already been implicated in ALS pathogenesis, including 
inflammatory signalling, excitotoxicity and oxidative stress, and could contribute in 
part or in full to the pathological activation of the kinase. 
 
4.5.4.1. Inflammatory signalling 
TNFα is a well-established activator of the p38 MAPK signalling cascade and is 
produced by astrocytes, microglia and neurons. TNFα was detected as one of the 
earliest inflammatory stimuli to be induced in SOD1G93A mice (11 weeks) 
(Yoshihara et al., 2002). This could be explained by the observation that there are 
an increased number of activated microglia in the ventral horn of presymptomatic 
SOD1G93A mice (Tortarolo et al., 2003). TNFα receptors (TNFR1 and R2) are also 
reported to be overexpressed in these mice (Veglianese et al., 2006). Pathological 
TNFα signalling could therefore be responsible for the early and persistent 
activation of p38 MAPK in ALS. TNFα knockout in SOD1G93A mice has been 
reported to have no effect on lifespan or motor neuron loss (Gowing et al., 2006). 
However, treatment of SOD1G93A mice with thalidomide, which reduces TNFα levels 
by causing degradation of its mRNA, was found to improve motor performance, 
reduce motor neuron death and increase lifespan (Damiano et al., 2006). This 
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discrepancy could be explained by the fact that thalidomide was also observed to 
reduce levels of interleukin-1α and β (IL-1α and β) and IL-12p40. It is therefore 
possible that reduction of a number of inflammatory mediators is required to effect 
disease progression in SOD1G93A mice. This is supported by the observation that 
knocking out IL-1β, another established activator of p38 MAPK (Sung et al., 2005) 
that is upregulated in the spinal cord of symptomatic SOD1G93A and SOD1G37R mice 
(Nguyen et al., 2001, Hensley et al., 2002), has no effect on disease progression in 
SOD1G37R mice (Nguyen et al., 2001). 
 
4.5.4.2. Excitotoxicity 
Glutamate-induced excitotoxicity is a well-established mechanism of motor neuron 
death in ALS. It has been proposed that the excitotoxic effect of glutamate is 
mediated in part by p38 MAPK. In vivo it has been demonstrated that intracortical 
injection of quinolinic acid (a glutamate analogue) leads to a transient increase in 
p38 MAPK activation in surrounding neurons and astrocytes prior to induction of 
neuronal death (Ferrer et al., 2001). The early appearance of cortical 
hyperexcitability in ALS patients suggests that dysregulated glutamate signalling 
could be responsible for the presymptomatic p38 MAPK-induced defects in 
retrograde axonal transport in ALS. In addition, the FDA-approved drug riluzole has 
been shown to cause a dose-dependent decrease in glutamate-induced activation 
of p38 MAPK (Stevenson et al., 2009). Riluzole could therefore mediate some of its 
beneficial effects by inhibiting aberrantly activated p38 MAPK.  
 
4.5.4.3. Oxidative stress 
There are a number of reports of increased oxidative stress in both sporadic and 
familial ALS patients and also mouse models of the disease (see Section 1.5.1). 
Although it is clear that reactive oxygen species (ROS) activate the p38 MAPK 
cascade, the mechanism(s) responsible are still not fully understood. One 
suggestion is that ROS alter the activity of key signalling proteins by modifying 
critical amino acids and/or inducing a change in the protein’s structure (Son et al., 
2011). Interestingly, streptozotocin-treated mice, which develop experimental 
diabetes, were found to have significantly higher levels of ROS and this was found 
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to correlate with slower axonal transport rates in the olfactory system (Sharma et 
al., 2010). Streptozotocin-treated mice were also shown to have increased p38 
MAPK activation and tau phosphorylation. This supports the idea that oxidative 
stress, p38 MAPK activation and axonal transport defects could be linked in ALS. 
Oxidative stress is reported to be present before the onset of disease and could 
therefore explain the presymptomatic activation of p38 MAPK in ALS mutant mice 
(Pollari et al., 2014).  
 
4.5.5. p38 MAPK as a potential therapeutic target 
In this Chapter we were able to demonstrate that the p38 MAPKα/β-specific 
inhibitor SB-239063 could correct retrograde axonal transport defects in the 
SOD1G93A mouse in vivo. The next step of the project will therefore be to perform a 
longitudinal study to test whether SB-239063 can affect disease progression in 
these mice.  
 
One past study has tested the effect of p38 MAPK inhibition on motor neuron 
survival and lifespan in the SOD1G93A mouse. Presymptomatic mice were treated 
daily until the end stage of the disease with semapimod, an inhibitor of c-Raf, which 
activates p38 MAPK and JNK through MEK phosphorylation. Although semapimod 
was able to significantly improve motor neuron survival both in vitro and in vivo, 
there were no significant changes in disease onset or survival in treated SOD1G93A 
mice (Dewil et al., 2007). However, treatment of SOD1G93A mice with semapimod 
daily decreased levels of phospho-p38 MAPK in the spinal cord by only 30%. It is 
possible that significant effects on survival would be seen with higher doses of the 
drug. However the toxicity of semapimod at higher concentrations prevented the 
authors from trying this. Alternatively, it is possible that inhibition of p38 MAPK is 
sufficient to prevent motor neuron death but is unable to fully restore the function of 
the entire motor unit in order to affect survival and disease onset significantly. 
Alternatively, the lack of effect on disease onset and survival could be because 
semapimod is not a specific inhibitor of p38 MAPK. Deleterious effects resulting 
from inhibition of JNK and MEK could have disguised the beneficial effects of p38 
MAPK inhibition. It is therefore necessary to test more potent and selective p38 
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MAPK inhibitors to truly understand whether axonal transport defects play an 
important role in ALS disease pathogenesis.  
 
p38 MAPK is activated at very low levels in wild type cells and therefore poses an 
attractive therapeutic target, as its inhibition should have few off-target effects in 
cells unaffected by the disease. Many compounds have been developed that are 
able to selectively target p38 MAPK, due to the role of the kinase in inflammatory 
diseases and cancer (Yong et al., 2009). However, to date, few have been tested 
for their effects in neurodegenerative diseases; most likely because many of these 
compounds do not efficiently cross the blood brain barrier (BBB). Finding isoform-
specific, BBB-permeable p38 MAPK inhibitors that do not cause adverse side 
effects is certainly a major challenge in the field.  
 
Pyridinyl-imidazole compounds, such as SB-203580 and SB-239063 used in this 
study, were the first p38 MAPK inhibitors to be identified that bind competitively at 
the ATP-binding pocket and exploit this to achieve isoform specificity (Tong et al., 
1997). These compounds are able to selectively inhibit p38 MAPKα and β because 
a substitution of threonine106 for a methionine in the ATP binding pocket of the γ 
and δ isoforms blocks the binding of the compounds (Cuadrado and Nebreda, 
2010). However, to date, pyridinyl-imidazole compounds have not been designed 
to selectively inhibit p38 MAPKα. 
 
There have been reports of p38 MAPKα-specific inhibitors. Vertex reported the 
development of a BBB permeable, orally available p38 MAPKα-specific inhibitor, 
VX-745. However, when undergoing clinical trials, the compound was found to 
cause adverse neurological effects (Kumar et al., 2003). This could be unrelated to 
the p38 MAPK activity and rather an off-target effect of this particular compound. 
Another example is MW01-2-069A-SRM, a CNS-penetrant, orally available, small 
molecule inhibitor of p38 MAPKα. MW01-2-069A-SRM has been shown to prevent 
excessive proinflammatory cytokine production in the hippocampus and reduce 
synaptic dysfunction and hippocampus-dependent behavioural deficits in a mouse 
model of Alzheimer’s disease, without causing any adverse effects (Munoz et al., 
2007).  The compound is also reported to have good oral bioavailability and brain 
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penetrance in rodents (Borders et al., 2008). However no clinical trial results using 
this compound have been reported to date.  
 
If we can identify the downstream target(s) of p38 MAPK that are responsible for its 
effects on axonal transport, an alternative therapeutic approach would be to inhibit 
these targets rather than the kinase itself. However, development of inhibitors that 
target the downstream kinases of p38 MAPK have not been very successful to date. 
Pfizer reported the development of PF-3644022, an orally available ATP-
competitive MK2 inhibitor. However, the clinical development of this compound was 
stopped due to poor serum availability and hepatotoxicity (Arthur and Ley, 2013). 
Chapter 5. Results 
 
 154 
Chapter 5. Inhibitors of the IGF1 receptor accelerate 
retrograde axonal transport 
5.1. Introduction 
Results presented in Chapter 3 suggest that inhibition of the insulin-like growth 
factor 1 receptor (IGF1R) accelerates retrograde axonal transport in vitro in both 
wild type and SOD1G93A primary motor neurons.  
 
The IGF signalling system is comprised of two peptide ligands – IGF1 and IGF2 - 
and two receptors – IGF1R and IGF2R (illustrated in Figure 5.1). IGF1R is a type II 
receptor tyrosine kinase and is involved in a variety of cellular processes, including 
cellular proliferation, growth, migration and apoptosis (Brahmkhatri et al., 2015). 
IGF2R, on the other hand, has no intracellular kinase domain and has in fact been 
shown to have an antagonistic role on IGF signalling – internalising IGF2 and 
targeting it for lysosomal degradation, thereby preventing it from binding to and 
activating IGF1R (Kornfeld, 1992).  
 
 
 
Figure 5.1. Insulin-like growth factors and their receptors 
The IGF signalling system is comprised of two ligands – IGF1 and IGF2, two membrane-
spanning receptors – IGF1R and IGF2R, and six high-affinity IGF-binding proteins – IGFBP1-6. 
IGF1R is a type 2 tyrosine kinase receptor that plays important roles in cellular proliferation, 
migration and apoptosis. IGF2R, on the other hand, is a type 1 integral membrane glycoprotein 
that targets IGF2 for lysosomal degradation. The insulin receptor (IR) is also able to bind IGF1 
and 2, and plays a key role in the regulation of glucose homeostasis. Figure modified from 
(Alberini and Chen, 2012). Reprinted with permission from Elsevier.  
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IGF2R is also known as the mannose-6-phosphate (M6P) receptor and has been 
shown to bind M6P-containing ligands both at the cell surface (e.g. transforming 
growth factor-1β, TGF-1β) and in the trans-Golgi network (e.g. lysosomal acid 
hydrolases). In addition to its role in regulating IGF signalling, IGF2R is known to 
play important roles in growth regulation and lysosomal biogenesis. For example, 
the receptor has been shown to facilitate activation of the growth suppressor 
TGF-1β (Dennis and Rifkin, 1991), mediate the internalisation of granzyme B, 
which is crucial for the induction of target cell apoptosis by cytotoxic T cells (Motyka 
et al., 2000), and regulate the targeting of acid hydrolases to the lysosome (Ludwig 
et al., 1994). 
 
IGF1R is not only expressed in insulin-responsive tissues (liver, adipose tissue and 
skeletal muscle) but also in many other tissues, including the brain and spinal cord 
(Kouroupi et al., 2010).  The receptor is a heterotetramer, consisting of two 
extracellular ligand-binding chains (IGF1Rα) and two membrane-spanning chains 
(IGF1Rβ), held together by disulphide bonds. The four IGF1R chains are encoded 
by a single gene. The IGF1Rβ subunits contain the tyrosine kinase domain. Ligand 
binding to the IGF1Rα subunits results in IGF1Rβ transphosphorylation of 
activation loop tyrosines (Tyr1161/Tyr1165/Tyr1166) and full kinase activation 
(Singh et al., 2014). 
 
There is 62% amino acid homology between IGF1 and IGF2 and 40% homology 
between the IGFs and pro-insulin (Li et al., 2009). IGF1 is the main ligand for 
IGF1R (KD = 1 nM), whilst IGF2 binds with a lower affinity (KD = 15-20 nM). Insulin 
can also bind to IGF1R, but with 100-fold lower affinity than IGF1 (KD = 100 nM). 
IGF1 is produced by various tissues in response to growth hormone, which is 
synthesised by the liver. In contrast, the regulation of IGF2 production is thought to 
be much more complex and is not controlled by growth hormone (Tognon and 
Sorensen, 2012). The majority of circulating IGF1 and 2 is found bound to IGF 
binding proteins, which have been proposed to act as “reservoirs”, increasing the 
half-life of the IGFs and extending signalling duration (Singh et al., 2014).  
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Figure 5.2. Signalling cascades activated by IGF1R stimulation  
IGF1R activates several downstream kinase cascades, including those involving ERK1/2, p38 
MAPK, JNK1/2 and Akt. As a result, it regulates a wide variety of cellular processes (Hematulin, 
2010). 
 
 
IGF1R signalling stimulates a cascade of complex cellular responses. After ligand 
binding and phosphorylation of the activation loop tyrosines, a number of other 
tyrosine residues in the juxtamembrane region, kinase domain, and carboxy-
terminus of the IGF1Rβ subunits are autophosphorylated. These phospho-
tyrosines act as docking sites for a variety of adaptor proteins, including the SH2 
domain-containing insulin receptor substrates (IRS1-4) and src homology 2 
containing (Shc) transforming protein (Singh et al., 2014). Ligand binding results in 
the activation of many signalling pathways, including a number of downstream 
kinase cascades, including ERK1/2, p38 MAPK, Akt and JNK (illustrated in Figure 
5.2). 
 
The aim of the experiments performed in this Chapter was to investigate the role of 
IGF1R signalling in the regulation of axonal transport.   
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5.2. In vitro validation of IGF1R as the target kinase  
The results of the preliminary screening assay and subsequent in vitro axonal 
transport assays suggested that inhibition of IGF1R accelerates retrograde axonal 
transport in motor neurons. In order to validate IGF1R as the target kinase, 
additional inhibitors were screened using the accumulation assay (Figure 3.25). 
From this target validation screen, three compounds were selected to investigate 
further: compounds 2-C1, 2-G2 and 2-B3.  
 
5.2.1. Investigating the hits of the target validation screen 
Compound 2-C1 was found to cause a significant increase in the somal 
accumulation of both HCT and α-p75NTR in ES-derived motor neurons. In vitro 
axonal transport assays were performed in wild type and SOD1G93A primary motor 
neurons, as our active inhibitor from the preliminary screen, compound E4, could 
accelerate retrograde axonal transport in motor neurons from both genotypes. All 
the IGF1R inhibitors were tested at 0.5 µM due to the previously observed toxicity 
of compound E4 at 2 µM in in vitro axonal transport assays.  
 
 
 
Figure 5.3. The effects of 2-C1 on the retrograde axonal transport of HCT-labelled vesicles 
in primary motor neurons 
(A) Speed profiles of HCT carriers in wild type motor neurons (black squares) treated with 0.5 µM 2-
C1 (green triangles). Wild type: 182 carriers, 14 axons; wild type + 2-C1: 233 carriers, 16 axons; 5 
independent experiments. (B) Speed profiles of HCT carriers in wild type motor neurons (black 
squares), SOD1G93A motor neurons (red diamonds) and SOD1G93A motor neurons treated with 
0.5 µM 2-C1 (green triangles). Wild type: 74 carriers, 10 axons; SOD1G93A: 119 carriers, 8 axons; 
SOD1G93A + 0.5 µM 2-C1: 110 carriers, 8 axons; 3 independent experiments. 
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Compound 2-C1 was found to cause a small increase in the retrograde axonal 
transport of HCT-labelled vesicles in wild type and SOD1G93A motor neurons (Figure 
5.3; WT + DMSO versus WT + 0.5 µM 2-C1: p = 0.130, SOD1G93A + DMSO versus 
SOD1G93A + 0.5 µM 2-C1: p = 0.428), but did not fully restore axonal transport 
speeds in SOD1G93A motor neurons to wild type levels.  
 
Compound 2-G2, on the other hand, had a more promising effect on the retrograde 
axonal transport of HCT. Incubation of wild type motor neurons with 0.5 µM 2-G2 
caused a shift to faster axonal transport speeds (p = 0.016; Figure 5.4A) and in 
SOD1G93A motor neurons, 2-G2 could fully restore HCT axonal transport to wild type 
levels (Figure 5.4B; SOD1G93A + DMSO versus SOD1G93A + 0.5 µM 2-G2: 
p = 0.046).  
 
However, compound 2-G2 did not have the same effects on the retrograde axonal 
transport of α-p75NTR. Compound 2-G2 was found to have very little effect on 
α-p75NTR axonal transport speeds in either wild type (p = 0.301) or SOD1G93A motor 
neurons (p = 0.227) (Figure 5.4C and D). 
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Figure 5.4. The effects of 2-G2 on retrograde axonal transport in primary motor neurons 
(A) Speed profiles of HCT carriers in wild type motor neurons (black squares) compared to wild 
type motor neurons treated with 0.5 µM 2-G2 (green triangles). Wild type: 141 carriers, 11 
axons; wild type + 2-G2: 164 carriers, 9 axons; 4 independent experiments. (B) Speed profiles 
of HCT carriers in wild type motor neurons (black squares), SOD1G93A motor neurons (red 
diamonds) and SOD1G93A motor neurons treated with 0.5 µM 2-G2 (green triangles). Wild type: 
74 carriers, 10 axons; SOD1G93A: 119 carriers, 8 axons; SOD1G93A + 0.5 µM 2-G2: 127 carriers, 
7 axons; 3 independent experiments. (C) Speed profiles of α-p75NTR carriers in wild type motor 
neurons (black squares) compared to wild type motor neurons treated with 0.5 µM 2-G2 (green 
triangles). Wild type: 100 carriers, 6 axons; wild type + 2-G2: 95 carriers, 6 axons; 3 
independent experiments. (D) Speed profiles of α-p75NTR carriers in wild type (black squares), 
SOD1G93A (red diamonds) and SOD1G93A motor neurons treated with 0.5 µM 2-G2 (green 
triangles). Wild type: 83 carriers, 7 axons; SOD1G93A: 77 carriers, 7 axons; SOD1G93A + 0.5 µM 
2-G2: 81 carriers, 7 axons; 3 independent experiments. 
 
 
The final compound selected from the target validation screen was 2-B3. In the 
accumulation assay, 2-B3 had no effect on HCT accumulation, but caused a 
significant increase in the accumulation of α-p75NTR (Figure 3.25). 
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Figure 5.5. The effects of 2-B3 on retrograde axonal transport in primary motor neurons 
(A) Speed profiles of HCT carriers in wild type motor neurons (black squares) treated with 
0.5 µM 2-B3 (light green triangles) and 1 µM 2-B3 (dark green triangles). Wild type: 157 
carriers, 8 axons; wild type + 0.5 µM 2-B3: 86 carriers, 13 axons; wild type + 1 µM 2-B3: 85 
carriers, 6 axons; 3 independent experiments. (B) Speed profiles of HCT carriers in wild type 
motor neurons (black squares), SOD1G93A motor neurons (red diamonds) and SOD1G93A motor 
neurons treated with 0.5 µM 2-B3 (green triangles). Wild type: 74 carriers, 10 axons; SOD1G93A: 
119 carriers, 9 axons; SOD1G93A + 0.5 µM 2-B3: 98 carriers, 8 axons; 3 independent 
experiments. (C) Speed profiles of α-p75NTR carriers in wild type motor neurons (black squares) 
treated with 0.5 µM 2-B3 (green triangles). Wild type: 75 carriers, 7 axons; wild type + 2-B3: 110 
carriers, 6 axons; 3 independent experiments. (D) Speed profiles of α-p75NTR carriers in wild 
type motor neurons (black squares), SOD1G93A motor neurons (red diamonds) and SOD1G93A 
motor neurons treated with 0.5 µM 2-B3 (green triangles). Wild type: 113 carriers, 8 axons; 
SOD1G93A: 126 carriers, 9 axons; SOD1G93A + 0.5 µM 2-B3: 149 carriers, 8 axons; 3 
independent experiments. 
 
 
However, when tested in our in vitro axonal transport assays, compound 2-B3 was 
able to accelerate axonal transport of HCT in both wild type and SOD1G93A motor 
neurons (WT + DMSO versus WT + 0.5 µM 2-B3: p = 0.104, SOD1G93A + DMSO 
versus SOD1G93A + 0.5 µM 2-B3: p = 0.037; Figure 5.5A and B). In addition, the 
enhancing effect of 2-B3 on HCT axonal transport in wild type neurons was found to 
be dose-dependent (0.5 µM versus 1 µM: p = 0.236; Figure 5.5A). Compound 2-B3 
was also found to accelerate the axonal transport of α-p75NTR in both wild type and 
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SOD1G93A motor neurons (WT + DMSO versus WT + 0.5 µM 2-B3: p = 0.046, 
SOD1G93A + DMSO versus SOD1G93A + 0.5 µM 2-B3: p = 0.027; Figure 5.5C and D).  
 
5.2.2. Investigating the effect of stimulating the IGF1R cascade on retrograde 
axonal transport in motor neurons 
 
To further confirm that IGF1R is a negative regulator of retrograde axonal transport, 
wild type motor neurons were stimulated with the receptor’s main ligand, IGF1. 
Treatment of wild type primary motor neurons with 50 ng/ml IGF1 was found to 
cause a strong stimulation of IGF1R phosphorylation (Figure 5.6A) and significant 
inhibition of the in vitro retrograde axonal transport of HCT-labelled vesicles 
compared to untreated wild type controls (p = 0.003; Figure 5.6B).  
 
 
 
Figure 5.6. Stimulation of IGF1R inhibits retrograde axonal transport in primary wild type 
motor neurons 
(A) Treatment of wild type motor neuron cultures with 50 ng/ml IGF-1 for 30 min causes a 
substantial activation of IGF1R. β actin is used as a loading control. (B) Speed profiles of HCT 
carriers in motor neuron cultures treated with either DMSO (black squares) or 50 ng/ml IGF-1 
(red diamonds). IGF-1 causes a shift to slower transport speeds (Untreated:  82 carriers, 11 
axons; IGF-1 treated: 83 carriers, 9 axons; 3 independent experiments). 
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5.2.3. Investigating the effects of compounds E4 and 2-B3 on the IGF1R 
signalling cascade 
As IGF1R stimulates a complex cascade of downstream pathways (illustrated in 
Figure 5.2), we investigated the effects of our active inhibitors (E4 and 2-B3) on the 
downstream signalling of the receptor (Figure 5.7).  
 
 
 
Figure 5.7. The effects of compounds E4 and 2-B3 on the activity of components of the 
IGF1R signalling cascade 
Western blots showing the effect of 0.5 µM E4 and 2-B3 on activation of IGF1R (A), Akt (B), 
ERK1/2 (C) and p38 MAPK (D) in wild type motor neuron cultures compared to DMSO treated 
controls (IGF1R: n = 3, Akt: n = 4, ERK1/2: n = 3, p38 MAPK: n = 2). ** p< 0.01, *** p < 0.001, 
NS = non significant (One-way ANOVA followed by Dunnett’s multiple comparison test). 
Chapter 5. Results 
 
 163 
Compound 2-B3 was tested alongside compound E4, as they had very similar 
effects on the axonal transport of HCT and α-p75NTR (Figure 3.23, Figure 3.24 and 
Figure 5.5). Firstly, we confirmed by western blot that E4 and 2-B3 were indeed 
acting to inhibit IGF1R activity (Figure 5.7A). Having established that both 
compounds caused a significant inhibition of IGF1R phosphorylation, we went on to 
investigate the effects of the inhibitors on three downstream kinases: Akt, ERK1/2 
and p38 MAPK (as shown in the IGF1R signalling schematic in Figure 5.2). Both 
E4 and 2-B3 were observed to inhibit Akt activity, although the effect of 2-B3 was 
not statistically significant (Figure 5.7B). Neither compound was found to have a 
significant effect on either ERK1/2 or p38 MAPK activation (Figure 5.7C and D). 
 
Finally, IGF1R activity was investigated in primary SOD1G93A motor neurons, as the 
aim of the project was to identify compounds that would ultimately be used to 
accelerate axonal transport in ALS. No significant difference in IGF1R activity was 
observed between wild type and SOD1G93A motor neurons (Figure 5.8A), nor did 
expression of the SOD1WT protein have any effect (Figure 5.8B). This was not 
surprising given the ability of E4 and 2-B3 to accelerate axonal transport in both 
wild type and SOD1G93A motor neurons.   
 
 
 
Figure 5.8. IGF1R activity is not altered in SOD1G93A motor neurons 
Western blots showing IGF1R activity in motor neurons overexpressing SOD1G93A (A) and 
SOD1WT protein (B). Western blot quantification detected no significant difference in IGF1R 
activity between wild type cultures and motor neurons overexpressing either SOD1G93A or 
SOD1WT (SOD1G93A n = 3, SOD1WT n = 1). Non-significant using unpaired Student’s t test. 
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5.2.4. Knockdown of IGF1R in N2A cells and primary motor neurons 
In order to determine whether IGF1R was the target kinase of our active 
compounds, we ordered four shRNAs targeted against different sequences within 
the IGF1R mRNA. The shRNA constructs contained an eGFP reporter gene, to 
allow easy identification of transfected/transduced cells. The shRNA constructs 
were first tested in N2A cells, in order to determine which caused the most efficient 
knockdown of IGF1R.  
 
 
 
Figure 5.9. Testing IGF1R shRNA constructs in N2A cells 
N2A cells were transfected with four different shRNA constructs against IGF1R, as well as a 
scrambled control. GFP indicates expression of the construct. Quantification of the western blot 
shows different levels of knockdown of IGF1R with different shRNA constructs. n = 1. 
 
 
Western blot analysis revealed that shRNA 3 caused the greatest reduction in 
IGF1R protein levels (Figure 5.9). The phospho-IGF1R antibody was used as we 
could not identify a suitable IGF1R antibody that worked in western blot. shRNA 
construct 3 was used to produce lentiviral particles, along with the scrambled 
construct as a control, to enable us to knockdown IGF1R in wild type and 
SOD1G93A primary motor neuron cultures.  
 
Transduction of primary motor neurons with IGF1R shRNA lentiviral particles was 
performed with the help of a rotation student in the laboratory, Alexander Fellows. 
Transduction of primary motor neurons with increasing amounts of IGF1R shRNA 
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was found to cause a dose-dependent reduction in IGF1R protein levels, whilst 
scrambled shRNA had no effect (Figure 5.10).  
 
 
 
Figure 5.10. Knocking down IGF1R in primary motor neuron cultures 
(A) Lysates were made from motor neurons transduced with increasing amounts of lentivirus 
expressing either scrambled or IGF1R shRNA. Western blotting with an antibody specific for 
phospho-IGF1R reveals a dose-dependent knockdown with the IGF1R shRNA but not when 
scrambled shRNA is used. GFP indicates expression of the shRNA construct. (B) Quantification 
of the blots shown in (A). Levels of IGF1R are normalised to the loading control GAPDH. n = 1. 
 
 
 
Our lentiviral IGF1R shRNA particles could therefore be used to determine whether 
knocking down IGF1R in primary motor neurons had the same effect on retrograde 
axonal transport as our active IGF1R inhibitors (compounds E4 and 2-B3).  
 
Treatment with 1 µl IGF1R shRNA lentivirus, however, was found to have no effect 
on the axonal transport of HCT in either wild type or SOD1G93A motor neuron 
cultures (WT + scram shRNA versus WT + IGF1R shRNA: p = 0.873, SOD1G93A + 
scram shRNA versus SOD1G93A + IGF1R shRNA: p = 0.231; Figure 5.11). In 
addition, higher concentrations of lentivirus were found to cause severe blebbing of 
axons and therefore could not be used for in vitro axonal transport assays. As a 
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result, we were unable to determine whether knockdown of IGF1R recapitulates the 
results observed with our active compounds. 
 
 
 
Figure 5.11. Retrograde axonal transport in primary motor neuron cultures treated with 
IGF1R shRNA 
(A) Speed profiles of HCT-labelled signalling endosomes in wild type motor neurons transduced with 
1 µl scrambled shRNA lentivirus (black squares) or 1 µl IGF1R shRNA lentivirus (green triangles). 
Comparison of the curves reveals that knocking down IGF1R in wild type motor neuron cultures has 
no effect on retrograde axonal transport (wild type + scrambled shRNA: 70 carriers, 16 axons; wild 
type + IGF1R shRNA: 93 carriers, 21 axons; 4 independent experiments). (B) Speed profiles of 
HCT-labelled signalling endosomes in SOD1G93A motor neurons transduced with 1 µl scrambled 
shRNA lentivirus (red diamonds) and SOD1G93A motor neurons transduced with 1 µl IGF1R shRNA 
lentivirus (green triangles). Comparison of the curves reveals that knocking down IGF1R in 
SOD1G93A motor neurons has little effect on retrograde axonal transport (SOD1G93A + scrambled 
shRNA: 84 carriers, 18 axons; SOD1G93A + IGF1R shRNA: 107 carriers, 25 axons; 5 independent 
experiments). 
 
 
5.3. Are IGF1R inhibitors general enhancers of axonal 
transport? 
As compound E4 was able to enhance the retrograde axonal transport of HCT and 
α-p75NTR in both wild type and SOD1G93A motor neurons, we wanted to investigate 
whether the compound was a general enhancer of axonal transport. We therefore 
tested the effect of compound E4 on the axonal transport of different cargoes 
(Lysotracker™ and WGA), on anterograde axonal transport and also in different 
neuronal types (sensory and hippocampal).  
 
Firstly, we investigated whether compound E4 affected the retrograde axonal 
transport of cargoes other than HCT and α-p75NTR. We therefore used 
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Lysotracker™ to label acidic organelles (late endosomes/lysosomes and 
autophagosomes). Motor neurons were co-incubated with Lysotracker™ and HCT 
so that the direction of axonal transport could be determined. Treatment of motor 
neurons with 0.5 µM E4 caused a small acceleration of the retrograde axonal 
transport of acidic organelles in wild type motor neurons (p = 0.312; Figure 5.12A). 
In SOD1G93A motor neurons, the ability of compound E4 to accelerate axonal 
transport was more pronounced and could restore retrograde axonal transport 
speeds to wild type levels (SOD1G93A + DMSO versus SOD1G93A + 0.5 µM E4: 
p = 0.147; Figure 5.12B). 
 
 
 
Figure 5.12. The effect of compound E4 on retrograde axonal transport of Lysotracker™ 
in wild type and SOD1G93A motor neurons 
(A) Retrograde speed profiles of Lysotracker™-labelled carriers in wild type motor neuron 
cultures treated with DMSO (black squares) or 0.5 µM E4 (green triangles) (DMSO:  85 carriers, 12 
axons; E4: 42 carriers, 13 axons; 3 independent experiments). (B) Retrograde speed profiles of 
Lysotracker™-labelled carriers in wild type (black squares), SOD1G93A (red diamonds) and 
SOD1G93A + 0.5 µM E4 (green triangles) motor neuron cultures (wild type:  85 carriers, 12 axons; 
SOD1G93A: 30 carriers, 15 axons; SOD1G93A + 0.5 µM E4: 16 carriers, 6 axons; 3 independent 
experiments).  
 
 
In vitro axonal transport experiments with Lysotracker™ also allowed us to analyse 
the effect of compound E4 on anterograde axonal transport. In contrast to its 
effects on retrograde axonal transport, treatment with 0.5 µM E4 had no effect on 
anterograde axonal transport speeds (Figure 5.13). This result was seen in assays 
performed in both wild type (p = 0.934; Figure 5.13A) and SOD1G93A motor neurons 
(p = 0.847; Figure 5.13B).  
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Our analysis of axonal transport had so far focused on motor neurons, due to our 
interest in correcting axonal transport defects in ALS. However, to determine 
whether compound E4 was a general enhancer of retrograde axonal transport, it 
was important to test its effects in other neuronal types.  
 
 
 
Figure 5.13. The effect of compound E4 on anterograde axonal transport of 
Lysotracker™ in primary wild type and SOD1G93A motor neurons 
(A) Anterograde speed profiles of Lysotracker™-labelled carriers in wild type motor neuron 
cultures treated with DMSO (black squares) or 0.5 µM E4 (green triangles) (DMSO:  44 carriers, 12 
axons; E4: 14 carriers, 6 axons; 3 independent experiments). (B) Anterograde speed profiles of 
Lysotracker™-labelled carriers in wild type (black squares), SOD1G93A (red diamonds) and 
SOD1G93A + 0.5 µM E4 (green triangles) motor neuron cultures (wild type:  44 carriers, 12 axons; 
SOD1G93A: 45 carriers, 15 axons; SOD1G93A + 0.5 µM E4: 12 carriers, 5 axons; 3 independent 
experiments).  
 
 
Firstly, we analysed the effect of compound E4 on the retrograde axonal transport 
of HCT-labelled vesicles in wild type adult DRG cultures. Treatment with 0.5 µM E4 
was found to have no effect on axonal transport speeds (p = 0.777; Figure 5.14). 
Next, we tested the effect of compound E4 on retrograde axonal transport in wild 
type hippocampal neurons. These experiments were performed during a visit to the 
laboratory of Bianxiao Cui (Stanford University, USA). Hippocampal neurons were 
plated in microfluidic chambers, allowing fluidic isolation of the axon terminals from 
the cell body. In this way, quantum dot-labelled WGA (QD-WGA) could be applied 
selectively to the axon compartment and its retrograde axonal transport imaged 
using fluorescence microscopy (as illustrated in Movie 2). WGA binds to sialic acid 
and N-acetylglucosaminyl residues and therefore labels all membranous 
compartments. Kymographs were generated from time-lapse images in order to 
analyse the speed of retrograde axonal transport (Figure 5.15A).  Incubation with 
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0.5 µM E4 was found to cause a small shift to faster axonal transport speeds 
(p = 0.062; Figure 5.15B).    
 
 
 
Figure 5.14. IGF1R inhibitor compound E4 has no effect on retrograde axonal transport in 
wild type sensory neurons 
Speed profiles of HCT carriers in wild type DRG cultures treated with either DMSO (black 
squares) or 0.5 µM E4 (green triangles). E4 has no effect on axonal transport speeds (DMSO:  
39 carriers, 6 axons; E4 treated: 35 carriers, 12 axons; 3 independent experiments). 
 
 
 
 
 
 
Figure 5.15. IGF1R inhibitor compound E4 accelerates retrograde axonal transport in 
hippocampal neurons 
The effect of 0.5 µM E4 on the retrograde axonal transport of QD-WGA was analysed in 
hippocampal neurons. (A) Kymographs were generated from time-lapse series in order to 
calculate the speed of individual cargoes. Scale bar, 15 µm. (B) Speed profiles of WGA-labelled 
carriers in hippocampal cultures treated with either DMSO (black squares) or 0.5 µM E4 (green 
triangles). DMSO:  127 carriers; PPP treated: 116 carriers; 3 independent experiments. 
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5.4. Determining the effect of IGF1R inhibitors on retrograde 
axonal transport in vivo 
Finally, we wanted to investigate the effect of IGF1R inhibitors on retrograde axonal 
transport in motor neurons in vivo. Unfortunately, neither of the inhibitors tested 
previously (E4 and 2-B3) were suitable to be used in vivo. We therefore had to 
identify a BBB permeable, in vivo tolerable IGF1R inhibitor that could be tested in 
our in vivo axonal transport assays.  
 
5.4.1. Picropodophyllotoxin accelerates retrograde axonal transport in vitro 
Picropodophyllotoxin (PPP) (shown in Figure 5.16) is a non-ATP competitive 
antagonist of IGF1R. It inhibits IGF1R auto-phosphorylation (IC50 ~ 1 nM), but does 
not inhibit the insulin receptor or other related growth factor receptors, such as 
epidermal growth factor receptor (Girnita et al., 2004). PPP has been previously 
demonstrated to be suitable for in vivo use and has been shown to cross the BBB 
(Yin et al., 2010).  
 
 
Figure 5.16. The chemical structure of the IGF1R inhibitor picropodophyllotoxin (PPP) 
 
Firstly, we confirmed that treatment with 0.5 µM PPP was able to inhibit IGF1R 
activity in primary motor neuron cultures. Western blot analysis revealed that 
incubation of wild type motor neurons with PPP caused a substantial reduction in 
the levels of phosphorylated IGF1R, similar to that seen with compounds E4 and 
2-B3 (Figure 5.17).  
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Next, we investigated whether PPP could also accelerate retrograde axonal 
transport in vitro. As with compounds E4 and 2-B3, incubation of wild type primary 
motor neurons with 0.5 µM PPP was found to accelerate the axonal transport of 
HCT-labelled vesicles (p = 0.083; Figure 5.18).  
 
 
 
Figure 5.17. Picropodophyllotoxin (PPP) inhibits IGF1R activity in primary motor neurons 
Western blot showing the effect of IGF1R inhibitors E4, 2-B3 and PPP on IGF1R activity in 
primary wild type motor neurons. Incubation of motor neurons with 0.5 µM PPP inhibits the 
IGF1R to a similar extent as E4 and 2-B3. n = 1.  
 
 
 
 
Figure 5.18. Treatment of primary motor neurons with 0.5 µM picropodophyllotoxin (PPP) 
accelerates retrograde axonal transport 
Speed profiles of HCT carriers in motor neuron cultures treated with either DMSO (black 
squares) or 0.5 µM PPP (green triangles). PPP causes a shift to faster transport speeds 
(DMSO:  84 carriers, 9 axons; PPP treated: 76 carriers, 10 axons; 3 independent experiments). 
Chapter 5. Results 
 
 172 
5.4.2. Investigating the effect of picropodophyllotoxin on retrograde axonal 
transport in vivo 
As PPP has been previously tested in vivo and shown to cross the BBB (Yin et al., 
2010), we could investigate the effect of PPP in our in vivo axonal transport assay 
(described in Section 4.4.1). We decided to test the effect of PPP in early 
symptomatic SOD1G93A mice, as the ultimate aim of the project was to determine 
the role of retrograde axonal transport defects in ALS pathogenesis. In previous 
studies, PPP was shown to inhibit IGF1R signalling when administered i.p. at 
20 mg/kg in rats, with no side effects reported. However, when this dose was 
tested in early symptomatic SOD1G93A mice, it caused severe adverse effects. 
Lowering the dose to 10 or 5 mg/kg reduced these adverse effects, allowing axonal 
transport to be assessed in vivo in treated mice. As described in Section 4.4.2, the 
compound was administered i.p. at the same time as the HCT fragment was 
injected i.m., and retrograde axonal transport was imaged in the sciatic nerve four 
hours later. Preliminary data collected from two mice treated with 5 mg/kg PPP and 
one mouse treated with 10 mg/kg PPP indicates that PPP is able to accelerate 
retrograde axonal transport in early symptomatic SOD1G93A mice, restoring axonal 
transport to almost wild type speeds (WT versus SOD1G93A + PPP: p = 0.859, 
SOD1G93A versus SOD1G93A + PPP: p = 0.0579; Figure 5.19). This work was 
performed with help from James Sleigh (Institute of Neurology, UCL).  
 
 
Figure 5.19. PPP accelerates retrograde axonal transport in vivo in the SOD1G93A mouse  
Retrograde axonal transport in single axons of the sciatic nerve was assessed in 73 d wild type 
(black squares), SOD1G93A (red diamonds) and SOD1G93A mice treated with PPP (green 
triangles). 5 mg/kg PPP (2 mice) and 10 mg/kg PPP (1 mouse) were found to have the same 
effect on retrograde axonal transport, therefore the data from all 3 treated mice were pooled. 
Wild type: 161 carriers, n (animals) = 4; SOD1G93A: 185 carriers, n = 5; SOD1G93A + PPP 
(5-10 mg/kg): 201 carriers, n = 3. 
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5.5. Discussion 
The aim of this Chapter was to investigate the effects of compound E4 on axonal 
transport in more detail and to determine whether inhibition of IGF1R was 
responsible for the acceleration of retrograde axonal transport caused by this 
compound. 
 
In this Chapter, I was able to demonstrate that compound E4 accelerates the in 
vitro retrograde axonal transport of HCT, α-p75NTR and Lysotracker™ in primary 
motor neurons and WGA in hippocampal neurons. However, compound E4 had no 
effect on the retrograde axonal transport of HCT in sensory neurons, nor any effect 
on the anterograde axonal transport of Lysotracker™ in motor neurons. These 
results suggest that the regulatory mechanisms governing axonal transport are 
highly specific for different neuronal types, transport directions and cargoes, and 
that these mechanisms can be exploited pharmacologically. This is particularly 
relevant for diseases such as ALS, where defects in retrograde axonal transport 
are found in motor neurons, and not sensory neurons for example, and it would 
therefore be advantageous to modify axonal transport only in affected neuronal 
types. This conclusion also indicates that more work must be done to investigate 
the effects of compound E4 and our other active inhibitors (compound 2-B3 and 
PPP) on axonal transport in different neuronal types. This will allow us to determine 
whether these compounds could be utilised in other neurodegenerative diseases in 
which axonal transport defects have been implicated as a pathogenic mechanism. 
 
In order to establish whether IGF1R was the target kinase of compound E4, 
additional structurally diverse IGF1R inhibitors were screened using the 
accumulation assay (described in Chapter 3) and hit compounds were tested in in 
vitro axonal transport assays in primary motor neurons in this Chapter. The effects 
of the hit compounds on retrograde axonal transport were varied. Compound 2-C1 
had little effect on retrograde axonal transport speeds, while compound 2-G2 
caused an enhancement of HCT axonal transport only, with no effect on α-p75NTR 
transport. Compound 2-B3, on the other hand, mimicked the effects of compound 
E4, accelerating the retrograde axonal transport of both probes. There are a 
number of possible explanations for the variable effects of the IGF1R inhibitors 
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tested. It could be that the compounds have differential effects on the kinase 
cascades downstream of IGF1R, such that different compounds cause preferential 
inhibition of different signalling cascades. Although pathway-selective antagonism 
of IGF1R has not been previously reported, I did observe that compounds E4 and 
2-B3 appeared to preferentially inhibit Akt over other kinases that are downstream 
of IGF1R. Additional signalling experiments, testing the effects of both axonal 
transport active and inactive compounds, would help elucidate whether there is a 
correlation between axonal transport activity and downstream kinase inhibition that 
would explain the results reported in this Chapter. Another possible explanation is 
that our active compounds, E4 and 2-B3, may not only inhibit IGF1R, but could also 
share additional target(s) that are critical for their effect on axonal transport. Given 
that picropodophyllotoxin (PPP), a published IGF1R inhibitor, also has the same 
effect as E4 and 2-B3, it is likely that inhibition of IGF1R does play a role in the 
enhancement of axonal transport, but it may not fully explain the results seen. This 
is supported by the fact that knocking down IGF1R had no effect on retrograde 
axonal transport in primary motor neuron cultures. The involvement of additional 
targets would also explain why some of our IGF1R inhibitors did not affect 
retrograde axonal transport in the same way as E4, 2-B3 and PPP. A detailed 
analysis of the structures of our active compounds plus a comparison of their 
known targets other than IGF1R could help elucidate whether these compounds 
share additional target(s) that may underlie their enhancing effects on retrograde 
axonal transport. It is also possible that compounds 2-C1 and 2-G2 have reduced 
plasma membrane permeability or lower efficacy than compounds E4 and 2-B3, 
and this may underlie their reduced effects on axonal transport. 
 
Although compound 2-G2 did not mimic the effects of compound E4 in in vitro 
axonal transport assays and was therefore not investigated further, it could in fact 
be an interesting compound to study in the future. Our experiments demonstrated 
that compound 2-G2 was able to accelerate HCT axonal transport but had little 
effect on α-p75NTR. These results support the idea that the intracellular sorting and 
trafficking of these two cargoes may be differentially regulated and further study of 
compound 2-G2 and its mechanism of action could help elucidate the signalling 
machinery involved. 
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Moving on to consider the IGF1R knockdown experiments performed in this 
Chapter, it is possible that a technical problem may have been responsible for the 
lack of effect of our lentiviral shRNA vectors on retrograde axonal transport. It is 
possible that the knockdown of IGF1R we observed in our primary motor neuron 
cultures by western blot was mostly a result of reduced IGF1R protein levels in glial 
cells, and not in the motor neurons themselves. If the acceleration of axonal 
transport caused by our active compounds is a result of IGF1R inhibition in motor 
neurons (i.e. our IGF1R inhibitors act cell autonomously), then this would explain 
the lack of effect of our IGF1R shRNA in axonal transport assays. Unfortunately we 
were unable to find an IGF1R antibody that worked in immunofluorescence, so we 
could not determine whether IGF1R was knocked down in motor neurons. In 
addition to identifying a better antibody, this problem could also be addressed by 
designing lentiviral vectors with neuron-specific promoters. Alternatively, our IGF1R 
shRNA lentivirus preparation may have been contaminated in some way, which 
obscured any effect of IGF1R knockdown on axonal transport. Finally, the 
discrepancy between the results could be due to the fact that pharmacological 
inhibition of IGF1R was always performed acutely (25 min for in vitro axonal 
transport assays), whilst the IGF1R shRNA was applied on the day of plating 
(DIV0) and transport assays were performed on DIV7. It is therefore possible that 
motor neurons are able to adapt to long-term reductions in IGF1R signalling. 
Further work is clearly required to optimise the knockdown experiments and 
confirm whether IGF1R is in fact the target responsible for the acceleration of 
retrograde axonal transport caused by our active compounds.  
 
5.5.1. Possible links between IGF1R and retrograde axonal transport 
To date, there have been few connections made between IGF1R signalling and the 
regulation of axonal transport. In this Chapter, we investigated the effect of our 
axonal transport-active IGF1R inhibitors (compounds E4 and 2-B3) on the 
downstream targets of IGF1R (Figure 5.2 and Figure 5.7). We found that 
compounds E4 and 2-B3 had little effect on the downstream kinases ERK1/2 and 
p38 MAPK, suggesting that the compounds do not accelerate axonal transport 
through inhibition of these kinases. ERK1/2 has in fact been shown to 
phosphorylate the intermediate chains of cytoplasmic dynein leading to enhanced 
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binding of dynein to the signalling endosome in cortical neurons (Mitchell et al., 
2012). Therefore inhibition of ERK1/2 would be expected to inhibit retrograde 
axonal transport, not accelerate it. We have also demonstrated in Chapter 3 that 
inhibition of p38 MAPK has no effect on axonal transport in wild type motor neurons, 
therefore we would not expect IGF1R to be acting through this kinase. Furthermore, 
JNK, another kinase downstream of IGF1R that was not investigated in this 
Chapter, has been previously shown to have no effect on anterograde or 
retrograde axonal transport velocities in rodent hippocampal and DRG neurons 
(Stagi et al., 2006, Fu and Holzbaur, 2013). Of course, the regulatory mechanisms 
governing axonal transport may be neuron-specific, so it will be necessary to test 
the effects of inhibiting ERK1/2 and JNK in motor neurons to truly determine 
whether or not they play a role in the acceleration of axonal transport caused by 
our active compounds.  
 
Compounds E4 and 2-B3 both caused a detectable reduction in Akt 
phosphorylation. As discussed earlier, htt has been proposed to act as a molecular 
switch between anterograde and retrograde axonal transport, and this “switch” 
activity is directly regulated by Akt (Colin et al., 2008). The authors demonstrated 
that if Akt-mediated phosphorylation of htt is prevented, the retrograde axonal 
transport of BDNF is accelerated in cortical neurons. Conversely, transfection of 
neurons with a phospho-mimic form of htt led to accelerated anterograde axonal 
transport. Stimulation of cortical neurons with 50 ng/ml IGF1 was shown to induce 
phosphorylation of htt and lead to an acceleration of anterograde axonal transport. 
However, in contrast to our results in motor neurons (where IGF1 was observed to 
inhibit HCT axonal transport), stimulation of cortical neurons with IGF1 had no effect 
on retrograde axonal transport speeds. The authors proposed that when htt is 
dephosphorylated, kinesin-1 is detached from the microtubules and vesicles. 
Activation of IGF1R leads to phosphorylation of htt and increased association of 
kinesin with microtubules and vesicles. Based on the “tug of war” theory of axonal 
transport, which proposes that the direction of cargo movement is determined by 
which pool of molecular motors successfully ‘outcompetes’ its counterpart for 
binding to the microtubule network (Welte, 2004, Gross, 2004), inhibition of IGF1R 
signalling should lead to enhanced binding of dynein to microtubules and therefore 
increased retrograde axonal transport. It would be interesting to test inhibitors of 
Chapter 5. Results 
 
 177 
Akt in our in vitro axonal transport assays in motor neurons to see if they mimic the 
effects of our active IGF1R inhibitors.   
 
It is worth noting that insulin has been described to positively regulate axonal 
transport through activation of Akt (Takach et al., 2015). The authors of this study 
proposed that, in response to insulin stimulation, Akt inhibits GSK3β, which has 
been shown to be a negative regulator of both anterograde and retrograde axonal 
transport (Weaver et al., 2013, Chen et al., 2007a, Morfini et al., 2002). These 
results indicate that the insulin and IGF1R signalling pathways may have distinct 
roles in the regulation of axonal transport. 
 
An alternate hypothesis to explain the ability of our IGF1R inhibitors to accelerate 
retrograde axonal transport comes from work performed in C. elegans. C. elegans 
have a single insulin/IGF receptor, DAF-2. RNAi-mediated knockdown of DAF-2 
results in long-lived, stress-resistant worms (Kenyon, 2005). Ewald et al. 
demonstrated that reduced insulin/IGF signalling leads to increased expression of 
collagens and other extracellular matrix (ECM) genes (Ewald et al., 2015). The 
authors proposed that ECM remodelling plays a key role in increasing longevity in 
DAF-2 knockdown worms. The ECM has been shown to sequester growth factors, 
storing them in the vicinity of cells and protecting them from degradation (Schultz 
and Wysocki, 2009). ECM remodelling in response to reduced IGF signalling in 
neurons could therefore lead to the local release of growth factors and stimulation 
of retrograde axonal transport. Such a mechanism could explain how our IGF1R 
inhibitors accelerate retrograde axonal transport. It would be interesting to 
investigate whether our active inhibitors stimulate ECM remodelling. Given it has 
been recently shown that the ECM component nidogen is internalised together with 
HCT in motor neurons (Bercsenyi et al., 2014), we could test whether our IGF1R 
inhibitors enhance the neuronal uptake of such ECM components.  
 
5.5.2. IGF1R and ALS 
It is important to acknowledge that stimulation of IGF1R signalling has been 
proposed to be beneficial in ALS. Firstly, experiments in SOD1G93A mice indicated 
that increased IGF1 was neuroprotective and could improve survival (Kaspar et al., 
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2003). The group demonstrated that adeno-associated virus (AAV)-mediated 
delivery of IGF1 could protect motor neurons and extend survival, when the virus 
was injected into the quadriceps muscle of symptomatic SOD1G93A mice. Delivery 
of AAV-IGF1 vectors to the deep cerebellar nuclei (DCN) has also been shown to 
have the same effects (Dodge et al., 2008). In fact, the delivery of a number of 
growth factors has been shown to be beneficial in ALS mouse models, including 
GDNF (Acsadi et al., 2002), VEGF (Azzouz et al., 2004) and CNTF (Sendtner et al., 
1992, Mitsumoto et al., 1994). It is therefore possible that the beneficial effects of 
increasing growth factor levels are not due to the fact that they are targeting a 
disease-specific pathology, but rather that growth factors act to boost motor neuron 
health and survival under disease conditions, due to their role in maintaining 
neuronal function and protecting against toxic insults. 
 
However, clinical trials with growth factors have been disappointing. Three clinical 
trials have been published testing the effect of subcutaneously administered IGF1 
in ALS patients. These trials reported few (Lai et al., 1997) or no beneficial effects 
(Borasio et al., 1998, Sorenson et al., 2008). In addition, the administration of 
growth hormone (which stimulates IGF1 production) has been tested in ALS 
patients and did not produce any benefit compared to patients that received 
placebo (Saccà et al., 2012). A similar lack of beneficial effects has also been seen 
for CNTF (ALS CNTF Treatment Study Group, 1996) and BDNF (The BDNF Study 
Group, 1999). These results may reflect the limitations of using proteins as 
therapeutics, such as their limited bioavailability, poor CNS penetration and short 
half-lives. Alternatively, they may be the result of poor trial design, inadequate 
dosing and/or poor translation of results from animal models.  
 
5.5.3. Inhibiting IGF1R as a potential therapeutic strategy  
Although more work is required to determine the mechanism of action of our active 
compounds, a key result in this Chapter was the demonstration that the IGF1R 
inhibitor PPP accelerates retrograde axonal transport in the mouse sciatic nerve in 
vivo. If retrograde axonal transport is shown to play a key role in motor neuron 
degeneration, PPP or similar compounds may have potential as therapeutic 
approaches for ALS. 
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Our in vitro assays indicate that, at the concentration required to accelerate 
retrograde axonal transport (0.5 µm), our active IGF1R inhibitors are not toxic to 
primary motor neurons. However, we did observe substantial toxicity of compound 
E4 at 2 µM, suggesting that careful dosing is required if the beneficial effects of 
IGF1R inhibitors are to be seen. In addition, when we tested the BBB-permeable 
IGF1R inhibitor PPP in vivo, it was found to cause a number of adverse effects in 
SOD1G93A mice. Adverse effects of PPP have not been previously reported in 
rodents with either i.p. or oral dosing (Yin et al., 2010, Economou et al., 2008). It is 
possible that our results may reflect a problem with the particular formulation of the 
compound we used or an interaction with the SOD1G93A pathology. Testing our 
batch of PPP in wild type mice will help determine where the problem lies. PPP has 
in fact reached clinical trials for the treatment of a number of different types of 
cancer (https://www.clinicaltrials.gov/ct2/results?term=axl1717) but was associated 
with an increased risk of neutropenic episodes, some of which developed into 
serious events and were fatal (Bergqvist et al., 2013).  
 
Reduced IGF1R signalling has been previously shown to have beneficial effects on 
longevity (Cohen, 2011). Mice with reduced IGF1R signalling (IGF1R+/-) have been 
shown to live 26% longer than control mice (Holzenberger et al., 2003). 
Furthermore, in humans, mutations in IGF1R that lead to reduced activity of the 
receptor have been associated with extreme longevity (Suh et al., 2008). Full 
knockout of IGF1R, however, causes neonatal lethality and dwarfism in mice (Liu et 
al., 1993). It has been proposed that the increased longevity of IGF1R+/- mice is a 
result of their improved resistance to oxidative stress (Holzenberger et al., 2003) 
and increased protection from proteotoxicity (El-Ami et al., 2014).  
 
The effects of reduced IGF1R signalling have also been investigated in relation to 
neurodegeneration. Crossing IGF1R+/- mice with an Alzheimer’s disease (AD) 
mouse model (APPSwe/Presenillin1ΔE9) led to an improvement in behavioural 
deficits in these mice. This was associated with reduced neuronal loss and reduced 
inflammatory signalling (fewer activated astrocytes) (Cohen et al., 2009). 
Furthermore, hippocampus-specific knockout of IGF1R (hIGF1R-/-) in another 
model of Alzheimer’s disease, Tg2576, has been shown to rescue these mice from 
the premature death associated with this model (Freude et al., 2009). However the 
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authors did not look at the effect of hIGF1R-/- on neuronal survival or behavioural 
deficits in these mice. Both groups proposed that reduced IGF1R signalling 
protected AD mice from Aβ toxicity, either by causing the formation of dense Aβ 
aggregates of lower toxicity (Cohen et al., 2009) or by reducing APP processing 
and therefore Aβ production (Freude et al., 2009).   
 
Unfortunately, the survival data for hIGF1R-/- mice was only collected until 60 
weeks of age, at which point survival of hIGF1R-/- mice was the same as controls. It 
would have been interesting to see whether the hIGF1R-/- mice live longer than 
controls, as is seen for IGF1R+/- mice (Holzenberger et al., 2003), as this would 
allow us to begin to understand how IGF1R signalling in different neuronal types 
may contribute to the regulation of lifespan. 
 
In all of the above studies, IGF1R signalling was reduced presymptomatically and 
therefore the results may not be clinically relevant when considering developing a 
new therapeutic approach for neurodegenerative diseases. There is, however, 
evidence to suggest that reducing IGF1R signalling after symptom onset may still 
be beneficial. C.elegans expressing Aβ in their body wall muscles develop 
progressive paralysis due to the formation of toxic Aβ aggregates. Cohen et al. 
demonstrated that RNAi-mediated knockdown of DAF-2 could protect C.elegans 
from Aβ-mediated toxicity, even when RNAi treatment was initiated later in life 
(Cohen et al., 2010). 
 
These studies suggest that reduced IGF1R signalling is neuroprotective and could 
be beneficial in neurodegenerative diseases associated with proteotoxicity. This 
neuroprotective effect has been explained by the fact that IGF1R signalling 
inhibition leads to enhanced resistance to oxidative stress (Holzenberger et al., 
2003), enhanced DNA repair (Cohen et al., 2009) and protection from proteotoxicity 
(Cohen et al., 2009, Cohen et al., 2006). IGF1 signalling has also been described 
to inhibit regeneration of aging adult motor neurons in C.elegans (Byrne et al., 
2014). It therefore appears that reduced IGF1R signalling could have a number of 
beneficial effects that are relevant to ALS and other neurodegenerative diseases. 
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Furthermore, reduced activity of downstream components of the IGF1R cascade 
has been previously shown to improve the survival of primary motor neurons 
transduced with mutant SOD1 in vitro. In mammals, activation of the 
IGF1R/PI3K/Akt cascade leads to phosphorylation of the transcription factor 
FOXO3a. FOXO3a controls the expression of genes that help the cell to cope with 
stress and promote longevity. Phosphorylation of FOXO3a leads to its translocation 
out of the nucleus (Birkenkamp and Coffer, 2003). Expression of HSV-TM-FOXO3a, 
which cannot be phosphorylated and therefore remains constitutively in the nucleus, 
was shown to restore the survival of primary motor neurons transduced with HSV-
SOD1G85R to wild type levels (Mojsilovic-Petrovic et al., 2009). In addition, the group 
were able to demonstrate that an inhibitor of FOXO3a nuclear export, 
Psammaplysene A, could also restore the survival of these motor neurons. This 
highlights an additional mechanism by which IGF1R inhibition could be beneficial in 
ALS. It will be interesting to test whether our axonal transport-active IGF1R 
inhibitors affect the phosphorylation state and cellular localisation of FOXO3a, and 
whether they are able to improve the survival of SOD1G93A motor neurons both in 
vitro and in vivo. 
 
Due to the interest in inhibiting IGF1R signalling for the treatment of cancer, a 
number of different targeting strategies have already been developed. These 
include antibodies against both IGF1 and IGF1R, IGF1R kinase inhibitors and also 
inhibitors of downstream kinases (Pollak, 2008). A number of IGF1R monoclonal 
antibodies and kinase inhibitors are currently in clinical development for various 
types of cancer. A disadvantage of the pharmacological inhibitors currently being 
investigated is the lack of specificity for IGF1R over the insulin receptor. Inhibition 
of the insulin receptor increases the risk of adverse events, particularly the risk of 
hyperglycaemia. PPP is the only BBB permeable IGF1R inhibitor in clinical 
development at the moment, so there is clearly a need to develop additional 
selective inhibitors suitable for use in CNS disorders. Of course, the usefulness of 
IGF1R inhibitors in ALS still needs to be determined. However, if we are to 
investigate the effect of IGF1R inhibition on disease progression in the SOD1G93A 
mouse, we will need to identify an IGF1R targeting strategy that is able to cross the 
BBB and does not cause the adverse effects we have observed with PPP.  
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Chapter 6. Conclusions and future perspectives 
 
The aim of the work presented in this Thesis was to develop and perform a screen 
to identify enhancers of retrograde axonal transport in motor neurons and validate 
the effects of hit compounds on axonal transport both in vitro and in vivo. 
 
I was able to demonstrate that the accumulation of HCT and α-p75NTR in the cell 
body of mouse ES-derived motor neurons is sensitive to changes in retrograde 
axonal transport efficiency and could therefore be used as a read-out in screening 
assays to identify novel pharmacological enhancers of retrograde axonal transport. 
This accumulation assay was successfully used to identify two novel enhancers of 
retrograde axonal transport (compounds A1 and E4) from a small library of kinase 
inhibitors.  
 
Compound A1 was found to correct SOD1G93A-induced deficits in retrograde axonal 
transport in primary motor neurons, whilst having no effect on axonal transport 
speeds in wild type motor neurons. Compound A1 was revealed to be an inhibitor 
of p38 MAPK. Additional, structurally diverse, inhibitors of p38 MAPK were also 
found to correct deficits in retrograde axonal transport in SOD1G93A motor neurons, 
indicating that p38 MAPK was the kinase responsible for transport defects. In 
agreement with this, p38 MAPK was found to be activated in both embryonic 
SOD1G93A motor neurons and in the spinal cord of adult SOD1G93A mice. Levels of 
phospho-p38 MAPK were found to be highest at an early symptomatic stage – the 
age at which in vivo axonal transport defects are most severe. Lentiviral-mediated 
knockdown experiments in primary motor neurons revealed that p38 MAPKα was 
responsible for SOD1G93A-induced deficits in retrograde axonal transport. This was 
also confirmed using a pharmacological approach. SB-239063, a p38 MAPKα/β 
specific inhibitor, was shown to correct defects in retrograde axonal transport in 
vitro in SOD1G93A motor neurons. Furthermore, we were able to demonstrate that 
SB-239063 could correct defects in retrograde axonal transport in early 
symptomatic SOD1G93A mice. Plans are now in action to determine the effect of 
SB-239063 on disease progression in the SOD1G93A mouse model. 
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In contrast to compound A1, compound E4 was found to accelerate retrograde 
axonal transport in vitro in both wild type and SOD1G93A motor neurons. The 
compound was revealed to be an inhibitor of IGF1R. Compound E4 was observed 
to have both direction- and neuron-specific effects on axonal transport. The 
compound was shown to accelerate the retrograde axonal transport of signalling 
endosomes and acidic organelles (late endosomes/lysosomes and 
autophagosomes) in motor and hippocampal neurons. However, it had no effect on 
the anterograde axonal transport of acidic organelles in motor neurons, nor any 
effect on the retrograde axonal transport of signalling endosomes in sensory 
neurons. We were able to identify additional IGF1R inhibitors that mimicked the 
effects of compound E4 (2-B3 and PPP). However, lentiviral-mediated knockdown 
of IGF1R had no effect on retrograde axonal transport speeds in motor neurons in 
vitro. It is therefore still unclear whether IGF1R is the kinase responsible for the 
effects of our active compounds. PPP, one of our IGF1R inhibitors that enhanced 
retrograde axonal transport in vitro, was suitable to be tested in vivo and was found 
to accelerate the axonal transport of HCT in the sciatic nerve of early symptomatic 
SOD1G93A mice. Future work must focus on determining the target(s) and 
mechanism of action of the axonal transport-active IGF1R inhibitors and identifying 
a compound suitable to be used in efficacy studies in mice.  
 
6.1. Future work 
The accumulation assay has proved successful in identifying novel modulators of 
retrograde axonal transport from a small library of compounds. The next step will 
therefore be to extend our pilot studies and screen larger compound libraries, 
looking for both enhancers and inhibitors of retrograde axonal transport. Since our 
pilot studies were carried out in wild type ES-derived motor neurons only, it will be 
interesting to perform the assay in both mouse ES-derived motor neurons 
expressing ALS-associated mutations and ALS patient iPSC-derived motor 
neurons (as described in Section 3.6.3), in order to generate more disease-relevant 
hits. However, preliminary work is required to determine whether ALS-associated 
ES- and iPSC-derived motor neurons display defects in retrograde axonal transport. 
In addition, the accumulation assay could also be used in other neuronal types, 
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such as cortical, sensory or hippocampal neurons, in order to identify modifiers of 
retrograde axonal transport relevant to other neurodegenerative diseases.  
 
One of the key results of this work was the discovery that the p38 MAPKα/β 
inhibitor SB-239063 is able to correct retrograde axonal transport defects in vivo in 
the SOD1G93A mouse, without causing overt adverse effects. This compound 
therefore has the potential to determine conclusively whether axonal transport 
defects play a key role in ALS pathogenesis. Plans are already in motion to perform 
a full efficacy study, testing the effect of SB-239063 on motor function, lifespan, 
muscle physiology and motor neuron survival when administered from an early 
symptomatic age. It would also be interesting to test this compound in other mouse 
models of ALS that display retrograde axonal transport defects, in order to 
determine whether pathological p38 MAPK activation and subsequent transport 
inhibition are unique to SOD1G93A-mediated ALS or a common pathological 
hallmark of the disease. In addition, given that ALS is thought to result from the 
interaction of multiple different pathological mechanisms, we could administer 
SB-239063 in combination with other disease-modifying agents, such as riluzole or 
dexpramipexole, to determine whether multi-target therapy has a synergistic effect 
on ALS disease progression.  
 
Given that approximately 15% of ALS patients display clinical symptoms of 
frontotemporal dementia (FTD), it will also be interesting to investigate the role of 
axonal transport defects and p38 MAPK in FTD. Axonal transport deficits have 
been reported in experimental models of FTD with parkinsonism-17 (FTDP-17). 
Mice expressing FTDP-17 associated P301L mutant tau were found to have 
significant impairments in axonal transport in olfactory neurons before cognitive 
dysfunction was first observed (Majid et al., 2014). In addition, knocking down 
components of the dynein/dynactin complex was found to exacerbate tau pathology 
and locomotor deficits in a Drosophila model overexpressing FTDP-17 associated 
R406W tau, indicating that retrograde axonal transport defects contribute to the 
pathology (Butzlaff et al., 2015). Given that hexanucleotide repeat expansions in 
C9orf72 are the major cause of both fALS and FTD and that C9orf72 has been 
implicated in the regulation of membrane trafficking (Farg et al., 2014), it will be 
interesting to see whether animal and cell culture models expressing expanded 
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C9orf72 display defects in axonal transport. Testing SB-239063 in FTD models will 
allow us to investigate whether p38 MAPK-induced axonal transport defects are a 
common pathogenic mechanism of ALS and FTD. 
 
Our p38 MAPK and IGF1R inhibitors could also potentially be used to determine 
the role of axonal transport defects in the pathogenesis of other neurodegenerative 
diseases, such as Huntington’s disease (Her and Goldstein, 2008) and Alzheimer’s 
disease (Smith et al., 2007). p38 MAPK has in fact already been implicated in the 
axonal transport defects found in Alzheimer’s disease (AD). Treatment with 
oligomeric Aβ has been shown to induce defects in mitochondrial axonal transport 
in cultured hippocampal neurons through activation of p38 MAPKα/β (Guo et al., 
2013). In addition, an isoform-selective inhibitor of p38 MAPKα has recently been 
demonstrated to attenuate declines in cognitive performance in two mouse models 
of AD (Roy et al., 2015), indicating that p38 MAPK-induced defects in axonal 
transport may play a key role in AD pathogenesis. Furthermore, it will also be 
interesting to explore whether our active IGF1R inhibitors (E4, 2-B3 and PPP) have 
the potential to correct axonal transport deficits in other neurodegenerative 
diseases. Compound E4 has already been shown to accelerate retrograde axonal 
transport in motor and hippocampal neurons, but not sensory neurons. It will be 
interesting to see if our active IGF1R inhibitors accelerate axonal transport in 
additional neuronal types, for example striatal neurons, in order to determine the 
full spectrum of neurodegenerative diseases in which they may be useful.  
 
6.2. Concluding remarks 
It is clear that ALS is a complex disease, likely resulting from the interaction of 
multiple different pathological mechanisms. The role of axonal transport defects in 
neurodegeneration is a subject of much controversy in the field. The 
pharmacological enhancers of retrograde axonal transport identified in this thesis 
will allow us to determine conclusively whether defects in axonal transport play a 
key role in ALS pathogenesis. However, even if restoring axonal transport does 
prove beneficial, the future of ALS therapy likely lies in a multi-target approach. 
Future work must focus on dissecting out the key pathological mechanisms 
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responsible for motor neuron degeneration in ALS and determining which 
combination of therapeutic approaches has the largest impact on disease 
progression. 
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